Djo Finance 10-K 20 Feb 15 2014 FY Annual report Financial data

Document_and_Entity_Informatio

Document and Entity Information (USD $)	0 Months Ended	12 Months Ended
	Feb. 20, 2015	Dec. 31, 2014	Feb. 20, 2015
Document Information [Line Items]
Document Type		10-K
Amendment Flag		FALSE
Document Period End Date		31-Dec-14
Document Fiscal Year Focus		2014
Document Fiscal Period Focus		FY
Entity Registrant Name		DJO FINANCE LLC
Entity Central Index Key		1395317
Current Fiscal Year End Date		-19
Entity Well-known Seasoned Issuer		No
Entity Current Reporting Status		No
Entity Voluntary Filers		Yes
Entity Filer Category		Non-accelerated Filer
Entity Common Stock, Shares Outstanding			0
Entity Public Float			$0
Membership Interests Percentage			100.00%
Membership Interests Description	100% of the issuer’s membership interests were owned by DJO Holdings LLC.

Consolidated_Balance_Sheets

Consolidated Balance Sheets (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Current assets:
Cash and cash equivalents	$31,144	$43,578
Accounts receivable, net	188,060	185,088
Inventories, net	175,340	154,983
Deferred tax assets, net	24,598	27,527
Prepaid expenses and other current assets	17,172	27,951
Total current assets	436,314	439,127
Property and equipment, net	120,107	107,829
Goodwill	1,141,188	1,149,331
Intangible assets, net	868,031	958,993
Other assets	32,853	39,499
Total assets	2,598,493	2,694,779
Current liabilities:
Accounts payable	62,960	56,374
Accrued interest	29,600	29,682
Current portion of debt obligations	8,975	8,620
Other current liabilities	99,145	109,472
Total current liabilities	200,680	204,148
Long-term debt obligations	2,261,941	2,251,167
Deferred tax liabilities, net	243,123	242,028
Other long-term liabilities	14,365	16,718
Total liabilities	2,720,109	2,714,061
Commitments and contingencies
DJO Finance LLC membership deficit:
Member capital	839,781	838,769
Accumulated deficit	-952,412	-861,878
Accumulated other comprehensive (loss) income	-11,603	1,183
Total membership deficit	-124,234	-21,926
Noncontrolling interests	2,618	2,644
Total deficit	-121,616	-19,282
Total liabilities and (deficit) equity	$2,598,493	$2,694,779

Consolidated_Statements_of_Ope

Consolidated Statements of Operations (USD $)	3 Months Ended								12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Sep. 27, 2014	Jun. 28, 2014	Mar. 29, 2014	Dec. 31, 2013	Sep. 28, 2013	Jun. 29, 2013	Mar. 30, 2013	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Net sales	$327,054	$305,501	$313,867	$282,744	$313,586	$288,049	$294,745	$279,077	$1,229,166	$1,175,457	$1,129,420
Costs and operating expenses:
Cost of sales (exclusive of amortization of intangible assets of $34,368, $35,125, and $38,355 for the year ended December 31, 2014, 2013 and 2012, respectively)									495,397	471,665	443,859
Selling, general and administrative									499,205	477,990	460,111
Research and development									37,742	33,221	27,892
Amortization of intangible assets									93,071	95,539	97,243
Impairment of goodwill										102,000
Impairment of intangible assets										4,600	7,397
Operating Expenses, Total									1,125,415	1,185,015	1,036,502
Operating income (loss)	41,167	26,861	25,521	10,202	-81,149	25,375	26,423	19,793	103,751	-9,558	92,918
Other (expense) income:
Interest expense, net									-174,291	-177,542	-182,854
Loss on modification and extinguishment of debt									-938	-1,059	-36,889
Other (expense) income, net									-5,194	-1,287	3,553
Nonoperating Income (Expense), Total									-180,423	-179,888	-216,190
Loss before income taxes									-76,672	-189,446	-123,272
Income tax (provision) benefit									-12,890	-13,116	4,904
Net loss	-7,049	-21,133	-25,207	-36,173	-131,419	-18,375	-20,642	-32,126	-89,562	-202,562	-118,368
Net income attributable to noncontrolling interests									-972	-890	-782
Net loss attributable to DJO Finance LLC	($7,372)	($21,206)	($25,434)	($36,522)	($131,786)	($18,488)	($20,814)	($32,364)	($90,534)	($203,452)	($119,150)

Consolidated_Statements_of_Ope1

Consolidated Statements of Operations (Parenthetical) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Amortization of intangible assets	$34,368	$35,125	$38,355

Consolidated_Statements_of_Com

Consolidated Statements of Comprehensive Loss (USD $)	3 Months Ended								12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Sep. 27, 2014	Jun. 28, 2014	Mar. 29, 2014	Dec. 31, 2013	Sep. 28, 2013	Jun. 29, 2013	Mar. 30, 2013	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Net loss	($7,049)	($21,133)	($25,207)	($36,173)	($131,419)	($18,375)	($20,642)	($32,126)	($89,562)	($202,562)	($118,368)
Other comprehensive (loss) income, net of taxes:
Foreign currency translation adjustments, net of tax benefit (provision) of $3,871, $(1,212), and $(1,386) for the year ended December 31, 2014, 2013, and 2012, respectively									-13,167	19	1,108
Other comprehensive (loss) income									-13,167	19	1,108
Comprehensive loss									-102,729	-202,543	-117,260
Comprehensive income attributable to non-controlling interests									-591	-1,010	-824
Comprehensive loss attributable to DJO Finance LLC									($103,320)	($203,553)	($118,084)

Consolidated_Statements_of_Com1

Consolidated Statements of Comprehensive Loss (Parenthetical) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Foreign currency translation adjustment, tax benefit (provision)	$3,871	($1,212)	($1,386)

Consolidated_Statements_of_Def

Consolidated Statements of (Deficit) Equity (USD $)	Total	Member capital	Accumulated deficit	Accumulated other comprehensive income (loss)	Total membership deficit	Noncontrolling interests
In Thousands
Beginning Balance at Dec. 31, 2011	$297,956	$834,871	($539,276)	$218	$295,813	$2,143
Net (loss) income	-118,368		-119,150		-119,150	782
Other comprehensive (loss) income, net of taxes	1,108			1,066	1,066	42
Investment by parent	2,000	2,000			2,000
Stock-based compensation	2,339	2,339			2,339
Exercise of stock options	24	24			24
Dividend paid by subsidiary to owners of non-controlling interests	-649					-649
Ending Balance at Dec. 31, 2012	184,410	839,234	-658,426	1,284	182,092	2,318
Net (loss) income	-202,562		-203,452		-203,452	890
Other comprehensive (loss) income, net of taxes	19			-101	-101	120
Stock-based compensation	2,155	2,155			2,155
Cancellation of vested options	-2,001	-2,001			-2,001
Exercise of stock options	-619	-619			-619
Dividend paid by subsidiary to owners of non-controlling interests	-684					-684
Ending Balance at Dec. 31, 2013	-19,282	838,769	-861,878	1,183	-21,926	2,644
Net (loss) income	-89,562		-90,534		-90,534	972
Other comprehensive (loss) income, net of taxes	-13,167			-12,786	-12,786	-381
Stock-based compensation	1,869	1,869			1,869
Exercise of stock options	-857	-857			-857
Dividend paid by subsidiary to owners of non-controlling interests	-617					-617
Ending Balance at Dec. 31, 2014	($121,616)	$839,781	($952,412)	($11,603)	($124,234)	$2,618

Consolidated_Statements_of_Cas

Consolidated Statements of Cash Flows (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Cash Flows from Operating Activities:
Net loss	($89,562)	($202,562)	($118,368)
Adjustments to reconcile net loss to net cash provided by operating activities:
Depreciation	35,739	33,127	30,216
Amortization of intangible assets	93,071	95,539	97,243
Amortization of debt issuance costs and non-cash interest expense	8,692	8,012	9,732
Stock-based compensation expense	1,869	2,155	2,339
Impairment of goodwill		102,000
Impairment of intangible assets		4,600	7,397
(Gain) loss on disposal of assets, net	-843	1,108	1,686
Deferred income tax provision (benefit)	6,358	4,738	-11,581
Loss on modification and extinguishment of debt	938	1,059	36,889
Changes in operating assets and liabilities, net of acquired assets and liabilities:
Accounts receivable	-7,271	-17,865	-7,264
Inventories	-20,531	4,473	-21,937
Prepaid expenses and other assets	11,064	-8,755	1,313
Accrued interest	-81	-1,969	10,723
Accounts payable and other current liabilities	7,044	4,120	6,231
Net cash (used in) provided by operating activities	46,487	29,780	44,619
Cash Flows From Investing Activities:
Purchases of property and equipment	-52,793	-37,484	-32,950
Cash paid in connection with acquisitions, net of cash acquired	-4,587	-1,953	-29,909
Other investing activities, net	-1,038	-1,626	-1,106
Net cash used in investing activities	-58,418	-41,063	-63,965
Cash Flows From Financing Activities:
Proceeds from issuance of debt	1,000,294	549,417	1,342,450
Repayments of debt obligations	-990,219	-523,037	-1,276,045
Payment of debt issuance, modification and extinguishment costs	-1,812	-2,387	-55,827
Payment of contingent consideration	-5,690
Investment by parent			2,000
Cash paid in connection with the cancellation of vested options	-2,001	-2,000
Dividend paid by subsidiary to owners of noncontrolling interests	-617	-684	-649
Exercise of stock options	22		24
Net cash (used in) provided by financing activities	-23	23,309	11,953
Effect of exchange rate changes on cash and cash equivalents	-480	329	447
Net (decrease) increase in cash and cash equivalents	-12,434	12,355	-6,946
Cash and cash equivalents at beginning of period	43,578	31,223	38,169
Cash and cash equivalents at end of period	31,144	43,578	31,223
Supplemental disclosures of cash flow information:
Cash paid for interest	165,469	171,361	162,579
Cash paid for taxes, net	$7,442	$7,834	$4,704

ORGANIZATION_AND_BASIS_OF_PRES

ORGANIZATION AND BASIS OF PRESENTATION	12 Months Ended
	Dec. 31, 2014
ORGANIZATION AND BASIS OF PRESENTATION	1. ORGANIZATION AND BASIS OF PRESENTATION
	Organization and Business
	We are a global developer, manufacturer and distributor of medical devices that provide solutions for musculoskeletal health, vascular health and pain management. Our products address the continuum of patient care from injury prevention to rehabilitation after surgery, injury or from degenerative disease, enabling people to regain or maintain their natural motion. Our products are used by orthopedic specialists, spine surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers and other healthcare professionals. Our product lines include rigid and soft orthopedic bracing, hot and cold therapy, bone growth stimulators, vascular therapy systems and compression garments, therapeutic shoes and inserts, electrical stimulators used for pain management and physical therapy products. Our surgical implant business offers a comprehensive suite of reconstructive joint products for the hip, knee and shoulder.
	DJO Finance LLC (DJOFL) is a wholly owned indirect subsidiary of DJO Global, Inc. (DJO). Substantially all business activities of DJO are conducted by DJOFL and its wholly owned subsidiaries. Except as otherwise indicated, references to “us,” “we,” “DJOFL,” “our,” or “the Company,” refers to DJOFL and its consolidated subsidiaries.
	Infrequent Events
	In September 2013, a fire occurred at our factory in Tunisia. As a result of the fire, certain inventory and fixed assets were destroyed and the leased facility became inoperable. Estimated losses of $5.0 million related to destroyed inventory and fixed assets, excess expenses incurred and building reconstruction costs were recorded for the year ended December 31, 2013. Additionally, we recorded $1.3 million in revenue from business interruption insurance proceeds for the year ended December 31, 2013. Final claims were settled against the policies in September 2014. As a result, estimated losses were adjusted to $3.3 million, and additional $2.3 million in revenue from business interruption insurance proceeds was recorded for the year ended December 31, 2014. The activity in the corresponding insurance receivable was follows (in thousands):
		Year Ended
		December 31, 2014
	Balance, beginning of period	$	6,261
	Change in estimated losses		(1,617	)
	Business interruption		2,274
	Claim payments		(6,918	)
	Balance, end of period	$	—
	Segment Reporting
	We market and distribute our products through four operating segments, Bracing and Vascular, Recovery Sciences, Surgical Implant, and International. Our Bracing and Vascular, Recovery Sciences, and Surgical Implant segments generate their revenues within the United States. Our Bracing and Vascular segment offers rigid knee braces, orthopedic soft goods, cold therapy products, vascular systems, compression therapy products and therapeutic footwear for the diabetes care market. Our Recovery Sciences segment offers home electrotherapy, iontophoresis, home traction products, bone growth stimulation products and clinical physical therapy equipment. Our Surgical Implant segment offers a comprehensive suite of reconstructive joint products for the knee, hip and shoulder. Our International segment offers all of our products to customers outside the United States. See Note 18 for additional information about our reportable segments.
	Use of Estimates
	The preparation of financial statements in conformity with accounting principles generally accepted in the United States (GAAP) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Estimates and assumptions are used in accounting for, among other things, contractual allowances, rebates, product returns, warranty obligations, allowances for doubtful accounts, valuation of inventories, self-insurance reserves, income taxes, loss contingencies, fair values of derivative instruments, fair values of long-lived assets and any related impairments, capitalization of costs associated with internally developed software and stock-based compensation. Actual results could differ from those estimates.
	Basis of Presentation
	We consolidate the results of operations of our 50% owned subsidiary, Medireha GmbH (Medireha), and reflect the 50% share of results not owned by us as noncontrolling interests in our Consolidated Statements of Operations. We maintain control of Medireha through certain rights that enable us to prohibit certain business activities that are not consistent with our plans for the business and provide us with exclusive distribution rights for products manufactured by Medireha.

SIGNIFICANT_ACCOUNTING_POLICIE

SIGNIFICANT ACCOUNTING POLICIES	12 Months Ended
	Dec. 31, 2014
SIGNIFICANT ACCOUNTING POLICIES	2. SIGNIFICANT ACCOUNTING POLICIES
	Cash and Cash Equivalents. Cash consists of deposits with financial institutions. We consider all short-term, highly liquid investments and investments in money market funds and commercial paper with remaining maturities of less than three months at the time of purchase to be cash equivalents. While our cash and cash equivalents are on deposit with high-quality institutions, such deposits exceed Federal Deposit Insurance Corporation insured limits.
	Allowance for Doubtful Accounts. We make estimates of the collectibility of accounts receivable. Management analyzes accounts receivable historical collection rates and bad debts write-offs, customer concentrations, customer credit-worthiness and current economic trends when evaluating the adequacy of the allowance for doubtful accounts.
	Sales Returns and Allowances. We make estimates of the amount of sales returns and allowances that will eventually be incurred. Management analyzes sales programs that are in effect, contractual arrangements, market acceptance and historical trends when evaluating the adequacy of sales returns and allowance accounts. We estimate contractual discounts and allowances for reimbursement amounts from our third party payor customers based on negotiated contracts and historical experience.
	Inventories. We state our inventories at the lower of cost or market. We use standard cost methodology to determine cost basis for our inventories. This methodology approximates actual cost on a first-in, first-out basis. We establish reserves for slow moving and excess inventory, product obsolescence, shrinkage and other valuation impairments based on future demand and historical experience.
	Property and Equipment. Property and equipment are stated at cost less accumulated depreciation and amortization. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets that range from three to 25 years. Leasehold improvements and equipment under capital leases are amortized on a straight-line basis over the shorter of the lease term or estimated useful life of the asset. We capitalize surgical implant instruments that we provide to surgeons, free of charge, for use while implanting our products and the related depreciation expense is recorded as a component of Selling, general and administrative expense. We also capitalize electrotherapy devices that we rent to patients and record the related depreciation expense in cost of sales.
	Software Developed For Internal Use. Software is stated at cost less accumulated amortization and is amortized on a straight-line basis over estimated useful lives ranging from three to ten years. We capitalize costs of internally developed software during the development stage, including external consulting costs, cost of software licenses, and internal payroll and payroll-related costs for employees who are directly associated with a software project. Software assets are reviewed for impairment when events or circumstances indicate that the carrying value may not be recoverable. Upgrades and enhancements are capitalized if they result in added functionality. Amortization expense related to internally developed software was $2.0 million, $1.9 million and $1.9 million for the years ended December 31, 2014, 2013 and 2012, respectively.
	As of December 31, 2014 and 2013, we had $8.5 million and $10.5 million respectively, of unamortized internally developed software costs included within property and equipment in our Consolidated Balance Sheets.
	Intangible Assets. Our primary intangible assets are goodwill, customer relationships, patents and technology and trademarks and trade names. Goodwill represents the excess purchase price over the fair value of the identifiable net assets acquired in business combinations. Goodwill and intangible assets with indefinite useful lives are not amortized, but instead are tested for impairment at least annually. Intangible assets with definite lives are amortized over their respective estimated useful lives and reviewed for impairment when circumstances warrant.
	We evaluate the carrying value of goodwill and indefinite life intangible assets annually on the first day of the fourth quarter or whenever events or circumstances indicate the carrying value may not be recoverable. We evaluate the carrying value of finite life intangible assets whenever events or circumstances indicate the carrying value may not be recoverable. Significant assumptions are required to estimate the fair value of goodwill and intangible assets, most notably estimated future cash flows generated by these assets. As such, these fair valuation measurements use significant unobservable inputs, which are inputs that are classified as Level 3 in the fair value hierarchy. Changes to these assumptions could require us to record impairment charges on these assets.
	Warranty Costs. We provide expressed warranties on certain products for periods typically ranging from one to three years. We estimate our warranty obligations at the time of sale based upon historical experience and known product issues, if any.
	A summary of the activity in our warranty reserves is as follows (in thousands):
		Year Ended December 31,
		2014			2013			2012
	Balance, beginning of year	$	1,847		$	1,488		$	1,756
	Amount charged to expense for estimated warranty costs		1,788			1,138			338
	Deductions for actual costs incurred		(1,693	)		(779	)		(606	)
	Balance, end of year	$	1,942		$	1,847		$	1,488
	Self Insurance. We are partially self-insured for certain employee health benefits and product liability claims. Accruals for losses are provided based upon claims experience and actuarial assumptions, including provisions for incurred but not reported losses.
	Revenue Recognition. We recognize revenue when all four of the following criteria are met: (i) persuasive evidence that an arrangement exists; (ii) shipment of goods and passage of title occurs; (iii) the selling price is fixed or determinable; and (iv) collectibility is reasonably assured.
	We sell our products through a variety of distribution channels. We generally recognize revenue when we ship our products to our customers. We include amounts billed to customers for freight in revenue. We recognize revenue, both rental and purchase, for products sold directly to patients or their third party insurance payors, when our product has been dispensed or shipped to the patient and the patient’s insurance has been verified.
	We record revenues from sales or our surgical implant products when the products are used in a surgical procedure (implanted in a patient).
	We reduce revenue by estimates of potential future product returns and other allowances. Revenues are also reduced by rebates related to sales transacted through distribution agreements that provide the distributors with a right to return inventory or take certain pricing adjustments based on sales mix or volume. Provisions for product returns and other allowances are recorded as a reduction to revenue in the period sales are recognized.
	Advertising Costs. We expense advertising costs as they are incurred. For the years ended December 31, 2014, 2013 and 2012, advertising costs were $4.7 million, $6.4 million and $6.5 million, respectively. In 2013 we revised our definition of advertising costs to exclude certain other marketing and promotion costs. The amounts for the year ended December 31, 2012 have been revised to conform to the current definition.
	Shipping and Handling Expenses. Shipping and handling expenses are included within cost of sales in our Consolidated Statements of Operations.
	Stock Based Compensation. We maintain a stock option plan under which stock options of our indirect parent, DJO, have been granted to both employees and non-employees. All share based payments to employees are recognized in the financial statements based on their grant date fair values and our estimates of forfeitures. We amortize stock-based compensation for service-based awards granted on a straight-line basis over the requisite service (vesting) period for the entire award. Other awards vest upon the achievement of certain pre-determined performance targets, and compensation expense is recognized to the extent the achievement of the performance targets is deemed probable.
	Income Taxes. Income taxes are accounted for under the asset and liability method, whereby deferred tax assets and liabilities are recognized and measured using enacted tax rates in effect for each taxing jurisdiction in which we operate for the year in which those temporary differences are expected to be recognized. Net deferred tax assets are then reduced by a valuation allowance if we believe it more-likely-than-not such net deferred tax assets will not be realized.
	Foreign Currency Translation and Transactions. The reporting currency of DJOFL is the U.S. Dollar. Assets and liabilities of foreign subsidiaries (including intercompany balances for which settlement is not anticipated in the foreseeable future) are translated at the spot rate in effect at the applicable reporting date, and our Consolidated Statement of Operations is translated at the average exchange rates in effect during the applicable period. The resulting unrealized cumulative translation adjustment, net of applicable income taxes, is recorded as a component of other comprehensive income (loss) in our Consolidated Statement of Comprehensive Loss. Cash flows from our operations in foreign countries are translated at the average rate for the applicable period. The effect of exchange rates on cash balances held in foreign currencies are separately reported in our Consolidated Statements of Cash Flows.
	Transactions denominated in currencies other than our or our subsidiaries’ functional currencies are recorded based on exchange rates at the time such transactions arise. Changes in exchange rates with respect to amounts recorded in our Consolidated Balance Sheets related to such transactions result in transaction gains and losses that are reflected in our Consolidated Statements of Operations as either unrealized (based on the applicable period end translation) or realized (upon settlement of the transactions). For the years ended December 31, 2014, 2013 and 2012, foreign transaction (losses) gains were $(5.3) million, $(1.5) million and $3.6 million, respectively.
	Derivative Financial Instruments. All derivative instruments are recognized in the financial statements and measured at fair value regardless of the purpose or intent for holding them.
	We use foreign exchange forward contracts to hedge expense commitments that are denominated in currencies other than the U.S. dollar. The purpose of our foreign currency hedging activities is to fix the dollar value of specific commitments and payments to foreign vendors. Before acquiring a derivative instrument to hedge a specific risk, potential natural hedges are evaluated. While our foreign exchange contracts act as economic hedges, we have not designated such instruments as hedges for accounting purposes. Therefore, gains and losses resulting from changes in the fair values of these derivative instruments are recorded in other income (expense), net, in our Consolidated Statements of Operations.
	The fair value of our derivative instruments has been determined through the use of models that consider various assumptions, including time value and other relevant economic measures, which are inputs that are classified as Level 2 in the fair value hierarchy (see Notes 10 and 11).
	Comprehensive Income (Loss). Comprehensive income (loss) includes net income (loss) as per our Consolidated Statement of Operations and other comprehensive income (loss). Other comprehensive income (loss), which is comprised of unrealized gains and losses on foreign currency translation adjustments, net of tax, is included in our Consolidated Statement of Comprehensive Loss.
	Concentration of Credit Risk. We sell the majority of our products in the United States to orthopedic professionals, hospitals, distributors, specialty dealers, insurance companies, managed care companies and certain governmental payors such as Medicare. International sales comprised 26.5%, 25.5% and 24.8% of our net sales for the years ended December 31, 2014, 2013 and 2012, respectively. International sales are generated from a diverse group of customers through our wholly owned subsidiaries and certain independent distributors. Credit is extended based on an evaluation of the customer’s financial condition and generally collateral is not required. We provide a reserve for estimated bad debts. Management reviews and revises its estimates for credit losses from time to time and such credit losses have generally been within management’s estimates. In each of the years ended December 31, 2014, 2013 and 2012, we had no individual customer or distributor that accounted for 10% or more of our total annual net sales.
	Fair Value of Financial Instruments. The carrying amounts of our short-term financial instruments, including cash and cash equivalents, accounts receivable and accounts payable, approximate fair values due to their short-term nature. See Note 12 for information concerning the fair value of our variable and fixed rate debt.
	Recent Accounting Standards. In July 2013, the Financial Accounting Standards Board (the “FASB”) issued an accounting standard update regarding the financial statement presentation of an unrecognized tax benefit when a net operating loss carryforward, a similar tax loss, or a tax credit carryforward exists. The guidance is effective prospectively for fiscal years, and interim periods within those years, beginning after December 15, 2013, with an option for early adoption. The adoption of this standard did not have an impact on the Company’s consolidated financial statements.
	In April 2014, the FASB issued accounting standards update, which includes amendments that change the requirements for reporting discontinued operations and require additional disclosures about discontinued operations. Under the new guidance, only disposals representing a strategic shift in operations—that is, a major effect on the organization’s operations and financial results should be presented as discontinued operations. Examples include a disposal of a major geographic area, a major line of business, or a major equity method investment. Additionally, the update requires expanded disclosures about discontinued operations that will provide financial statement users with more information about the assets, liabilities, income, and expenses of discontinued operations. The guidance is effective prospectively for fiscal years beginning after December 15, 2014 and interim periods within annual periods beginning on or after December 15, 2015. The adoption of this standard has the potential to impact the Company’s accounting for and disclosure of any future discontinued operations.
	In May 2014, the FASB issued an accounting standards update related to revenue from contracts with customers. The new standard provides a five-step approach to be applied to all contracts with customers. The accounting standards update also requires expanded disclosures about revenue recognition. The guidance is effective for fiscal years beginning after December 15, 2016 and interim periods within that reporting period. Early adoption is not permitted. The Company is currently evaluating the new guidance to determine the impact it may have to its consolidated financial statements.
	In June 2014, the FASB issued an accounting standards update related accounting for share-based payments. The standard requires that a performance target that affects vesting and that could be achieved after the requisite service period be treated as a performance condition. The guidance is effective for annual periods and interim periods within those annual periods, beginning after December 15, 2015. Early application is permitted. Adoption of this new guidance is not expected to have a material effect on the Company’s financial statements.
	In August 2014, the FASB issued an accounting standards update related to going concern disclosures. The standard requires an entity’s management to evaluate whether there are conditions or events that raise substantial doubt about the entity’s ability to continue as a going concern within one year after the date that the financial statements are issued. The guidance is effective for annual reporting periods ending after December 15, 2016, and interim periods thereafter. Early application is permitted. Adoption of this new guidance is not expected to have a material effect on the Company’s financial statements.

ACQUISITIONS

ACQUISITIONS	12 Months Ended
	Dec. 31, 2014
ACQUISITIONS	3. ACQUISITIONS
	On January 23, 2014, we acquired all of the outstanding shares of capital stock of Speetec Implantate GmbH (“Speetec”). Speetec is a distributor and manufacturer of knee, hip and shoulder arthroplasty products in Germany. The purchase price consisted of a cash payment at closing of $5.0 million, a holdback of $1.3 million for potential indemnity claims and $1.6 million for the fair value of contingent consideration. The fair value of contingent consideration equals approximately 25% of the total potential contingent consideration of $7.3 million. The valuation was based on the probability weighted average estimate of achievement of revenue targets for 2014 and 2015.
	The indemnity holdback accrues interest at the Euribor rate plus 100 basis points and is 50% payable in March 2015 and March 2016, respectively, if not used for indemnification claims. The contingent consideration is 50% payable in March 2015 and March 2016, respectively, if earned.
	On July 1, 2013 we acquired certain assets of Blue Leaf Medical CC, (“Blue Leaf”) for a total purchase price of $0.6 million. The assets acquired relate to certain vascular product lines in South Africa, Namibia, Botswana, Mozambique and Zambia. The purchase price consisted of a cash payment at closing of $0.4 million, $0.1 million for the purchase of inventory on hand at closing and $0.1 million which was held back to provide security for potential indemnification claims. The hold back payment was paid to the sellers in September 2014.
	On March 7, 2013 we acquired certain assets of Vasyli Medical Asia/Pacific Pty Ltd, (“Vasyli”) for a total purchase price of $2.2 million. The assets acquired relate to the distribution of certain vascular product lines in Australia and New Zealand. The purchase price consisted of a cash payment at closing of $1.3 million, $0.5 million for the purchase of inventory on hand at closing and $0.4 million which was held back to provide security for potential indemnification claims. The hold back payment was paid to the sellers in March 2014. Additionally, there was $0.3 million of contingent consideration payable one year from the acquisition date if certain revenue targets were met by December 31, 2013; however, these targets were not achieved and therefore no payment was made.
	Our primary reason for the acquisitions was to move from an indirect sales model (i.e., sales to distributors at a discount) to a direct sales model, resulting in increased gross profit and operating income. All goodwill associated with these acquisitions is allocated to our International reporting segment.
	On December 28, 2012, we acquired all of the outstanding shares of capital stock of Exos Corporation (Exos) for a total purchase price of $40.6 million. The purchase price consisted of a cash payment of $31.2 million, settlement of the existing distributor agreement with Exos at a fair value of $1.2 million and $8.2 million for the fair value of contingent consideration. Of the initial cash payment, $3.0 million was withheld from the closing date payment and was paid to a third party escrow agent to secure the indemnity obligations of the seller. The $10.0 million contingent consideration was initially measured at a fair value of $8.2 million based on the probability weighted estimate of approximately 95% for the achievement of certain specified milestones and the budgeted 2013 Exos product line revenues.
	Exos is a medical device company focused on thermoformable external musculoskeletal stabilization systems for the treatment of fractures and other injuries requiring stabilization. All goodwill arising from the Exos acquisition was allocated to our Bracing and Vascular reporting segment. In connection with the acquisition of Exos, we incurred $1.3 million of direct acquisition costs comprised of $0.5 million of legal and other professional fees and $0.8 million of transaction and advisory fees to Blackstone Advisory Partners L.P., and Blackstone Management Partners LLC, affiliates of our major shareholder (see Note 17). These costs are included in Selling, general and administrative expense in our Consolidated Statement of Operations. The acquisition was partially funded using proceeds from $25.0 million of new term loans issued on December 28, 2012 (see Note 12).
	The purchase price for each of these acquisitions was allocated to the fair values of the net tangible and intangible assets acquired as follows (in thousands):
	(in thousands):		Speetec			Blue Leaf		Vasyli		Exos
	Cash		$	489		$	—	$	—	$	1,282
	Accounts receivable			608			—		—		1,138
	Inventory			2,766			59		542		1,754
	Other current assets			154			—		31		105
	Property and equipment			379			—		12		584
	Other non-current assets			—			—		—		12
	Liabilities assumed			(1,642	)		—		—		(474	)
	Deferred tax liabilities			(1,003	)		—		—		(9,137	)
	Identifiable intangible assets (1):
	Customer relationships			2,861			90		308		—
	Technology			—			—		—		24,200
	Non-compete			569			111		930		1,900
	Trademarks and trade names			320			—		—		1,000
	Goodwill (2)			2,383			322		363		18,211
	Total purchase price		$	7,884		$	582	$	2,186	$	40,575
	-1	The fair value of customer relationships was assigned to relationships with major customers existing on the acquisition date based upon an estimate of the future discounted cash flows that would be derived from those customers, after deducting contributory asset charges.
	The fair value of technology was determined primarily by estimating the present value of future royalty costs that will be avoided due to our ownership of the patents and technology acquired.
	The fair value of non-compete agreements relate to non-compete agreements entered into with certain members of senior management. The values were determined by estimating the present value of the cash flows associated with having these agreements in place, less the present value of the cash flows assuming the non-compete agreements were not in place.
	The fair value of trademarks and trade names was determined primarily by estimating the present value of future royalty costs that will be avoided due to our ownership of the trade names and trademarks acquired.
	The useful lives of the intangible assets acquired were estimated based on the underlying agreements and/or the future economic benefit expected to be received from the assets.
	-2	Goodwill represents the excess purchase price over the fair value of the identifiable net assets acquired. Among the factors which resulted in the recognition of goodwill for the Speetec acquisition was the opportunity to expand our direct presences in the German market with our surgical products. Among the factors which resulted in the recognition of goodwill for the Blue Leaf and Vasyli assets was the opportunity to expand our direct presence in the local markets with our vascular products. Among the factors which resulted in the recognition of goodwill for Exos was improved our margins on the sale of Exos products and being able to control the rights to future products developed by Exos.

ACCOUNTS_RECEIVABLE_RESERVES

ACCOUNTS RECEIVABLE RESERVES	12 Months Ended
	Dec. 31, 2014
ACCOUNTS RECEIVABLE RESERVES	4. ACCOUNTS RECEIVABLE RESERVES
	A summary of activity in our accounts receivable reserves for doubtful accounts is presented below (in thousands):
		Year Ended December 31,
		2014			2013			2012
	Balance, beginning of year	$	32,957		$	25,211		$	35,649
	Provision for doubtful accounts		40,164			33,129			19,586
	Write-offs, net of recoveries		(31,719	)		(25,383	)		(30,024	)
	Balance, end of year	$	41,402		$	32,957		$	25,211
	Our allowance for sales returns balance was $3.6 million $3.9 million, and $4.0 million as of December 31, 2014, 2013 and 2012, respectively.

INVENTORIES

INVENTORIES	12 Months Ended
	Dec. 31, 2014
INVENTORIES	5. INVENTORIES
	Inventories consist of the following (in thousands):
		December 31,2014			December 31,2013
	Components and raw materials	$	59,578		$	59,825
	Work in process		5,718			7,373
	Finished goods		103,042			83,502
	Inventory held on consignment		30,978			27,969
			199,316			178,669
	Inventory reserves		(23,976	)		(23,686	)
		$	175,340		$	154,983
	A summary of the activity in our reserves for estimated slow moving, excess, obsolete and otherwise impaired inventory is presented below (in thousands):
		Year Ended December 31,
		2014			2013			2012
	Balance, beginning of year	$	23,686		$	17,313		$	14,146
	Provision charged to costs of sales		8,924			10,121			6,350
	Write-offs, net of recoveries		(8,634	)		(3,748	)		(3,183	)
	Balance, end of year	$	23,976		$	23,686		$	17,313
	The write-offs to the reserve were principally related to the disposition of fully reserved inventory.

PROPERTY_AND_EQUIPMENT_NET

PROPERTY AND EQUIPMENT, NET	12 Months Ended
	Dec. 31, 2014
PROPERTY AND EQUIPMENT, NET	6. PROPERTY AND EQUIPMENT, NET
	Property and equipment consists of the following (in thousands):
		December 31,			December 31,			Depreciable lives
		2014			2013			(years)
	Land	$	266		$	266		Indefinite
	Buildings and improvements		28,967			27,229		3 to 25
	Equipment		137,468			132,688		2 to 7
	Software		38,627			33,817		3 to 10
	Furniture and fixtures		12,618			12,223		3 to 8
	Surgical implant instrumentation		78,275			55,841		5
	Construction in progress		12,027			7,919		N/A
			308,248			269,983
	Accumulated depreciation and amortization		(188,141	)		(162,154	)
	Property and equipment, net	$	120,107		$	107,829
	Depreciation and amortization expense relating to property and equipment was $35.7 million, $33.1 million and $30.2 million for the years ended December 31, 2014, 2013 and 2012, respectively.

LONGLIVED_ASSETS

LONG-LIVED ASSETS	12 Months Ended
	Dec. 31, 2014
LONG-LIVED ASSETS	7. LONG-LIVED ASSETS
	Goodwill
	Changes in the carrying amount of goodwill for the year ended December 31, 2014 are presented in the table below (in thousands):
		Bracing &		Recovery			Surgical			International			Total
		Vascular		Sciences			Implant
	Balance, beginning of period
	Goodwill	$	483,258	$	495,999		$	47,406		$	348,774		$	1,375,437
	Accumulated impairment losses		—		(178,700	)		(47,406	)		—			(226,106	)
			483,258		317,299			—			348,774			1,149,331
	Acquisitions (see Note 3)		—		—			—			2,383			2,383
	Foreign currency translation		—		—			—			(10,526	)		(10,526	)
	Balance, end of period
	Goodwill		483,258		495,999			47,406			340,631			1,367,294
	Accumulated impairment losses		—		(178,700	)		(47,406	)		—			(226,106	)
		$	483,258	$	317,299		$	—		$	340,631		$	1,141,188
	In performing our 2014 goodwill impairment test, we estimated the fair values of our reporting units using the income approach which includes the discounted cash flow method and the market approach which includes the use of market multiples. These fair value measurements are categorized within Level 3 of the fair value hierarchy. The discounted cash flows for each reporting unit were based on discrete financial forecasts developed by management for planning purposes, and required significant judgment with respect to forecasted sales, gross margin, selling, general and administrative expenses, depreciation, income taxes, capital expenditures, working capital requirements and the selection and use of an appropriate discount rate. For purposes of calculating the discounted cash flows of our reporting units, we used estimated revenue growth rates averaging between 1% and 6% for the discrete forecast period. Cash flows beyond the discrete forecasts were estimated using a terminal value calculation, which incorporated historical and forecasted financial trends for each identified reporting unit and considered long-term earnings growth rates for publicly traded peer companies. Future cash flows were then discounted to present value at discount rates ranging from 9.6% to 11.3%, and terminal value growth rates ranging from 1.4% to 3.0%. Publicly available information regarding comparable market capitalization was also considered in assessing the reasonableness of the cumulative fair values of our reporting units estimated using the discounted cash flow methodology. We determined that the fair value of the six reporting units with goodwill assigned to them exceeds their carrying value and no reporting unit was at risk of failing the test. The percentage by which the fair value of the six reporting units exceeded their carrying value ranged from 30.9% to 126.1%. As such, we determined that the goodwill of our reporting units was not impaired.
	In the fourth quarter of 2013, we determined that the carrying values of our Empi and Chattanooga reporting units were in excess of their estimated fair values. As a result, we recorded goodwill impairment charges for the Empi and Chattanooga reporting units of $52.5 million and $49.5 million, respectively. The impairment charges were included in Impairment of goodwill and intangible assets in our Consolidated Statement of Operations. The goodwill impairment in our Empi reporting unit resulted primarily from reductions in our projected operating results due to unfavorable decisions made by certain third party payors related to insurance pricing for certain products sold by the Empi reporting unit. The goodwill impairment in the Chattanooga reporting unit resulted primarily from reductions in our projected operating results and estimated future cash flows due to slow market conditions for capital equipment.
	Intangible Assets
	Identifiable intangible assets consisted of the following (in thousands):
	December 31, 2014	Gross Carrying		Accumulated			Intangible
		Amount		Amortization			Assets, Net
	Definite-lived intangible assets:
	Customer relationships	$	569,360	$	(341,353	)	$	228,007
	Patents and technology		486,466		(264,132	)		222,334
	Trademarks and trade names		25,970		(9,902	)		16,068
	Distributor contracts and relationships		4,771		(3,401	)		1,370
	Non-compete agreements		6,824		(4,723	)		2,101
		$	1,093,391	$	(623,511	)		469,880
	Indefinite-lived intangible assets:
	Trademarks and trade names							398,151
	Net identifiable intangible assets						$	868,031
	December 31, 2013	Gross Carrying		Accumulated			Intangible
		Amount		Amortization			Assets, Net
	Definite-lived intangible assets:
	Customer relationships	$	570,070	$	(290,359	)	$	279,711
	Patents and technology		486,246		(230,111	)		256,135
	Trademarks and trade names		25,820		(7,102	)		18,718
	Distributor contracts and relationships		5,054		(3,183	)		1,871
	Non-compete agreements		6,423		(3,149	)		3,274
		$	1,093,613	$	(533,904	)		559,709
	Indefinite-lived intangible assets:
	Trademarks and trade names							399,284
	Net identifiable intangible assets						$	958,993
	In the fourth quarter of 2014 we tested our indefinite lived trade name intangible assets for impairment. This test work compares the fair value of the asset with its carrying amount. To determine the fair value we applied the relief from royalty (RFR) method. Under the RFR method, the value of the trade name is determined by calculating the present value of the after-tax cost savings associated with owning the asset and therefore not being required to pay royalties for its use during the asset’s indefinite life. Significant judgments inherent in this analysis include the selection of appropriate discount rates, estimating future cash flows and the identification of appropriate terminal growth rate assumptions. Discount rate assumptions are based on an assessment of the risk inherent in the projected future cash generated by the respective intangible assets. Future cash flows were discounted to present value at discount rates ranging from 9.6% to 11.3%, and terminal value growth rates ranging from 1.4% to 3.0%. Also subject to judgment are assumptions about royalty rates, which are based on the estimated rates at which similar brands and trademarks are being licensed in the marketplace. We used market average royalty rates ranging from 0.5% to 5.0%. These fair value measurements are categorized within Level 3 of the fair value hierarchy. We determined that that the fair value of these trade names exceed their carrying value. The percentage by which the fair value of these trade names exceeded their carrying value ranged from 10.5% to 89.6%. As such, we determined that these indefinite lived intangible assets are not impaired. This fair value measurement is categorized within Level 3 of the fair value hierarchy.
	In the fourth quarter of 2013 we determined that the carrying value of our Empi trade name was in excess of its estimated fair value, and recorded an impairment charge of $4.5 million. The impairment charge was included in Impairment of goodwill and intangible assets line item in the Consolidated Statement of Operations.
	Our definite lived intangible assets are being amortized using the straight line method over their remaining weighted average useful lives of 5.1 years for customer relationships, 8.3 years for patents and technology, 2.7 years for distributor contracts and relationships, 6.2 years for trademarks and trade names, and 2.2 years for non-compete agreements. Based on our amortizable intangible asset balance as of December 31, 2014, we estimate that amortization expense will be as follows for the next five years and thereafter (in thousands):
	2015	$	88,405
	2016		83,874
	2017		72,712
	2018		62,552
	2019		51,742
	Thereafter		110,595
		$	469,880
	Our goodwill and intangible assets by segment are as follows (in thousands):
	December 31, 2014	Goodwill		Intangible
				Assets, Net
	Bracing and Vascular	$	483,258	$	487,122
	Recovery Sciences		317,299		218,260
	International		340,631		150,128
	Surgical Implant		—		12,521
		$	1,141,188	$	868,031
	December 31, 2013	Goodwill		Intangible
				Assets, Net
	Bracing and Vascular	$	483,258	$	527,806
Recovery Sciences		317,299		250,725
International		348,774		165,569
Surgical Implant		—		14,893
	$	1,149,331	$	958,993

OTHER_CURRENT_LIABILITIES

OTHER CURRENT LIABILITIES	12 Months Ended
	Dec. 31, 2014
OTHER CURRENT LIABILITIES	8. OTHER CURRENT LIABILITIES
	Other current liabilities consist of the following (in thousands):
		December 31,		December 31,
		2014		2013
	Accrued wages and related expenses	$	32,220	$	33,128
	Accrued commissions		16,611		16,489
	Accrued rebates		12,981		10,731
	Accrued other taxes		4,987		4,734
	Accrued professional expenses		2,682		3,372
	Income taxes payable		2,477		2,877
	Deferred tax liability		343		445
	Other accrued liabilities		26,844		37,696
		$	99,145	$	109,472

EMPLOYEE_BENEFIT_PLANS

EMPLOYEE BENEFIT PLANS	12 Months Ended
	Dec. 31, 2014
EMPLOYEE BENEFIT PLANS	9. EMPLOYEE BENEFIT PLANS
	We have multiple qualified defined contribution plans, which allow for voluntary pre-tax contributions by employees. We pay all general and administrative expenses of the plans and make matching and may make certain discretionary contributions to the plans. Based on 100% of the first 1% and 50% of the next 5% of compensation deferred by employees (subject to IRS limits and non-discrimination testing), we made matching contributions of $4.1 million, $4.2 million and $4.0 million, to the plans for the years ended December 31, 2014, 2013 and 2012, respectively. The plans provide for discretionary contributions by us, as approved by the Board of Directors. There have been no such discretionary contributions through December 31, 2014. In addition, we made contributions to our international pension plans of $1.7 million, $1.1 million and $1.3 million for the years ended December 31, 2014, 2013 and 2012, respectively.

DERIVATIVE_INSTRUMENTS

DERIVATIVE INSTRUMENTS	12 Months Ended
	Dec. 31, 2014
DERIVATIVE INSTRUMENTS	10. DERIVATIVE INSTRUMENTS
	From time to time, we use derivative financial instruments to manage interest rate risk related to our variable rate credit facilities and risk related to foreign currency exchange rates. Our objective is to reduce the risk to earnings and cash flows associated with changes in interest rates and changes in foreign currency exchange rates. Before acquiring a derivative instrument to hedge a specific risk, we evaluate potential natural hedges. Factors considered in the decision to hedge an underlying market exposure include the materiality of the risk, the volatility of the market, the duration of the hedge, and the availability, effectiveness and cost of derivative instruments. We do not use derivative instruments for speculative or trading purposes.
	All derivatives, whether designated as hedging relationships or not, are recorded on the balance sheet at fair value. The fair value of our derivatives is determined through the use of models that consider various assumptions, including time value, yield curves and other relevant economic measures which are inputs that are classified as Level 2 in the fair value hierarchy. The classification of gains and losses resulting from changes in the fair values of derivatives is dependent on the intended use of the derivative and its resulting designation. Our foreign exchange contracts have not been designated as hedges, and accordingly, changes in the fair value of the derivatives are recorded in income (loss).
	Foreign Exchange Rate Contracts. We utilize Mexican Peso (MXN) foreign exchange forward contracts to hedge a portion of our exposure to fluctuations in foreign exchange rates, as our Mexico-based manufacturing operations incur costs that are largely denominated in MXN. Foreign exchange forward contracts held as of December 31, 2014 are short term contracts expiring in January 2015. While our foreign exchange forward contracts act as economic hedges, we have not designated such instruments as hedges for accounting purposes. Therefore, gains and losses resulting from changes in the fair values of these derivative instruments are recorded in Other income (expense), net, in our accompanying Consolidated Statements of Operations.
	Information regarding the notional amounts of our foreign exchange forward contracts is presented in the table below (in thousands):
		Notional Amount (MXN)								Notional Amount (USD)
		December 31,				December 31,				December 31,				December 31,
		2014				2013				2014				2013
	Foreign exchange contracts not designated as hedges		7,682				302,730			$	526			$	22,959
	The following table summarizes the fair value of derivative instruments in our Consolidated Balance Sheets (in thousands):
		Balance Sheet Location		December 31,				December 31,
				2014				2013
	Derivative Liabilities:
	Foreign exchange forward contracts not designated as hedges	Other current liabilities		$	4			$	44
	The following table summarizes the effect our derivative instruments have on our Consolidated Statements of Operations (in thousands):
				Year Ended December 31,
		Location of gain (loss)		2014				2013				2012
	Foreign exchange forward contracts not designated as hedges	Other income (expense), net		$	40				(821	)			1,322
				$	40			$	(821	)		$	1,322

FAIR_VALUE_MEASUREMENTS

FAIR VALUE MEASUREMENTS	12 Months Ended
	Dec. 31, 2014
FAIR VALUE MEASUREMENTS	11. FAIR VALUE MEASUREMENTS
	Financial assets and liabilities are classified based on the lowest level of input that is significant to the fair value measurements. Our assessment of the significance of a particular input to the fair value measurements requires judgment and may affect the valuation of the assets and liabilities being measured and their placement within the fair value hierarchy.
	During the year ended December 31, 2014, we remeasured the fair value of contingent consideration related to our January 2014 acquisition of Speetec. We initially valued the contingent consideration at $1.6 million which equaled approximately 25% of the total potential contingent consideration of $7.3 million. The valuation was based on the probability weighted average estimate of achievement of revenue targets for 2014 and 2015. The fair value of the expected payment was then calculated using a 9.9% discount rate as the contingent consideration is 50% payable in March 2015 and March 2016, respectively, if earned. Our remeasurement of the fair value based on the probability of achieving the Speetec revenue targets and the discounted present value of the current estimate of the future contingent payments reduced the net fair value of the contingent consideration to zero. This fair value measurement is categorized within Level 3 of the fair value hierarchy.
	During the year ended December 31, 2013, we remeasured the fair value of the contingent consideration related to our December 2012 acquisition of Exos Corporation. We initially valued the contingent consideration at $8.2 million based on the probability weighted estimate of approximately 95% for the achievement of certain specified milestones and the budgeted 2013 Exos product line revenues. Our remeasurement of the fair value based on the probability of achieving the budgeted Exos revenue and certain specified milestones and the discounted present value of the current estimate of the future contingent payment resulted in a reduction of $2.5 million to the net fair value of the contingent consideration. This fair value measurement is categorized within Level 3 of the fair value hierarchy. The $5.7 million of contingent consideration was paid to Exos Corporation in April 2014.
	The following tables present the balances of financial assets and liabilities measured at fair value on a recurring basis (in thousands):
	As of December 31, 2014	Quoted Prices			Significant		Significant		Recorded
		in Active			Other		Unobservable		Balance
		Markets for			Observable		Inputs
		Identical Assets			Inputs		(Level 3)
		(Level 1)			(Level 2)
	Liabilities:
	Foreign exchange forward contracts not designated as hedges	$	—		$	4	$	—	$	4
	As of December 31, 2013	Quoted Prices			Significant		Significant		Recorded
		in Active			Other		Unobservable		Balance
		Markets for			Observable		Inputs
		Identical Assets			Inputs		(Level 3)
		(Level 1)			(Level 2)
	Liabilities:
	Foreign exchange forward contracts not designated as hedges	$	—		$	44	$	—	$	44
	Contingent consideration	$	—		$	—	$	5,690	$	5,690
	The table below presents reconciliation of all financial assets and liabilities measured at fair value on a recurring basis using significant unobservable inputs (Level 3) for the year ended December 31, 2014 (in thousands):
		Year Ended
		December 31, 2014
	Balance, beginning of period	$	5,690
	Acquisitions		1,627
	Payment of contingent consideration		(5,690	)
	Adjustment of contingent consideration included in SG&A		(1,482	)
	Foreign currency translation		(145	)
	Balance, end of period	$	—

DEBT

DEBT	12 Months Ended
	Dec. 31, 2014
DEBT	12. DEBT
	Debt obligations consist of the following (in thousands):
			December 31,			December 31,
			2014			2013
	Senior secured credit facilities:
	Revolving credit facility		$	17,000		$	38,000
	Term Loan:
	$884.6 million New Tranche B term loans, net of unamortized original issuance discount of $5.1 million as of December 31, 2014			879,476			—
	$853.4 million Tranche B term loans, net of unamortized original issuance discount of $7.1 million as of December 31, 2013			—			846,297
	8.75% Second priority senior secured notes, including unamortized original issue premium of $4.4 million and $5.5 million as of December 31, 2014 and December 31, 2013, respectively			334,377			335,490
	9.875% Senior unsecured notes			440,000			440,000
	7.75% Senior unsecured notes			300,000			300,000
	9.75% Senior subordinated notes			300,000			300,000
	Other			63			—
	Total debt			2,270,916			2,259,787
	Current maturities			(8,975	)		(8,620	)
	Long-term debt		$	2,261,941		$	2,251,167
	Senior Secured Credit Facilities
	Our senior secured credit facilities consist of term loans and a $100.0 million revolving credit facility, originally entered into on November 20, 2007 and subsequently amended and restated on March 20, 2012.
	On March 21, 2013, we entered into an amendment to the senior secured credit facilities which, among other things, (1) provided for the issuance of $421.4 million of additional term loans issued at par, the proceeds of which were used to prepay existing term loans; (2) extended the maturity of the term loans issued under the original senior secured credit facilities to September 15, 2017 (“extended term loans”); (3) combined the additional term loans and the extended term loans into one new tranche (“tranche B term loans”); (4) reduced the interest rate margin applicable to all borrowings under the senior secured credit facilities; and (5) set the senior secured first lien leverage ratio covenant at a level of 4.25x for the duration of the agreement.
	On April 8, 2014, we entered into an amendment (the “Amendment”) to the senior secured credit facilities that, among other things, (1) provided for the issuance of $851.2 million of refinancing term loans (the “Refinancing Term Loans”) at par, the proceeds of which were used to prepay existing tranche B term loans; (2) provided for the issuance of $40.0 million of incremental term loans (the “Incremental Term Loans”) at par, the proceeds of which were used, among other things, to prepay the loans then-outstanding under the revolving credit facility and fees and expenses associated with the Amendment; (3) combined the Refinancing Term Loans and the Incremental Term Loans into one new tranche ( the “New Tranche B Term Loans”); (4) reduced the interest rate margin applicable to all borrowings (including the revolving borrowing) under the senior secured credit facilities; and (5) set the senior secured first lien leverage ratio covenant at a level of 4.75x for the duration of the agreement. The remaining unamortized original issue discounts from the previous term loan issuances are being amortized over the term of the New Tranche B Term Loans using the effective interest method.
	As of December 31, 2014, the market values of our New Tranche B Term Loans and drawings under our revolving credit facility were $862.4 million and $15.6 million, respectively. We determine market value using trading prices for the senior secured credit facilities on or near that date. This fair value measurement is categorized within Level 2 of the fair value hierarchy.
	Interest Rates. Effective April 8, 2014, the interest rate margins applicable to borrowings under the senior secured revolving credit facilities are, at our option, either (a) the Eurodollar rate, plus 325 basis points or (b) a base rate determined by reference to the highest of (1) the prime rate, (2) the federal funds rate, plus 0.50% and (3) the Eurodollar rate for a one-month interest period, plus in each case 325 basis points. The interest rate margins applicable to the New Tranche B Term Loans are, at our option, either (a) the Eurodollar rate plus 325 basis points or (b) a base rate plus 325 basis points. There is a minimum LIBOR rate applicable to the Eurodollar component of interest rates on New Tranche B Term Loans of 1.00%. The applicable margin for borrowings under the senior secured revolving credit facilities may be reduced, subject to our attaining certain leverage ratios. As of December 31, 2014, our weighted average interest rate for all borrowings under the senior secured credit facilities was 4.23%.
	Fees. In addition to paying interest on outstanding principal under the senior secured credit facilities, we are required to pay a commitment fee to the lenders under the senior secured revolving credit facilities with respect to the unutilized commitments thereunder. The current commitment fee rate is 0.50% per annum, subject to step-downs based upon the achievement of certain leverage ratios. We must also pay customary letter of credit fees.
	Principal Payments. We are required to pay annual payments in equal quarterly installments on the New Tranche B Term Loans in an amount equal to 1.00% of the funded total principal amount through June 2017, with any remaining amount payable in full at maturity in September 2017.
	Prepayments. The senior secured credit facilities require us to prepay outstanding term loans, subject to certain exceptions, with (1) 50% (which percentage can be reduced to 25% or 0% upon our attaining certain leverage ratios) of our annual excess cash flow, as defined in the credit agreement relating to the senior secured credit facilities (such agreement, the “Credit Agreement”); (2) 100% of the net cash proceeds above an annual amount of $25.0 million from non-ordinary course asset sales (including insurance and condemnation proceeds) by us and our restricted subsidiaries, subject to certain exceptions, including a 100% reinvestment right if reinvested or committed to be reinvested within 15 months of such asset sale or disposition so long as such reinvestment is completed within 180 days thereafter; and (3) 100% of the net cash proceeds from the issuance or incurrence of debt by us and our restricted subsidiaries, other than proceeds from debt permitted to be incurred under the senior secured credit facilities and related amendments. Any mandatory prepayments are applied to the term loan facility in direct order of maturity. We were not required to make any such prepayments in the year ended December 31, 2014.
	Subject to certain exceptions, voluntary prepayments of the New Tranche B Term Loans within one year of the effective date of the Amendment are subject to a 1.0% “soft call” premium, while other voluntary prepayments of outstanding loans under the senior secured credit facilities may be made at any time without premium or penalty, provided that voluntary prepayments of Eurodollar loans made on a date other than the last day of an interest period applicable thereto shall be subject to customary breakage costs.
	Guarantee and Security. All obligations under the senior secured credit facilities are unconditionally guaranteed by DJO Holdings LLC (“DJO Holdings”) and each of our existing and future direct and indirect wholly-owned domestic subsidiaries other than immaterial subsidiaries, unrestricted subsidiaries and subsidiaries that are precluded by law or regulation from guaranteeing the obligations (collectively, the “Guarantors”).
	All obligations under the senior secured credit facilities, and the guarantees of those obligations, are secured by pledges of 100% of our capital stock, 100% of the capital stock of each wholly-owned domestic subsidiary and 65% of the capital stock of each wholly owned foreign subsidiary that is, in each case, directly owned by us or one of the Guarantors, and a security interest in, and mortgages on, substantially all tangible and intangible assets of DJO Holdings, DJOFL and each Guarantor.
	Certain Covenants and Events of Default. The senior secured credit facilities contain a number of covenants that, among other things, restrict, subject to certain exceptions, our and our subsidiaries’ ability to:
		•		incur additional indebtedness;
		•		create liens on assets;
		•		change fiscal years;
		•		enter into sale and leaseback transactions;
		•		engage in mergers or consolidations;
		•		sell assets;
		•		pay dividends and other restricted payments;
		•		make investments, loans or advances;
		•		repay subordinated indebtedness;
		•		make certain acquisitions;
		•		engage in certain transactions with affiliates;
		•		restrict the ability of restricted subsidiaries that are not Guarantors to pay dividends or make distributions;
		•		amend material agreements governing our subordinated indebtedness; and
		•		change our lines of business.
	In addition, the senior secured credit facilities require us to maintain a maximum senior secured first lien leverage ratio of consolidated senior secured first lien debt to Adjusted EBITDA (as defined in the Credit Agreement) of 4.75:1 for the trailing twelve months ended December 31, 2014. The senior secured credit facilities also contain certain customary affirmative covenants and events of default. As of December 31, 2014, our actual senior secured first lien net leverage ratio was 3.08:1, and we were in compliance with all other applicable covenants.
	8.75% Second Priority Senior Secured Notes
	On March 20, 2012 and October 1, 2012, we issued $330.0 million aggregate principal amount of 8.75% second priority senior secured notes (8.75% Notes) maturing on March 15, 2018. The 8.75% Notes are guaranteed jointly and severally and on a senior secured basis by each of DJOFL’s existing and future direct and indirect wholly-owned domestic subsidiaries that guarantee any of DJOFL’s indebtedness, or any indebtedness of DJOFL’s domestic subsidiaries, or is an obligor under the senior secured credit facilities.
	Pursuant to a second lien security agreement, the 8.75% Notes are secured by second priority liens, subject to permitted liens, on certain of our assets that secure borrowings under the senior secured credit facilities.
	As of December 31, 2014, the market value of the 8.75% Notes was $344.0 million. We determined market value using trading prices for the 8.75% Notes on or near that date. This fair value measurement is categorized within Level 2 of the fair value hierarchy.
	Optional Redemption. Under the agreement governing the 8.75% Notes (8.75% Indenture), prior to March 15, 2015, we have the option to redeem some or all of the 8.75% Notes for cash at a redemption price equal to 100% of the then outstanding principal balance plus an applicable make-whole premium, plus accrued and unpaid interest. Beginning on March 15, 2015, we may redeem some or all of the 8.75% Notes at a redemption price of 104.375% of the then outstanding principal balance, plus accrued and unpaid interest. The redemption price decreases to 102.188% and 100% of the then outstanding principal balance at March 15, 2016 and 2017, respectively, plus accrued and unpaid interest. Additionally, from time to time, before March 15, 2015, we may redeem up to 35% of the 8.75% Notes at a redemption price equal to 108.75% of the then outstanding principal balance, plus accrued and unpaid interest, in each case, with proceeds we raise, or a direct or indirect parent company raises, in certain offerings of equity of DJOFL or its direct or indirect parent companies, as long as at least 65% of the aggregate principal amount of the 8.75% Notes issued remains outstanding.
	9.875% Senior Unsecured Notes
	On October 1, 2012, we issued $440.0 million aggregate principal amount of new 9.875% senior unsecured notes (9.875% Notes) maturing on April 15, 2018. The 9.875% Notes are guaranteed jointly and severally and on an unsecured senior basis by each of DJOFL’s existing and future direct and indirect wholly owned domestic subsidiaries that guarantee any of DJOFL’s indebtedness or any indebtedness of DJOFL’s domestic subsidiaries or is an obligor under DJOFL’s senior secured credit facilities.
	As of December 31, 2014, the market value of the 9.875% Notes was $442.2 million. We determined market value using trading prices for the 9.875% Notes on or near that date. This fair value measurement is categorized within Level 2 of the fair value hierarchy.
	Optional Redemption. Under the agreement governing the 9.875% Notes (the 9.875% Indenture), prior to April 15, 2015, we have the option to redeem some or all of the 9.875% Notes for cash at a redemption price equal to 100% of the then outstanding principal balance plus an applicable make-whole premium plus accrued and unpaid interest. Beginning on April 15, 2015, we may redeem some or all of the 9.875% Notes at a redemption price of 104.938% of the then outstanding principal balance plus accrued and unpaid interest. The redemption price decreases to 102.469% and 100% of the then outstanding principal balance at April 2016 and 2017, respectively. Additionally, from time to time, before April 15, 2015, we may redeem up to 35% of the 9.875% Notes at a redemption price equal to 109.875% of the principal amount then outstanding, plus accrued and unpaid interest, in each case, with proceeds we raise, or a direct or indirect parent company raises, in certain offerings of equity of DJOFL or its direct or indirect parent companies, as long as at least 65% of the aggregate principal amount of the 9.875% Notes issued remains outstanding.
	7.75% Senior Unsecured Notes
	On April 7, 2011, we issued $300.0 million aggregate principal amount of 7.75% senior unsecured notes (7.75% Notes) maturing on April 15, 2018. The 7.75% Notes are guaranteed jointly and severally and on a senior unsecured basis by each of DJOFL’s existing and future direct and indirect wholly-owned domestic subsidiaries that guarantee any of DJOFL’s indebtedness, or any indebtedness of DJOFL’s domestic subsidiaries, or is an obligor under the senior secured credit facilities.
	As of December 31, 2014, the market value of the 7.75% Notes was $286.5 million. We determined market value using trading prices for the 7.75% Notes on or near that date. This fair value measurement is categorized within Level 2 of the fair value hierarchy.
	Optional Redemption. Under the agreement governing the 7.75% Notes (the 7.75% Indenture), prior to April 15, 2014, we have the option to redeem some or all of the 7.75% Notes for cash at a redemption price equal to 100% of the then outstanding principal balance plus an applicable make-whole premium plus accrued and unpaid interest. As of April 15, 2014, we were able to redeem some or all of the 7.75% Notes at a redemption price of 105.813% of the then outstanding principal balance plus accrued and unpaid interest. The redemption price decreases to 103.875%, 101.938% and 100% of the then outstanding principal balance at April 15, 2015, 2016 and 2017, respectively.
	9.75% Senior Subordinated Notes
	On October 18, 2010, we issued $300.0 million aggregate principal amount of 9.75% senior subordinated notes (9.75% Notes) maturing on October 15, 2017. The 9.75% Notes are guaranteed jointly and severally and on an unsecured senior basis by each of DJOFL’s existing and future direct and indirect wholly-owned domestic subsidiaries that guarantee any of DJOFL’s indebtedness, or any indebtedness of DJOFL’s domestic subsidiaries, or is an obligor under the senior secured credit facilities.
	As of December 31, 2014, the market value of the 9.75% Notes was $294.0 million. We determined market value using trading prices for the 9.75% Notes on or near that date. This fair value measurement is categorized within Level 2 of the fair value hierarchy.
	Optional Redemption. Under the agreement governing the 9.75% Notes (the 9.75% Indenture), prior to October 15, 2013, we have the option to redeem some or all of the 9.75% Notes for cash at a redemption price equal to 100% of the then outstanding principal balance plus an applicable make-whole premium, plus accrued and unpaid interest. As of October 15, 2014, we were able to redeem some or all of the 9.75% Notes at a redemption price 104.875% of the then outstanding principal balance, plus accrued and unpaid interest. The redemption price decreases to 102.438% and 100% of the then outstanding principal balance at October 15, 2015 and 2016, respectively.
	Change of Control
	Upon the occurrence of a change of control, unless DJOFL has previously sent or concurrently sends a notice exercising its optional redemption rights with respect to its 8.75% Notes, 9.875% Notes, 7.75% Notes, and 9.75% Notes (collectively, the Notes), DJOFL will be required to make an offer to repurchase all of the Notes at 101% of the then outstanding principal balance, plus accrued and unpaid interest.
Covenants
The 8.75% Indenture, the 9.75% Indenture, the 9.875% Indenture and the 7.75% Indenture (collectively, the Indentures) each contain covenants limiting, among other things, our and our restricted subsidiaries’ ability to (i) incur additional indebtedness or issue certain preferred and convertible shares, pay dividends on, redeem, repurchase or make distributions in respect of the capital stock of DJO or make other restricted payments, (ii) make certain investments, (iii) sell certain assets, (iv) create liens on certain assets to secure debt, (v) consolidate, merge, sell or otherwise dispose of all or substantially all of our assets, (vi) enter into certain transactions with affiliates, or (vii) designate our subsidiaries as unrestricted subsidiaries. As of December 31, 2014, we were in compliance with all applicable covenants.
Our ability to continue to meet the covenants related to our indebtedness specified above in future periods will depend, in part, on events beyond our control, and we may not continue to meet those covenants. A breach of any of these covenants in the future could result in a default under the Agreement or the Indentures, at which time the lenders could elect to declare all amounts outstanding under the senior secured credit facilities to be immediately due and payable. Any such acceleration would also result in a default under the Indentures.
At December 31, 2014, the aggregate amounts of annual principal maturities of long-term debt for the next five years and thereafter are as follows (in thousands):
Years Ending December 31,
2015		$	8,975
2016			8,912
2017			1,183,736
2018			1,070,000
2019			—
		$	2,271,623
Loss on Modification and Extinguishment of Debt
During the year ended December 31, 2014, we recognized a loss on modification and extinguishment of debt of $0.9 million. The loss consists of $0.3 million of arrangement and amendment fees and other fees and expenses incurred in connection with the amendment of our senior secured credit facilities and $0.6 million related to the non-cash write off of unamortized debt issuance costs and original issue discount associated with the portion of our original term loans which were extinguished.
During the year ended December 31, 2013, we recognized a loss on modification and extinguishment of debt of $1.1 million. The loss consists of $0.9 million of arrangement and amendment fees and other fees and expenses incurred in connection with the amendment of our senior secured credit facilities and $0.2 million related to the non-cash write off of unamortized debt issuance costs and original issue discount associated with the portion of our original term loans which were extinguished.
Debt Issuance Costs
As of December 31, 2014 and December 31, 2013, we had $28.6 million and $35.7 million, respectively, of unamortized debt issuance costs, which are included in Other assets in our Consolidated Balance Sheets. For each of the years ended December 31, 2014 and 2013, we capitalized $1.5 million of debt issuance costs incurred in connection with the amendment of our senior secured credit facilities.
For the years ended December 31, 2014, 2013 and 2012 amortization of debt issuance costs was $8.1 million, $7.3 million and $8.9 million, respectively. Amortization of debt issuance costs was included in Interest expense in our Consolidated Statements of Operations for each of the periods presented.

MEMBERSHIP_DEFICIT

MEMBERSHIP DEFICIT	12 Months Ended
	Dec. 31, 2014
MEMBERSHIP DEFICIT	13. MEMBERSHIP DEFICIT
	During the year ended December 31, 2014, DJO issued 115,693 shares of its common stock upon the net exercise of vested stock options that had been granted to two former members of DJO’s Board of Directors in 2006 and to employees in 2007 in exchange for options that had previously been granted in the predecessor company to DJO (“Rollover Options”). Our stock incentive plan permits participants to exercise stock options using a net exercise method. In a net exercise, we withhold from the total number of shares that otherwise would be issued to a participant upon exercise of the stock option such number of shares having a fair market value at the time of exercise equal to the aggregate option exercise price and applicable income tax withholdings, and remit the remaining shares to the participant. The two former directors and employees exercised these Rollover Options for a total of 507,088 shares of DJO’s common stock, from which we withheld 391,395 shares to cover $6.5 million of aggregate option exercise price and income tax withholdings and issued the remaining 115,693 shares.
	Additionally, during the year ended December 31, 2014, DJO issued 6,447 shares of its common stock upon the exercise of stock options. Net proceeds from the share sales were contributed by DJO to us, and are included in Member capital in our Consolidated Balance Sheet as of December 31, 2014.
	During the year ended December 31, 2013, DJO issued 72,151 shares of common stock upon the net exercise of Rollover Options. During the year ended December 31, 2013, the net exercise method was employed by the participants to exercise Rollover Options to acquire 221,057 shares of our common stock; we withheld 148,906 of the shares subject to the Rollover Options to cover $2.5 million of aggregate option exercise price and income tax withholdings and issued the remaining 72,151 shares to the participants.
	Additionally, during the year ended December 31, 2013, we entered into an agreement to repurchase Rollover Options from our former chief financial officer, upon her departure, which cancelled vested Rollover Options for 313,681 shares of common stock held by her. The $2.0 million amount to be paid represents the excess of the fair market value of the shares over the exercise price of the options. This amount is included as a reduction to Member capital in our Consolidated Balance Sheet as of December 31, 2013.
	During the year ended December 31, 2012, DJO sold 121,506 shares of its common stock at $16.46 per share, consisting of 60,753 shares purchased by the new Chairman of its Board of Directors, and 60,753 shares purchased by another new member of the Board of Directors. Additionally, DJO issued 18,622 shares of its common stock upon the exercise of stock options. Net proceeds of $2.0 million from the share sales were contributed by DJO to us, and are included in Member capital in our Consolidated Balance Sheet as of December 31, 2012.
	The proceeds from the DJO sales of shares were used for working capital purposes. All such sales were subject to execution of a stockholder agreement including certain rights and restrictions (See Note 17).

STOCK_OPTION_PLANS_AND_STOCKBA

STOCK OPTION PLANS AND STOCK-BASED COMPENSATION	12 Months Ended
	Dec. 31, 2014
STOCK OPTION PLANS AND STOCK-BASED COMPENSATION	14. STOCK OPTION PLANS AND STOCK-BASED COMPENSATION
	Stock Option Plan
	We have one active equity compensation plan, the DJO 2007 Incentive Stock Plan (2007 Plan) under which we are authorized to grant awards of restricted and unrestricted stock, options, and other stock-based awards based on the shares of common stock of our indirect parent, DJO, subject to adjustment in certain events. The total number of shares available to grant under the 2007 plan is 10,575,529.
	Options issued under the 2007 Plan can be either incentive stock options or non-qualified stock options. The exercise price of stock options granted will not be less than 100% of the fair market value of the underlying shares on the date of grant and will expire no more than ten years from the date of grant.
	Options granted prior to 2012 vest as follows: one-third of each stock option grant vests over a specified period of time contingent solely upon the awardees’ continued employment with us (Time-Based Options). Another one-third of each stock option grant will vest upon achieving a minimum return of money on invested capital (MOIC), as defined, with respect to Blackstone’s aggregate investment in DJO’s capital stock, to be achieved by Blackstone following a liquidation of all or a portion of its investment in DJO’s capital stock (Market Return Options). The final one-third of each stock option grant will vest based upon achieving an increased minimum return of MOIC, as defined, with respect to Blackstone’s aggregate investment in DJO’s capital stock, to be achieved by Blackstone following a liquidation of all or a portion of its investment in DJO’s capital stock (Enhanced Market Return Options).
	Options granted to employees in 2012 vest in four equal installments beginning in 2012 and for each of the three calendar years following 2012, with each such installment vesting only if the final reported financial results for such year show that the Adjusted EBITDA for such year equaled or exceeded the Adjusted EBITDA amount in the financial plan approved by DJO’s Board of Directors for such year (Performance Options). In the event that the Adjusted EBITDA in any of such four years falls short of the amount of Adjusted EBITDA in the financial plan for that year, the installment that did not therefore vest at the end of such year shall be eligible for subsequent vesting at the end of the four year vesting period if the cumulative Adjusted EBITDA for such four years equals or exceeds the cumulative Adjusted EBITDA in the financial plans for such four years and the Adjusted EBITDA in the fourth vesting year equals or exceeds the Adjusted EBITDA in the financial plan for such year. In addition, in the event Blackstone achieves a minimum return of MOIC with respect to Blackstone’s aggregate investment in DJO’s capital stock following a liquidation of all or a portion of its investment in DJO’s capital stock, any unvested installments from prior years and all installments for future years shall thereupon vest.
	In February 2013, 310,000 options previously granted to new employees in 2012 were amended to convert one-third of such options into Time-Based Options, with the remaining two-thirds continuing to be Performance Options. Additionally, all 2012 Performance Options were amended to allow for vesting of the 2012 Adjusted EBITDA tranche if the 2013 Adjusted EBITDA results equal or exceed an enhanced amount of Adjusted EBITDA over the amount reflected in the 2013 financial plan. Options granted in 2013 and 2014 to existing employees had the same terms as the Performance Options described above and options granted to new employees in 2013 and 2014 had the same terms as the options amended in February 2013.
	In December 2013 and December 2014, options were granted to employees following the net exercise of their Rollover Options which were scheduled to expire in December 2013 and December 2014, respectively. These new options were fully vested on the date of grant and have a term of ten years (“Vested Options”).
	In February 2014, all 2012 and 2013 Performance Options were amended to allow for vesting of the 2012 and 2013 Adjusted EBITDA tranches if the 2014 Adjusted EBITDA results equal or exceed an enhanced amount of Adjusted EBITDA reflected in the 2014 financial plan.
	Except for options granted to the Chairman of the Board and two other board members as described below, options are typically granted annually to members of our Board of Directors who are not affiliates of Blackstone (referred to as Director Service Options). The Director Service Options vest in increments of 33 1/3% per year on each of the first through third anniversary dates of the grant date, contingent upon the optionee’s continued service as a director. The options granted to the Chairman of the Board and the two other board members vest as follows: one-third of the stock option grant vests in increments of 33 1/3% per year on each of the first through third anniversary dates from the grant date contingent upon the optionee’s continued service as a director; one-third of the stock option grant will vest in the same manner as the Market Return Options; and one-third of the stock option grant will vest in the same manner as the Enhanced Market Return Options.
	Stock-Based Compensation
	During the year ended December 31, 2014, the compensation committee granted 1,747,268 options to employees, of which 1,221,162 were Performance Options, 498,338 were Time-Based Options and 27,768 were Vested Options. The weighted average grant date fair values of the Time-Based Options and the Vested Options granted during the year ended December 31, 2014 were $6.05 and $5.28, respectively.
	During the year ended December 31, 2013, the compensation committee granted 1,082,397 options to employees, of which 768,677 were Performance Options, 243,323 were Time-Based Options and 70,397 were 2013 Vested Options. Additionally, the compensation committee granted 100,000 options to one board member and 13,800 Director Service Options to certain members of the Board of Directors. The weighted average grant date fair values of the Time-Based Options, the 2013 Vested Options and the Director Service Options granted during the year ended December 31, 2013 were $5.99, $5.23 and $6.02, respectively.
	During the year ended December 31, 2012, we granted 2,482,100 Performance Options to employees, 303,767 options to DJO’s Chairman of the Board, 100,000 to one other board member, and 18,400 Director Service Options to certain members of our Board of Directors. The weighted average grant date fair value of the Performance Options and the Director Service Options granted during the year ended December 31, 2012 was $6.09.
	The fair value of each option award is estimated on the date of grant, or modification, using the Black-Scholes option pricing model for service based awards, and a binomial model for market based awards. In estimating fair value for options issued under the 2007 Plan, expected volatility was based on historical volatility of comparable publicly-traded companies. As our historical share option exercise experience does not provide a reasonable basis upon which to estimate the expected term, we used the simplified method. Expected life is calculated in two tranches based on the employment level defined as executive or employee. The risk-free rate used in calculating fair value of stock options for periods within the expected term of the option is based on the U.S. Treasury yield bond curve in effect on the date of grant.
	The following table summarizes certain assumptions we used to estimate the fair value of the Time-Based Options, the Vested Options and the Director Service Options of stock options granted during the years ended December 31, 2014, 2013, and 2012:
		Year Ended December 31,
		2014			2013			2012
	Expected volatility		31.7-33.4	%		33.4-35.1	%		35.3-37.7	%
	Risk-free interest rate		1.7-2.2	%		0.7-2.0	%		0.8-1.5	%
	Expected term until exercise		5.0-6.4			5.0-6.3			6.1-6.2
	Expected dividend yield		0	%		0	%		0	%
	We recorded non-cash stock-based compensation expense during the periods presented as follows (in thousands):
		Year Ended December 31,
		2014			2013			2012
	Cost of goods sold	$	82		$	52		$	78
	Operating expenses:
	Selling, general and administrative		1,782			2,049			2,206
	Research and development		5			54			55
		$	1,869		$	2,155		$	2,339
	We have determined that it is not probable that we will meet the Adjusted EBITDA targets related to the Performance Options granted. As such, we did not recognize expense for any of the options which had the potential to vest in 2014. Additionally, we have not recognized expense for any of the options which have the potential to vest based on Adjusted EBITDA for 2015, 2016 and 2017, as some of these targets have not yet been established and we are unable to assess the probability of achieving such targets. Accordingly, we recognized stock-based compensation expense only for the Time-Based Options, the Vested Options and the Director Service Options granted in 2013 or 2014.
	In each of the periods presented above, for the options granted prior to 2012, we recognized stock-based compensation expense only for Time-Based Options granted to employees, as the performance components of the Market Return and Enhanced Market Return Options are not deemed probable at this time.
	Stock based compensation expense for options granted to non-employees was not significant to the Company for all periods presented, and was included in Selling, general and administrative expense in our Consolidated Statements of Operations.
	A summary of option activity under the 2007 Plan is presented below:
		Number of			Weighted-			Weighted-			Aggregate
		Shares			Average			Average			Intrinsic
					Exercise Price			Remaining			Value
								Contractual Term
								(Years)
	Outstanding at December 31, 2013		9,017,290		$	15.79			6.1		$	6,133,210
	Granted		1,747,268		$	16.46
	Exercised		(513,535	)	$	10.89
	Forfeited or expired		(1,011,857	)	$	16.44
	Outstanding at December 31, 2014		9,239,166		$	16.11			6.3		$	3,197,576
	Vested or expected to vest at December 31, 2014		5,793,957		$	15.91			5.5		$	3,197,576
	Exercisable at December 31, 2014		2,496,422		$	15.18			3.6		$	3,197,576
	The Company’s stock incentive plan permits optionees to exercise stock options using a net exercise method. In a net exercise, the Company withholds from the total number of shares that otherwise would be issued to an optionee upon exercise of the stock option such number of shares having a fair market value at the time of exercise equal to the option exercise price and applicable income tax withholdings and remits the remaining shares to the optionee.
	The following table provides information regarding the use of the net exercise method during the periods presented:
		Year Ended December 31,
		2014			2013
	Options exercised		507,088			221,057
	Shares withheld		391,395			148,906
	Shares issued		115,693			72,151
	Average market value per share withheld	$	16.46		$	16.46
	Aggregate market value of shares withheld (in thousands)	$	6,442		$	2,451
	As of December 31, 2014, total unrecognized stock-based compensation expense related to unvested stock options granted under the 2007 Plan, excluding options subject to the performance components of the Market Return and Enhanced Market Return Options, was $2.0 million, net of expected forfeitures. We anticipate this expense to be recognized over a weighted-average period of approximately four years. Compensation expense associated with the Market Return and Enhanced Market Return Options granted under the 2007 Plan, with the exception of those that were issued in connection with a modification, will be recognized only to the extent achievement of the performance components are deemed probable.

INCOME_TAXES

INCOME TAXES	12 Months Ended
	Dec. 31, 2014
INCOME TAXES	15. INCOME TAXES
	The components of loss before income tax provision (benefit) consist of the following (in thousands):
		Year Ended December 31,
		2014			2013			2012
	U.S. operations	$	(94,111	)	$	(206,769	)	$	(137,268	)
	Foreign operations		17,439			17,323			13,996
		$	(76,672	)	$	(189,446	)	$	(123,272	)
	The income tax provision (benefit) consists of the following (in thousands):
		Year Ended December 31,
		2014			2013			2012
	Current income taxes:
	U.S. federal	$	(309	)	$	1,135		$	(1,205	)
	U.S. state		852			870			1,347
	Foreign		5,989			6,373			6,330
	Total current income taxes		6,532			8,378			6,472
	Deferred income taxes:
	U.S. federal		8,676			7,460			(3,558	)
	U.S. state		(307	)		(2,154	)		(5,751	)
	Foreign		(2,011	)		(568	)		(2,067	)
	Total deferred income taxes		6,358			4,738			(11,376	)
	Total income tax provision (benefit)	$	12,890		$	13,116		$	(4,904	)
	The difference between the income tax provision (benefit) derived by applying the U.S. federal statutory income tax rate of 35% and the recognized income tax provision (benefit) is as follows (in thousands):
		Year Ended December 31,
		2014			2013			2012
	Income tax provision (benefit) derived by applying the U.S. federal statutory income tax rate to loss before income taxes	$	(26,835	)	$	(66,306	)	$	(43,145	)
	Add (deduct) the effect of:
	State tax benefit, net		(2,476	)		(3,323	)		(4,275	)
	Change in state effective tax rates		(722	)		(992	)		(639	)
	Foreign earnings repatriation		(1,646	)		2,678			3,199
	Unrecognized tax benefits		949			2,216			(7,723	)
	Goodwill impairment		—			33,687			—
	Prepaid tax asset impairment		(1	)		229			5,479
	Valuation allowance		40,692			50,516			38,845
	Research tax credit		(618	)		(1,249	)		—
	Equity compensation benefit		—			(2,864	)		—
	Permanent differences and other, net		3,547			(1,476	)		3,355
		$	12,890		$	13,116		$	(4,904	)
	The components of deferred income tax assets and liabilities are as follows (in thousands):
		December 31,			December 31,
		2014			2013
	Deferred tax assets:
	Net operating loss carryforwards	$	214,319		$	202,387
	Receivables reserve		26,709			23,878
	Other		39,284			38,766
	Gross deferred tax assets		280,312			265,031
	Valuation allowance		(137,520	)		(94,741	)
	Net deferred tax assets		142,792			170,290
	Deferred tax liabilities:
	Intangible assets		(343,370	)		(362,950	)
	Foreign earnings repatriation		(13,012	)		(14,092	)
	Other		(3,987	)		(7,038	)
	Gross deferred tax liabilities		(360,369	)		(384,080	)
	Net deferred tax liabilities	$	(217,577	)	$	(213,790	)
	At December 31, 2014, we maintain federal and state net operating loss carryforwards of $563.1 million and $336.5 million respectively, which expire over a period of 1 to 20 years. Our foreign net operating loss carryforwards of $2.8 million generally are not subject to expiration dates, unless we trigger certain events.
	At December 31, 2014 and 2013 we had gross deferred tax assets of $280.3 million and $265.0 million, respectively, which we reduced by valuation allowances of $137.5 million and $94.7 million, respectively.
	We do not intend to permanently reinvest the earnings of foreign operations. Accordingly, we recorded a deferred tax (income) expense of $(0.6) million, $1.8 million and $2.5 million for the years ended December 31, 2014, 2013 and 2012, respectively, for unrepatriated foreign earnings in those years.
	We file income tax returns in U.S. federal, state and foreign jurisdictions. With few exceptions, we are no longer subject to income tax examinations by tax authorities for years before 2009.
	A reconciliation of the beginning and ending amount of gross unrecognized tax benefits is as follows (in thousands):
		Year Ended December 31,
		2014			2013			2012
	Balance, beginning of year	$	14,469		$	12,342		$	19,443
	Additions based on tax positions related to current year		1,502			1,531			817
	Additions for tax positions related to prior years		354			975			892
	Reductions for tax positions of prior years		—			—			—
Reduction due to lapse of statute of limitations		(709	)		(379	)		(990	)
Reductions for settlements of tax positions		(1,711	)		—			(7,820	)
Balance, end of year	$	13,905		$	14,469		$	12,342
To the extent all or a portion of our gross unrecognized tax benefits are recognized in the future, no U.S. federal tax benefit for related state income tax deductions would result due to the existence of a U.S. federal valuation allowance. We anticipate that approximately $0.6 million of uncertain tax positions, each of which are individually immaterial, will decrease in the next twelve months due to the expiration of the statutes of limitations. We have various unrecognized tax benefits totaling approximately $5.2 million, which, if recognized, would impact our effective tax rate in future periods. We recognized interest and penalties of $0.4 million, $0.5 million and $0.3 million in the years ended December 31, 2014, 2013 and 2012, respectively, which was included as a component of income tax benefit in our Consolidated Statements of Operations. As of December 31, 2014 and 2013, we have $2.3 million and $2.6 million, respectively, accrued for interest and penalties.

COMMITMENTS_AND_CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	12 Months Ended
	Dec. 31, 2014
COMMITMENTS AND CONTINGENCIES	16. COMMITMENTS AND CONTINGENCIES
	Operating Leases. We lease building space, manufacturing facilities and equipment under non-cancelable operating lease agreements that expire at various dates. We record rent incentives as deferred rent and amortize as reductions to lease expense over the lease term. The aggregate minimum rental commitments under non-cancelable leases for the next five years and thereafter, as of December 31, 2014, are as follows (in thousands):
	Years Ending December 31,
	2015	$	17,374
	2016		15,645
	2017		9,698
	2018		8,966
	2019		7,352
	Thereafter		14,219
		$	73,254
	Rental expense under operating leases totaled $17.4 million, $17.6 million, and $16.4 million for the years ended December 31, 2014, 2013, and 2012, respectively. Scheduled increases in rent expense are amortized on a straight line basis over the life of the lease.
	Pain Pump Litigation
	Over the past 7 years, we have been named in numerous product liability lawsuits involving our prior distribution of a disposable drug infusion pump product (pain pump) manufactured by two third-party manufacturers that was distributed through our Bracing and Vascular segment. We currently are a defendant in two U.S. cases and a lawsuit in Canada which has been granted class action status for a class of approximately 45 claimants. We discontinued our sale of these products in the second quarter of 2009. These cases have been brought against the manufacturers and certain distributors of these pumps. All of these lawsuits allege that the use of these pumps with certain anesthetics for prolonged periods after certain shoulder surgeries or, less commonly, knee surgeries, has resulted in cartilage damage to the plaintiffs. In the past four years, we have entered into settlements with plaintiffs in approximately 140 pain pump lawsuits. Except for the payment by the Company of policy deductibles or self-insured retentions, our products liability carriers in three policy periods have paid the defense costs and settlements related to these claims, subject to reservation of rights to deny coverage for customary matters, including punitive damages and off-label promotion. The range of potential loss for these claims is not estimable, although we believe we have adequate insurance coverage for such claims. As of December 31, 2014, we have accrued $0.7 million for unpaid settlements in this case, and a corresponding receivable as all of the settlements will be paid by our product liability carriers.
	Lawsuit by Insurance Carrier
	In December 2013, one of our product liability insurance carriers, Ironshore Specialty Ins. Co. filed a complaint in the U.S. District Court for the Southern District of California, which seeks (a) either (i) rescission of an insurance policy (the “Policy”) purchased by the Company from the plaintiff and repayment by the Company of all amounts allegedly paid under the Policy, approximately $10 million, less premiums paid by the Company for the Policy, or, in the alternative, (ii) reformation of the Policy to exclude coverage for pain pump claims and repayment by the Company of all amounts allegedly paid under the Policy for such claims, in an unspecified amount; and/or (b) damages and other relief in an unspecified amount for alleged fraud and negligent misrepresentation based on an alleged failure by the Company and/or the involved Policy producers to disclose alleged material information while applying for the Policy. While we believe this case is without merit, we have brought third-party indemnification claims against our insurance broker and a wholesale broker who were involved in securing the Policy. The carrier under our directors and officers liability policy has agreed to reimburse defense costs incurred in this matter, subject to reservation of rights to deny coverage for customary matters. A tentative settlement has been reached in this case, which if completed will result in a dismissal of the lawsuit and complete resolution of this matter.
	Cold Therapy Litigation
	DJO was named in nine multi-plaintiff lawsuits involving a total of 172 plaintiffs which alleged that the plaintiffs had been injured following use of certain cold therapy products manufactured by DJO. The complaints alleged various product liability theories, including inadequate warnings regarding the risks associated with the use of cold therapy and failure to incorporate certain safety features into the design. No specific dollar amounts of damages were alleged in the complaints. These cases were included in a coordinated proceeding in San Diego Superior Court with a similar number of cases filed against one of our competitors. The first of these cases was tried and ended with a deadlocked jury, resulting in no verdict and a declaration of a mistrial; therefore, the range of potential loss for these claims was not estimable at that time. In October 2014, the company reached a settlement agreement with plaintiffs’ counsel that effectively resolves all of the claims. The settlement amount was paid by our product liability carriers. As such, there was no impact to the financial results.
	State Licensing Subpoenas
	In July 2013 and October 2014, we were served with subpoenas under the Health Insurance Portability and Accountability Act (HIPAA) seeking documents relating to the fitting of custom-fabricated or custom-fitted orthoses in the States of New Jersey, Washington and Texas. The subpoenas were issued by the United States Attorney’s Office for the District of New Jersey in connection with an investigation of compliance with professional licensing statutes in those states relating to the practice of orthotics. We responded to the first subpoena, and are in the process of responding to the second subpoena.
	BGS Qui Tam Action
	We are a defendant in a qui tam action filed in Federal Court in Boston, Massachusetts, captioned United States, ex rel. Bierman v. Orthofix International, N.V. et al., in which the relator, or whistleblower, names us and each other company engaged in the external bone growth stimulator industry as defendants. The case was filed under seal in March 2005 and unsealed in March 2009, during which time the government investigated the claims made by relator and decided not to intervene in the case. The government continued its investigation of DJO for several years following the unsealing of the case but did not ultimately bring any criminal or civil charges against us relating to the investigation. The relator alleges that the defendants have engaged in Medicare fraud and violated federal and state false claims acts from the time of the original introduction of the bone growth stimulation devices by each defendant to the present by seeking reimbursement for such devices as purchased items rather than rental items. The relator also alleges that the defendants are engaged in other marketing practices constituting violations of the federal and various state false claim and anti-kickback statutes. Orthofix International, N.V. has settled with both the government and the relator, and the case continues against the remaining defendants, with the relator pressing for discovery after years of inactivity on the case. While we believe the case against us has no merit, we can make no assurances as to the resources that will be needed to respond to this matter or the final outcome of the case.
	California Qui Tam Action
	On October 11, 2013, we were served with a summons and complaint related to a qui tam action filed in U.S. District Court in Los Angeles, California in August 2012 and amended in December 2012 that names us as a defendant along with each of the other companies that manufactures and sells external bone growth stimulators for spinal applications. The case is captioned United States of America, et al.ex re. Doris Modglin and Russ Milko, v. DJO Global, Inc., DJO, LLC, DJO Finance LLC, Orthofix, Inc., Biomet, Inc., and EBI, LP., Case No. CV12-7152-MMM (JCGx) (C.D. Cal.). The plaintiffs, or relators, allege that the defendants have violated federal and state false claim acts by seeking reimbursement for bone growth stimulators for uses outside of the FDA approved indications for use for such products. The plaintiffs are seeking treble damages alleged to have been sustained by the U.S. and the states, penalties and attorney’s fees and costs. The federal government and all of the named states have declined to intervene in this case. We filed a motion to dismiss the second amended complaint, which motion was granted with leave to amend. Relators then filed a third amended complaint and we filed a motion to dismiss the third amended complaint and that motion is pending. We believe that this lawsuit is without merit and intend to vigorously defend this case.

RELATED_PARTY_TRANSACTIONS

RELATED PARTY TRANSACTIONS	12 Months Ended
	Dec. 31, 2014
RELATED PARTY TRANSACTIONS	17. RELATED PARTY TRANSACTIONS
	Blackstone Management Partners LLC (BMP) has agreed to provide certain monitoring, advisory and consulting services to us for an annual monitoring fee equal to the greater of $7.0 million or 2% of consolidated EBITDA as defined in the Transaction and Monitoring Fee Agreement, payable in the first quarter of each year. The monitoring fee agreement will continue until the earlier of November 2019, or such date as DJO and BMP may mutually determine. DJO has agreed to indemnify BMP and its affiliates, directors, officers, employees, agents and representatives from and against all liabilities relating to the services contemplated by the Transaction and Monitoring Fee Agreement and the engagement of BMP pursuant to, and the performance of BMP and its affiliates of the services contemplated by, the Transaction and Monitoring Fee Agreement. At any time in connection with or in anticipation of a change of control of DJO, a sale of all or substantially all of DJO’s assets or an initial public offering of common stock of DJO, BMP may elect to receive, in lieu of remaining annual monitoring fee payments, a single lump sum cash payment equal to the then-present value of all then-current and future annual monitoring fees payable under the Transaction and Monitoring Fee Agreement, assuming a hypothetical termination date of the agreement to be November 2019. For each of the years presented, we expensed $7.0 million related to the annual monitoring fee, which is recorded as a component of Selling, general and administrative expense in the Consolidated Statements of Operations.

SEGMENT_AND_GEOGRAPHIC_INFORMA

SEGMENT AND GEOGRAPHIC INFORMATION	12 Months Ended
	Dec. 31, 2014
SEGMENT AND GEOGRAPHIC INFORMATION	18. SEGMENT AND GEOGRAPHIC INFORMATION
	For the years ended December 31, 2014, 2013 and 2012, we reported our business in four operating segments: Bracing and Vascular; Recovery Sciences; Surgical Implant and International.
	Bracing and Vascular Segment
	Our Bracing and Vascular segment, which generates its revenues in the United States, offers our rigid knee bracing products, orthopedic soft goods, cold therapy products, vascular systems, therapeutic shoes and inserts and compression therapy products, primarily under the DonJoy, ProCare, Aircast, Dr. Comfort, Bell-Horn and Exos brands. This segment also includes our OfficeCare channel, through which we maintain an inventory of soft goods and other products at healthcare facilities, primarily orthopedic practices, for immediate distribution to patients. The Bracing and Vascular segment primarily sells its products to orthopedic and sports medicine professionals, hospitals, podiatry practices, orthotic and prosthetic centers, home medical equipment providers and independent pharmacies. In 2014 we expanded our consumer channel to focus on marketing, selling and distributing our products, including bracing and vascular products, to professional and consumer retail customers and on-line. The bracing and vascular products sold through the channel will principally be sold under the DonJoy Performance, Bell-Horn and Doctor Comfort brands.
	Recovery Sciences Segment
	Our Recovery Sciences segment, which generates its revenues in the United States, is divided into four main channels:
		•		Empi. Our Empi channel offers our home electrotherapy, iontophoresis, and home traction products. We primarily sell these products directly to patients or to physical therapy clinics. For products sold to patients, we arrange billing to the patients and their third party payors.
		•		CMF. Our CMF channel sells our bone growth stimulation products. We sell these products either directly to patients or to independent distributors. For products sold to patients, we arrange billing to the patients and their third party payors.
		•		Chattanooga. Our Chattanooga channel offers products in the clinical rehabilitation market in the category of clinical electrotherapy devices, clinical traction devices, and other clinical products and supplies such as treatment tables, continuous passive motion (CPM) devices and dry heat therapy.
		•		Consumer. Our consumer channel offers professional and consumer retail customers our Compex electrostimulation device, which is used in training programs to aid muscle development and to accelerate muscle recovery after training sessions.
	Surgical Implant Segment
	Our Surgical Implant segment, which generates its revenues in the United States, develops, manufactures and markets a wide variety of knee, hip and shoulder implant products that serve the orthopedic reconstructive joint implant market.
	International Segment
	Our International segment, which generates most of its revenues in Europe, sells all of our products and certain third party products through a combination of direct sales representatives and independent distributors.
	Information regarding our reportable business segments is presented below (in thousands). Segment results exclude the impact of amortization and impairment of goodwill and intangible assets, certain general corporate expenses, and charges related to various integration activities, as defined by management. The accounting policies of the reportable segments are the same as the accounting policies of the Company. We allocate resources and evaluate the performance of segments based on net sales, gross profit, operating income and other non-GAAP measures, as defined in the senior secured credit facilities. We do not allocate assets to reportable segments because a significant portion of our assets are shared by the segments.
			Year Ended December 31,
			2014			2013			2012
	Net sales:
	Bracing and Vascular		$	504,590		$	476,492		$	444,444
	Recovery Sciences			299,122			312,783			331,461
	Surgical Implant			100,139			87,088			72,980
	International			325,315			299,094			280,535
			$	1,229,166		$	1,175,457		$	1,129,420
	Operating income (loss):
	Bracing and Vascular		$	102,933		$	86,447		$	87,694
	Recovery Sciences			84,322			83,028			90,353
	Surgical Implant			12,712			8,669			6,747
	International			62,304			57,515			54,442
	Expenses not allocated to segments and eliminations			(158,520	)		(245,217	)		(146,318	)
			$	103,751		$	(9,558	)	$	92,918
	Geographic Area
	Following are our net sales by geographic area (in thousands):
			Year Ended December 31,
			2014			2013			2012
	United States		$	903,851		$	876,363		$	848,885
	Other Europe, Middle East, and Africa			156,339			139,252			135,030
	Germany			91,754			88,236			84,527
	Australia and Asia Pacific			39,990			35,025			26,786
	Canada			26,481			27,035			24,588
	Latin America			10,751			9,546			9,604
			$	1,229,166		$	1,175,457		$	1,129,420
	Net sales are attributed to countries based on location of customer. In each of the years ended December 31, 2014, 2013 and 2012, no individual customer or distributor accounted for 10% or more of total annual net sales.
	Following are our long-lived assets by geographic area (in thousands):
			December 31,			December 31,
			2014			2013
	United States		$	136,490		$	130,498
	International			16,470			16,830
			$	152,960		$	147,328

UNAUDITED_QUARTERLY_CONSOLIDAT

UNAUDITED QUARTERLY CONSOLIDATED FINANCIAL DATA	12 Months Ended
	Dec. 31, 2014
UNAUDITED QUARTERLY CONSOLIDATED FINANCIAL DATA	19. UNAUDITED QUARTERLY CONSOLIDATED FINANCIAL DATA
	We operate our business on a manufacturing calendar, with our fiscal year always ending on December 31. Each quarter is 13 weeks, consisting of two four-week periods and one five-week period. Our first and fourth quarters may have more or fewer shipping days from year to year based on the days of the week on which holidays and December 31 fall.
	The following table presents our unaudited quarterly consolidated financial data (in thousands):
		Three months ended
		March 29,			June 28,			September 27,			December 31,
		2014			2014			2014			2014
	Net sales	$	282,744		$	313,867		$	305,501		$	327,054
	Operating income		10,202			25,521			26,861			41,167
	Net loss		(36,173	)		(25,207	)		(21,133	)		(7,049	)
	Net loss attributable to DJOFL		(36,522	)		(25,434	)		(21,206	)		(7,372	)
		Three months ended
		March 30,			June 29,			September 28,			December 31,
		2013			2013			2013			2013
	Net sales	$	279,077		$	294,745		$	288,049		$	313,586
	Operating income (loss)		19,793			26,423			25,375			(81,149	)
	Net loss		(32,126	)		(20,642	)		(18,375	)		(131,419	)
	Net loss attributable to DJOFL		(32,364	)		(20,814	)		(18,488	)		(131,786	)

SUPPLEMENTAL_GUARANTOR_CONDENS

SUPPLEMENTAL GUARANTOR CONDENSED CONSOLIDATING FINANCIAL STATEMENTS	12 Months Ended
	Dec. 31, 2014
SUPPLEMENTAL GUARANTOR CONDENSED CONSOLIDATING FINANCIAL STATEMENTS	20. SUPPLEMENTAL GUARANTOR CONDENSED CONSOLIDATING FINANCIAL STATEMENTS
	DJOFL and its direct wholly owned subsidiary, DJO Finco, jointly issued the 9.75% Notes, 7.75% Notes, 8.75% Notes and the 9.875% Notes. DJO Finco was formed solely to act as a co-issuer of the notes, has only nominal assets and does not conduct any operations. The Indentures generally prohibit DJO Finco from holding any assets, becoming liable for any obligations or engaging in any business activity.
	The 8.75% Notes are jointly and severally, fully and unconditionally guaranteed, on a senior secured basis by all of DJOFL’s domestic subsidiaries (other than the co-issuer) that are 100% owned, directly or indirectly, by DJOFL (the Guarantors). The 9.875% Notes and the 7.75% Notes are jointly and severally, fully and unconditionally guaranteed, on an unsecured senior basis by the Guarantors. The 9.75% Notes are jointly and severally, fully and unconditionally guaranteed, on an unsecured senior subordinated basis by the Guarantors. Our foreign subsidiaries (the Non-Guarantors) do not guarantee the notes.
	The following tables present the financial position, results of operations and cash flows of DJOFL, the Guarantors, the Non-Guarantors and certain eliminations for the periods presented.
	DJO Finance LLC
	Condensed Consolidating Balance Sheets
	As of December 31, 2014
	(in thousands)
		DJOFL			Guarantors			Non-Guarantors			Eliminations			Consolidated
	Assets
	Current assets:
	Cash and cash equivalents	$	12,958		$	3		$	18,183		$	—		$	31,144
	Accounts receivable, net		—			140,782			47,278			—			188,060
	Inventories, net		—			145,046			31,134			(840	)		175,340
	Deferred tax assets, net		—			24,351			247			—			24,598
	Prepaid expenses and other current assets		160			11,464			5,548			—			17,172
	Total current assets		13,118			321,646			102,390			(840	)		436,314
	Property and equipment, net		—			106,191			14,071			(155	)		120,107
	Goodwill		—			1,066,479			109,260			(34,551	)		1,141,188
	Intangible assets, net		—			853,023			15,008			—			868,031
	Investment in subsidiaries		1,297,699			1,686,557			56,572			(3,040,828	)		—
	Intercompany receivables		836,759			—			—			(836,759	)		—
	Other non-current assets		28,632			1,822			2,399			—			32,853
	Total assets	$	2,176,208		$	4,035,718		$	299,700		$	(3,913,133	)	$	2,598,493
	Liabilities and (Deficit) Equity
	Current liabilities:
	Accounts payable	$	—		$	50,590		$	12,370		$	—		$	62,960
	Current portion of debt obligations		8,912			—			63			—			8,975
	Other current liabilities		29,589			70,073			29,083			—			128,745
	Total current liabilities		38,501			120,663			41,516			—			200,680
	Long-term debt obligations		2,261,941			—			—			—			2,261,941
	Deferred tax liabilities, net		—			237,813			5,310			—			243,123
	Intercompany payables, net		—			552,612			135,833			(688,445	)		—
	Other long-term liabilities		—			12,243			2,122			—			14,365
	Total liabilities		2,300,442			923,331			184,781			(688,445	)		2,720,109
	Noncontrolling interests		—			—			2,618			—			2,618
	Total membership (deficit) equity		(124,234	)		3,112,387			112,301			(3,224,688	)		(124,234	)
	Total liabilities and (deficit) equity	$	2,176,208		$	4,035,718		$	299,700		$	(3,913,133	)	$	2,598,493
	DJO Finance LLC
	Condensed Consolidating Statements of Operations
	For the Year Ended December 31, 2014
	(in thousands)
		DJOFL			Guarantors			Non-			Eliminations			Consolidated
								Guarantors
	Net sales	$	—		$	1,059,241		$	318,849		$	(148,924	)	$	1,229,166
	Costs and operating expenses:
	Cost of sales (exclusive of amortization of intangible assets of $34,368)		—			433,692			230,721			(169,016	)		495,397
	Selling, general and administrative		—			398,491			100,714			—			499,205
	Research and development		—			33,525			4,245			(28	)		37,742
	Amortization of intangible assets		—			89,172			3,899			—			93,071
			—			954,880			339,579			(169,044	)		1,125,415
	Operating (loss) income		—			104,361			(20,730	)		20,120			103,751
	Other (expense) income:
	Interest (expense) income, net		(174,309	)		128			(110	)		—			(174,291	)
	Loss on modification of debt		(938	)		—			—			—			(938	)
	Other income (expense), net		—			(277	)		(4,917	)		—			(5,194	)
	Intercompany income (expense), net		—			(14,848	)		24,037			(9,189	)		—
	Equity in loss of subsidiaries, net		84,713			—			—			(84,713	)		—
			(90,534	)		(14,997	)		19,010			(93,902	)		(180,423	)
	(Loss) income before income taxes		(90,534	)		89,364			(1,720	)		(73,782	)		(76,672	)
	Income tax benefit (provision)		—			(8,638	)		(4,252	)		—			(12,890	)
	Net (loss) income		(90,534	)		80,726			(5,972	)		(73,782	)		(89,562	)
	Net income attributable to noncontrolling interests		—			—			(972	)		—			(972	)
	Net (loss) income attributable to DJOFL	$	(90,534	)	$	80,726		$	(6,944	)	$	(73,782	)	$	(90,534	)
DJO Finance LLC
Condensed Consolidating Statements of Comprehensive Loss
For the Year Ended December 31, 2014
(in thousands)
	DJOFL			Guarantors			Non-			Eliminations			Consolidated
							Guarantors
Net (loss) income	$	(90,534	)	$	80,726		$	(5,972	)	$	(73,782	)	$	(89,562	)
Other comprehensive income, net of taxes:
Foreign currency translation adjustments, net of tax benefit of $3,871		—			—			(13,167	)		—			(13,167	)
Other comprehensive income (loss)		—			—			(13,167	)		—			(13,167	)
Comprehensive (loss) income		(90,534	)		80,726			(19,139	)		(73,782	)		(102,729	)
Comprehensive income attributable to noncontrolling interests		—			—			(591	)		—			(591	)
Comprehensive (loss) income attributable to DJO Finance LLC	$	(90,534	)	$	80,726		$	(19,730	)	$	(73,782	)	$	(103,320	)
DJO Finance LLC
Condensed Consolidating Statements of Cash Flows
For the Year Ended December 31, 2014
(in thousands)
	DJOFL			Guarantors			Non-			Eliminations			Consolidated
							Guarantors
Cash Flows From Operating Activities:
Net (loss) income	$	(90,534	)	$	80,726		$	(5,972	)	$	(73,782	)	$	(89,562	)
Adjustments to reconcile net (loss) income to net cash (used in) provided by operating activities:
Depreciation		—			29,653			6,265			(179	)		35,739
Amortization of intangible assets		—			89,172			3,899			—			93,071
Amortization of debt issuance costs and non-cash interest expense		8,692			—			—			—			8,692
Loss on modification and extinguishment of debt		938			—			—			—			938
Stock-based compensation expense		—			1,869			—			—			1,869
(Gain) loss on disposal of assets, net		—			(948	)		105			—			(843	)
Deferred income tax expense (benefit)		—			8,450			(1,104	)		(988	)		6,358
Equity in loss of subsidiaries, net		(84,713	)		—			—			84,713			—
Changes in operating assets and liabilities, net of acquired assets and liabilities:
Accounts receivable		—			338			(7,609	)		—			(7,271	)
Inventories		—			(13,212	)		12,746			(20,065	)		(20,531	)
Prepaid expenses and other assets		—			6,504			4,851			(291	)		11,064
Accounts payable and other current liabilities		(83	)		3,376			1,618			2,052			6,963
Net cash (used in) provided by operating activities		(165,700	)		205,928			14,799			(8,540	)		46,487
Cash Flows From Investing Activities:
Cash paid in connection with acquisitions, net of cash acquired		—			—			(4,587	)		—			(4,587	)
Purchases of property and equipment		—			(46,321	)		(6,597	)		125			(52,793	)
Other investing activities, net		—			(676	)		(362	)		—			(1,038	)
Net cash (used in) provided by investing activities		—			(46,997	)		(11,546	)		125			(58,418	)
Cash Flows From Financing Activities:
Intercompany		149,870			(153,596	)		(4,687	)		8,413			—
Proceeds from issuance of debt		1,000,294			—			—			—			1,000,294
Repayments of debt obligations		(990,085	)		—			(134	)		—			(990,219	)
Payment of debt issuance, modification and extinguishment costs		(1,812	)		—			—			—			(1,812	)
Investment by parent		22			—			—			—			22
Payment of contingent consideration		—			(5,690	)		—			—			(5,690	)
Cancellation of vested options		(2,001	)		—			—			—			(2,001	)
Dividend paid by subsidiary to owners of noncontrolling interests		—			—			(617	)		—			(617	)
Net cash provided by (used in) financing activities		156,288			(159,286	)		(5,438	)		8,413			(23	)
Effect of exchange rate changes on cash and cash equivalents		—			—			(480	)		—			(480	)
Net decrease in cash and cash equivalents		(9,412	)		(355	)		(2,665	)		(2	)		(12,434	)
Cash and cash equivalents, beginning of year		22,370			358			20,848			2			43,578
Cash and cash equivalents, end of year	$	12,958		$	3		$	18,183		$	—		$	31,144
DJO Finance LLC
Condensed Consolidating Balance Sheets
As of December 31, 2013
(in thousands)
	DJOFL			Guarantors			Non-Guarantors			Eliminations			Consolidated
Assets
Current assets:
Cash and cash equivalents	$	22,370		$	358		$	20,848		$	2		$	43,578
Accounts receivable, net		—			141,121			43,967			—			185,088
Inventories, net		—			126,529			33,439			(4,985	)		154,983
Deferred tax assets, net		—			27,286			241			—			27,527
Prepaid expenses and other current assets		160			16,469			10,596			726			27,951
Total current assets		22,530			311,763			109,091			(4,257	)		439,127
Property and equipment, net		—			93,229			14,834			(234	)		107,829
Goodwill		—			1,066,479			121,998			(39,146	)		1,149,331
Intangible assets, net		—			941,550			17,443			—			958,993
Investment in subsidiaries		1,297,699			1,686,557			62,344			(3,046,600	)		—
Intercompany receivables		911,630			—			—			(911,630	)		—
Other non-current assets		35,675			1,828			1,996			—			39,499
Total assets	$	2,267,534		$	4,101,406		$	327,706		$	(4,001,867	)	$	2,694,779
Liabilities and (Deficit) Equity
Current liabilities:
Accounts payable	$	—		$	45,639		$	10,736		$	(1	)	$	56,374
Current portion of debt obligations		8,620			—			—			—			8,620
Other current liabilities		29,673			77,220			31,564			697			139,154
Total current liabilities		38,293			122,859			42,300			696			204,148
Long-term debt obligations		2,251,167			—			—			—			2,251,167
Deferred tax liabilities, net		—			236,230			5,798			—			242,028
Intercompany payables, net		—			693,513			143,637			(837,150	)		—
Other long-term liabilities		—			13,820			2,898			—			16,718
Total liabilities		2,289,460			1,066,422			194,633			(836,454	)		2,714,061
Noncontrolling interests		—			—			2,644			—			2,644
Total membership (deficit) equity		(21,926	)		3,034,984			130,429			(3,165,413	)		(21,926	)
Total liabilities and (deficit) equity	$	2,267,534		$	4,101,406		$	327,706		$	(4,001,867	)	$	2,694,779
DJO Finance LLC
Condensed Consolidating Statements of Operations
For the Year Ended December 31, 2013
(in thousands)
	DJOFL			Guarantors			Non-Guarantors			Eliminations			Consolidated
Net sales	$	—		$	1,026,249		$	282,317		$	(133,109	)	$	1,175,457
Costs and operating expenses:
Cost of sales (exclusive of amortization of intangible assets of $35,125)		—			426,889			191,135			(146,359	)		471,665
Selling, general and administrative		—			383,961			94,022			7			477,990
Research and development		—			29,621			3,577			23			33,221
Amortization of intangible assets		—			90,170			5,369			—			95,539
Impairment of goodwill		—			102,000			—			—			102,000
Impairment of intangible assets		—			4,600			—			—			4,600
		—			1,037,241			294,103			(146,329	)		1,185,015
Operating (loss) income		—			(10,992	)		(11,786	)		13,220			(9,558	)
Other (expense) income:
Interest (expense) income, net		(177,570	)		109			(81	)		—			(177,542	)
Loss on modification and extinguishment of debt		(1,059	)		—			—			—			(1,059	)
Other income (expense), net		—			(315	)		(10,684	)		9,712			(1,287	)
Intercompany income (expense), net		—			4,379			17,799			(22,178	)		—
Equity in (loss) income of subsidiaries, net		(24,823	)		—			—			24,823			—
		(203,452	)		4,173			7,034			12,357			(179,888	)
(Loss) income before income taxes		(203,452	)		(6,819	)		(4,752	)		25,577			(189,446	)
Income tax provision		—			(7,828	)		(5,288	)		—			(13,116	)
Net (loss) income		(203,452	)		(14,647	)		(10,040	)		25,577			(202,562	)
Net income attributable to noncontrolling interests		—			—			(890	)		—			(890	)
Net (loss) income attributable to DJOFL	$	(203,452	)	$	(14,647	)	$	(10,930	)	$	25,577		$	(203,452	)
DJO Finance LLC
Condensed Consolidating Statements of Comprehensive Loss
For the Year Ended December 31, 2013
(in thousands)
	DJOFL			Guarantors			Non-Guarantors			Eliminations			Consolidated
Net (loss) income	$	(203,452	)	$	(14,647	)	$	(10,040	)	$	25,577		$	(202,562	)
Other comprehensive income, net of taxes:
Foreign currency translation adjustments, net of tax provision of $1,212		—			—			19			—			19
Other comprehensive income		—			—			19			—			19
Comprehensive (loss) income		(203,452	)		(14,647	)		(10,021	)		25,577			(202,543	)
Comprehensive income attributable to noncontrolling interests		—			—			(1,010	)		—			(1,010	)
Comprehensive (loss) income attributable to DJO Finance LLC	$	(203,452	)	$	(14,647	)	$	(11,031	)	$	25,577		$	(203,553	)
DJO Finance LLC
Condensed Consolidating Statements of Cash Flows
For the Year Ended December 31, 2013
(in thousands)
	DJOFL			Guarantors			Non-			Eliminations			Consolidated
							Guarantors
Cash Flows from Operating Activities:
Net (loss) income	$	(203,452	)	$	(14,647	)	$	(10,040	)	$	25,577		$	(202,562	)
Adjustments to reconcile net (loss) income to net cash (used in) provided by operating activities:
Depreciation		—			28,002			5,383			(258	)		33,127
Amortization of intangible assets		—			90,170			5,369			—			95,539
Amortization of debt issuance costs and non-cash interest expense		8,012			—			—			—			8,012
Loss on modification and extinguishment of debt		1,059			—			—			—			1,059
Stock-based compensation expense		—			2,155			—			—			2,155
Impairment of goodwill		—			102,000			—			—			102,000
Impairment of intangible assets		—			4,600			—			—			4,600
Loss on disposal of assets, net		—			424			684			—			1,108
Deferred income tax expense (benefit)		—			5,824			(1,233	)		147			4,738
Equity in income of subsidiaries, net		24,823			—			—			(24,823	)		—
Changes in operating assets and liabilities:
Accounts receivable		—			(11,533	)		(6,332	)		—			(17,865	)
Inventories		—			5,799			7,738			(9,064	)		4,473
Prepaid expenses and other assets		—			(1,076	)		(7,368	)		(311	)		(8,755	)
Accounts payable and other current liabilities		(1,839	)		(2,863	)		7,597			(744	)		2,151
Net cash (used in) provided by operating activities		(171,397	)		208,855			1,798			(9,476	)		29,780
Cash Flows from Investing Activities:
Cash paid in connection with acquisitions, net of cash acquired		—			(192	)		(1,761	)		—			(1,953	)
Purchases of property and equipment		—			(29,158	)		(8,310	)		(16	)		(37,484	)
Other investing activities, net		—			(1,239	)		(387	)		—			(1,626	)
Net cash used in investing activities		—			(30,589	)		(10,458	)		(16	)		(41,063	)
Cash Flows from Financing Activities:
Intercompany		156,598			(181,030	)		14,944			9,488			—
Proceeds from issuance of debt		549,417			—			—			—			549,417
Repayments of debt obligations		(523,037	)		—			—			—			(523,037	)
Payment of debt issuance costs		(2,387	)		—			—			—			(2,387	)
Dividend paid by subsidiary to owners of noncontrolling interest		—			—			(684	)		—			(684	)
Net cash provided by (used in) financing activities		180,591			(181,030	)		14,260			9,488			23,309
Effect of exchange rate changes on cash and cash equivalents		—			—			329			—			329
Net increase (decrease) in cash and cash equivalents		9,194			(2,764	)		5,929			(4	)		12,355
Cash and cash equivalents at beginning of period		13,176			3,122			14,919			6			31,223
Cash and cash equivalents at end of period	$	22,370		$	358		$	20,848		$	2		$	43,578
DJO Finance LLC
Condensed Consolidating Statements of Operations
For the Year Ended December 31, 2012
(in thousands)
	DJOFL			Guarantors			Non-			Eliminations			Consolidated
							Guarantors
Net sales	$	—		$	976,874		$	265,137		$	(112,591	)	$	1,129,420
Costs and operating expenses:
Cost of sales (exclusive of amortization of intangible assets of $38,355)		—			392,369			178,626			(127,136	)		443,859
Selling, general and administrative		—			377,086			83,021			4			460,111
Research and development		—			23,600			4,292			—			27,892
Amortization of intangible assets		—			93,038			4,205			—			97,243
Impairment of intangible assets		—			—			7,397			—			7,397
		—			886,093			277,541			(127,132	)		1,036,502
Operating income (loss)		—			90,781			(12,404	)		14,541			92,918
Other (expense) income:
Interest (expense) income, net		(182,909	)		93			(38	)		—			(182,854	)
Loss on modification of debt		(36,889	)		—			—			—			(36,889	)
Other income, net		—			2,453			1,100			—			3,553
Intercompany (expense) income, net		—			(1,297	)		10,584			(9,287	)		—
Equity in income of subsidiaries, net		100,648			—			—			(100,648	)		—
		(119,150	)		1,249			11,646			(109,935	)		(216,190	)
(Loss) income before income taxes		(119,150	)		92,030			(758	)		(95,394	)		(123,272	)
Income tax benefit (provision)		—			8,333			(3,429	)		—			4,904
Net (loss) income		(119,150	)		100,363			(4,187	)		(95,394	)		(118,368	)
Net income attributable to noncontrolling interests		—			—			(782	)		—			(782	)
Net (loss) income attributable to DJOFL	$	(119,150	)	$	100,363		$	(4,969	)	$	(95,394	)	$	(119,150	)
DJO Finance LLC
Condensed Consolidating Statements of Comprehensive Loss
For the Year Ended December 31, 2012
(in thousands)
	DJOFL			Guarantors			Non-Guarantors			Eliminations			Consolidated
Net (loss) income	$	(119,150	)	$	100,363		$	(4,187	)	$	(95,394	)	$	(118,368	)
Other comprehensive income, net of taxes:
Foreign currency translation adjustments, net of tax provision of $1,386		—			—			1,108			—			1,108
Other comprehensive income		—			—			1,108			—			1,108
Comprehensive (loss) income		(119,150	)		100,363			(3,079	)		(95,394	)		(117,260	)
Comprehensive income attributable to noncontrolling interests		—			—			(824	)		—			(824	)
Comprehensive (loss) income attributable to DJO Finance LLC	$	(119,150	)	$	100,363		$	(3,903	)	$	(95,394	)	$	(118,084	)
DJO Finance LLC
Condensed Consolidating Statements of Cash Flows
For the Year Ended December 31, 2012
(in thousands)
	DJOFL			Guarantors			Non-Guarantors			Eliminations			Consolidated
Cash Flows From Operating Activities:
Net (loss) income	$	(119,150	)	$	100,363		$	(4,187	)	$	(95,394	)	$	(118,368	)
Adjustments to reconcile net (loss) income to net cash (used in) provided by operating activities:
Depreciation		—			25,529			5,049			(362	)		30,216
Amortization of intangible assets		—			93,038			4,205			—			97,243
Amortization of debt issuance costs and non-cash interest expense		9,732			—			—			—			9,732
Stock-based compensation expense		—			2,339			—			—			2,339
Loss on disposal of assets, net		—			1,098			588			—			1,686
Impairment of intangible assets		—			—			7,397			—			7,397
Deferred income benefit		—			(8,493	)		(3,088	)		—			(11,581	)
Equity in (income) loss of subsidiaries, net		(100,648	)		—			—			100,648			—
Loss on modification and extinguishment of debt		36,889			—			—			—			36,889
Changes in operating assets and liabilities, net of acquired assets and liabilities:
Accounts receivable		—			(4,491	)		(2,773	)		—			(7,264	)
Inventories		—			(18,687	)		9,725			(12,975	)		(21,937	)
Prepaid expenses and other assets		—			1,108			169			36			1,313
Accounts payable and other current liabilities		10,648			9,675			(5,420	)		2,051			16,954
Net cash (used in) provided by operating activities		(162,529	)		201,479			11,665			(5,996	)		44,619
Cash Flows From Investing Activities:
Cash paid in connection with acquisitions, net of cash acquired		—			(29,909	)		—			—			(29,909	)
Purchases of property and equipment		—			(27,929	)		(5,008	)		(13	)		(32,950	)
Other investing activities, net		—			(1,106	)		—			—			(1,106	)
Net cash used in investing activities		—			(58,944	)		(5,008	)		(13	)		(63,965	)
Cash Flows From Financing Activities:
Intercompany		149,292			(141,153	)		(14,153	)		6,014			—
Proceeds from issuance of debt		1,342,450			—			—			—			1,342,450
Repayments of debt obligations		(1,276,007	)		(38	)		—			—			(1,276,045	)
Payment of debt issuance, modification and extinguishment costs		(55,827	)		—			—			—			(55,827	)
Investment by parent		2,000			—			—			—			2,000
Exercise of indirect parent stock options		24			—			—			—			24
Dividend paid by subsidiary to owners of noncontrolling interests		—			—			(649	)		—			(649	)
Net cash provided by (used in) financing activities		161,932			(141,191	)		(14,802	)		6,014			11,953
Effect of exchange rate changes on cash and cash equivalents		—			—			447			—			447
Net (decrease) increase in cash and cash equivalents		(597	)		1,344			(7,698	)		5			(6,946	)
Cash and cash equivalents, beginning of year		13,773			1,778			22,617			1			38,169
Cash and cash equivalents, end of year	$	13,176		$	3,122		$	14,919		$	6		$	31,223

SCHEDULE_IIVALUATION_AND_QUALI

SCHEDULE II-VALUATION AND QUALIFYING ACCOUNTS	12 Months Ended
	Dec. 31, 2014
SCHEDULE II-VALUATION AND QUALIFYING ACCOUNTS	DJO FINANCE LLC
	SCHEDULE II—VALUATION AND QUALIFYING ACCOUNTS
	(in thousands)
		Allowance for
		Sales
		Discounts and
		Other Allowances
	Balance as of December 31, 2011	$	53,370
	Provision		194,656
	Write-offs, net of recoveries		(186,203	)
	Balance as of December 31, 2012	$	61,823
	Provision		209,057
	Write-offs, net of recoveries		(203,857	)
	Balance as of December 31, 2013	$	67,023
	Provision		225,528
	Write-offs, net of recoveries		(226,316	)
	Balance as of December 31, 2014	$	66,235

ORGANIZATION_AND_BASIS_OF_PRES1

ORGANIZATION AND BASIS OF PRESENTATION (Policies)	12 Months Ended
	Dec. 31, 2014
Infrequent Events	Infrequent Events
	In September 2013, a fire occurred at our factory in Tunisia. As a result of the fire, certain inventory and fixed assets were destroyed and the leased facility became inoperable. Estimated losses of $5.0 million related to destroyed inventory and fixed assets, excess expenses incurred and building reconstruction costs were recorded for the year ended December 31, 2013. Additionally, we recorded $1.3 million in revenue from business interruption insurance proceeds for the year ended December 31, 2013. Final claims were settled against the policies in September 2014. As a result, estimated losses were adjusted to $3.3 million, and additional $2.3 million in revenue from business interruption insurance proceeds was recorded for the year ended December 31, 2014. The activity in the corresponding insurance receivable was follows (in thousands):
		Year Ended
		December 31, 2014
	Balance, beginning of period	$	6,261
	Change in estimated losses		(1,617	)
	Business interruption		2,274
	Claim payments		(6,918	)
	Balance, end of period	$	—
Segment Reporting	Segment Reporting
	We market and distribute our products through four operating segments, Bracing and Vascular, Recovery Sciences, Surgical Implant, and International. Our Bracing and Vascular, Recovery Sciences, and Surgical Implant segments generate their revenues within the United States. Our Bracing and Vascular segment offers rigid knee braces, orthopedic soft goods, cold therapy products, vascular systems, compression therapy products and therapeutic footwear for the diabetes care market. Our Recovery Sciences segment offers home electrotherapy, iontophoresis, home traction products, bone growth stimulation products and clinical physical therapy equipment. Our Surgical Implant segment offers a comprehensive suite of reconstructive joint products for the knee, hip and shoulder. Our International segment offers all of our products to customers outside the United States. See Note 18 for additional information about our reportable segments.
Use of Estimates	Use of Estimates
	The preparation of financial statements in conformity with accounting principles generally accepted in the United States (GAAP) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Estimates and assumptions are used in accounting for, among other things, contractual allowances, rebates, product returns, warranty obligations, allowances for doubtful accounts, valuation of inventories, self-insurance reserves, income taxes, loss contingencies, fair values of derivative instruments, fair values of long-lived assets and any related impairments, capitalization of costs associated with internally developed software and stock-based compensation. Actual results could differ from those estimates.
Basis of Presentation	Basis of Presentation
	We consolidate the results of operations of our 50% owned subsidiary, Medireha GmbH (Medireha), and reflect the 50% share of results not owned by us as noncontrolling interests in our Consolidated Statements of Operations. We maintain control of Medireha through certain rights that enable us to prohibit certain business activities that are not consistent with our plans for the business and provide us with exclusive distribution rights for products manufactured by Medireha.
Cash and Cash Equivalents	Cash and Cash Equivalents. Cash consists of deposits with financial institutions. We consider all short-term, highly liquid investments and investments in money market funds and commercial paper with remaining maturities of less than three months at the time of purchase to be cash equivalents. While our cash and cash equivalents are on deposit with high-quality institutions, such deposits exceed Federal Deposit Insurance Corporation insured limits.
Allowance for Doubtful Accounts	Allowance for Doubtful Accounts. We make estimates of the collectibility of accounts receivable. Management analyzes accounts receivable historical collection rates and bad debts write-offs, customer concentrations, customer credit-worthiness and current economic trends when evaluating the adequacy of the allowance for doubtful accounts.
Sales Returns and Allowances	Sales Returns and Allowances. We make estimates of the amount of sales returns and allowances that will eventually be incurred. Management analyzes sales programs that are in effect, contractual arrangements, market acceptance and historical trends when evaluating the adequacy of sales returns and allowance accounts. We estimate contractual discounts and allowances for reimbursement amounts from our third party payor customers based on negotiated contracts and historical experience.
Inventories	Inventories. We state our inventories at the lower of cost or market. We use standard cost methodology to determine cost basis for our inventories. This methodology approximates actual cost on a first-in, first-out basis. We establish reserves for slow moving and excess inventory, product obsolescence, shrinkage and other valuation impairments based on future demand and historical experience.
Property and Equipment	Property and Equipment. Property and equipment are stated at cost less accumulated depreciation and amortization. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets that range from three to 25 years. Leasehold improvements and equipment under capital leases are amortized on a straight-line basis over the shorter of the lease term or estimated useful life of the asset. We capitalize surgical implant instruments that we provide to surgeons, free of charge, for use while implanting our products and the related depreciation expense is recorded as a component of Selling, general and administrative expense. We also capitalize electrotherapy devices that we rent to patients and record the related depreciation expense in cost of sales.
Software Developed For Internal Use	Software Developed For Internal Use. Software is stated at cost less accumulated amortization and is amortized on a straight-line basis over estimated useful lives ranging from three to ten years. We capitalize costs of internally developed software during the development stage, including external consulting costs, cost of software licenses, and internal payroll and payroll-related costs for employees who are directly associated with a software project. Software assets are reviewed for impairment when events or circumstances indicate that the carrying value may not be recoverable. Upgrades and enhancements are capitalized if they result in added functionality. Amortization expense related to internally developed software was $2.0 million, $1.9 million and $1.9 million for the years ended December 31, 2014, 2013 and 2012, respectively.
	As of December 31, 2014 and 2013, we had $8.5 million and $10.5 million respectively, of unamortized internally developed software costs included within property and equipment in our Consolidated Balance Sheets.
Intangible Assets	Intangible Assets. Our primary intangible assets are goodwill, customer relationships, patents and technology and trademarks and trade names. Goodwill represents the excess purchase price over the fair value of the identifiable net assets acquired in business combinations. Goodwill and intangible assets with indefinite useful lives are not amortized, but instead are tested for impairment at least annually. Intangible assets with definite lives are amortized over their respective estimated useful lives and reviewed for impairment when circumstances warrant.
	We evaluate the carrying value of goodwill and indefinite life intangible assets annually on the first day of the fourth quarter or whenever events or circumstances indicate the carrying value may not be recoverable. We evaluate the carrying value of finite life intangible assets whenever events or circumstances indicate the carrying value may not be recoverable. Significant assumptions are required to estimate the fair value of goodwill and intangible assets, most notably estimated future cash flows generated by these assets. As such, these fair valuation measurements use significant unobservable inputs, which are inputs that are classified as Level 3 in the fair value hierarchy. Changes to these assumptions could require us to record impairment charges on these assets.
Warranty Costs	Warranty Costs. We provide expressed warranties on certain products for periods typically ranging from one to three years. We estimate our warranty obligations at the time of sale based upon historical experience and known product issues, if any.
	A summary of the activity in our warranty reserves is as follows (in thousands):
		Year Ended December 31,
		2014			2013			2012
	Balance, beginning of year	$	1,847		$	1,488		$	1,756
	Amount charged to expense for estimated warranty costs		1,788			1,138			338
	Deductions for actual costs incurred		(1,693	)		(779	)		(606	)
	Balance, end of year	$	1,942		$	1,847		$	1,488
Self Insurance	Self Insurance. We are partially self-insured for certain employee health benefits and product liability claims. Accruals for losses are provided based upon claims experience and actuarial assumptions, including provisions for incurred but not reported losses.
Revenue Recognition	Revenue Recognition. We recognize revenue when all four of the following criteria are met: (i) persuasive evidence that an arrangement exists; (ii) shipment of goods and passage of title occurs; (iii) the selling price is fixed or determinable; and (iv) collectibility is reasonably assured.
	We sell our products through a variety of distribution channels. We generally recognize revenue when we ship our products to our customers. We include amounts billed to customers for freight in revenue. We recognize revenue, both rental and purchase, for products sold directly to patients or their third party insurance payors, when our product has been dispensed or shipped to the patient and the patient’s insurance has been verified.
	We record revenues from sales or our surgical implant products when the products are used in a surgical procedure (implanted in a patient).
	We reduce revenue by estimates of potential future product returns and other allowances. Revenues are also reduced by rebates related to sales transacted through distribution agreements that provide the distributors with a right to return inventory or take certain pricing adjustments based on sales mix or volume. Provisions for product returns and other allowances are recorded as a reduction to revenue in the period sales are recognized.
Advertising Costs	Advertising Costs. We expense advertising costs as they are incurred. For the years ended December 31, 2014, 2013 and 2012, advertising costs were $4.7 million, $6.4 million and $6.5 million, respectively. In 2013 we revised our definition of advertising costs to exclude certain other marketing and promotion costs. The amounts for the year ended December 31, 2012 have been revised to conform to the current definition.
Shipping and Handling Expenses	Shipping and Handling Expenses. Shipping and handling expenses are included within cost of sales in our Consolidated Statements of Operations.
Stock Based Compensation	Stock Based Compensation. We maintain a stock option plan under which stock options of our indirect parent, DJO, have been granted to both employees and non-employees. All share based payments to employees are recognized in the financial statements based on their grant date fair values and our estimates of forfeitures. We amortize stock-based compensation for service-based awards granted on a straight-line basis over the requisite service (vesting) period for the entire award. Other awards vest upon the achievement of certain pre-determined performance targets, and compensation expense is recognized to the extent the achievement of the performance targets is deemed probable.
Income Taxes	Income Taxes. Income taxes are accounted for under the asset and liability method, whereby deferred tax assets and liabilities are recognized and measured using enacted tax rates in effect for each taxing jurisdiction in which we operate for the year in which those temporary differences are expected to be recognized. Net deferred tax assets are then reduced by a valuation allowance if we believe it more-likely-than-not such net deferred tax assets will not be realized.
Foreign Currency Translation and Transactions	Foreign Currency Translation and Transactions. The reporting currency of DJOFL is the U.S. Dollar. Assets and liabilities of foreign subsidiaries (including intercompany balances for which settlement is not anticipated in the foreseeable future) are translated at the spot rate in effect at the applicable reporting date, and our Consolidated Statement of Operations is translated at the average exchange rates in effect during the applicable period. The resulting unrealized cumulative translation adjustment, net of applicable income taxes, is recorded as a component of other comprehensive income (loss) in our Consolidated Statement of Comprehensive Loss. Cash flows from our operations in foreign countries are translated at the average rate for the applicable period. The effect of exchange rates on cash balances held in foreign currencies are separately reported in our Consolidated Statements of Cash Flows.
	Transactions denominated in currencies other than our or our subsidiaries’ functional currencies are recorded based on exchange rates at the time such transactions arise. Changes in exchange rates with respect to amounts recorded in our Consolidated Balance Sheets related to such transactions result in transaction gains and losses that are reflected in our Consolidated Statements of Operations as either unrealized (based on the applicable period end translation) or realized (upon settlement of the transactions). For the years ended December 31, 2014, 2013 and 2012, foreign transaction (losses) gains were $(5.3) million, $(1.5) million and $3.6 million, respectively.
Derivative Financial Instruments	Derivative Financial Instruments. All derivative instruments are recognized in the financial statements and measured at fair value regardless of the purpose or intent for holding them.
	We use foreign exchange forward contracts to hedge expense commitments that are denominated in currencies other than the U.S. dollar. The purpose of our foreign currency hedging activities is to fix the dollar value of specific commitments and payments to foreign vendors. Before acquiring a derivative instrument to hedge a specific risk, potential natural hedges are evaluated. While our foreign exchange contracts act as economic hedges, we have not designated such instruments as hedges for accounting purposes. Therefore, gains and losses resulting from changes in the fair values of these derivative instruments are recorded in other income (expense), net, in our Consolidated Statements of Operations.
	The fair value of our derivative instruments has been determined through the use of models that consider various assumptions, including time value and other relevant economic measures, which are inputs that are classified as Level 2 in the fair value hierarchy (see Notes 10 and 11).
Comprehensive Income (Loss)	Comprehensive Income (Loss). Comprehensive income (loss) includes net income (loss) as per our Consolidated Statement of Operations and other comprehensive income (loss). Other comprehensive income (loss), which is comprised of unrealized gains and losses on foreign currency translation adjustments, net of tax, is included in our Consolidated Statement of Comprehensive Loss.
Concentration of Credit Risk	Concentration of Credit Risk. We sell the majority of our products in the United States to orthopedic professionals, hospitals, distributors, specialty dealers, insurance companies, managed care companies and certain governmental payors such as Medicare. International sales comprised 26.5%, 25.5% and 24.8% of our net sales for the years ended December 31, 2014, 2013 and 2012, respectively. International sales are generated from a diverse group of customers through our wholly owned subsidiaries and certain independent distributors. Credit is extended based on an evaluation of the customer’s financial condition and generally collateral is not required. We provide a reserve for estimated bad debts. Management reviews and revises its estimates for credit losses from time to time and such credit losses have generally been within management’s estimates. In each of the years ended December 31, 2014, 2013 and 2012, we had no individual customer or distributor that accounted for 10% or more of our total annual net sales.
Fair Value of Financial Instruments	Fair Value of Financial Instruments. The carrying amounts of our short-term financial instruments, including cash and cash equivalents, accounts receivable and accounts payable, approximate fair values due to their short-term nature. See Note 12 for information concerning the fair value of our variable and fixed rate debt.
Recent Accounting Standards	Recent Accounting Standards. In July 2013, the Financial Accounting Standards Board (the “FASB”) issued an accounting standard update regarding the financial statement presentation of an unrecognized tax benefit when a net operating loss carryforward, a similar tax loss, or a tax credit carryforward exists. The guidance is effective prospectively for fiscal years, and interim periods within those years, beginning after December 15, 2013, with an option for early adoption. The adoption of this standard did not have an impact on the Company’s consolidated financial statements.
	In April 2014, the FASB issued accounting standards update, which includes amendments that change the requirements for reporting discontinued operations and require additional disclosures about discontinued operations. Under the new guidance, only disposals representing a strategic shift in operations—that is, a major effect on the organization’s operations and financial results should be presented as discontinued operations. Examples include a disposal of a major geographic area, a major line of business, or a major equity method investment. Additionally, the update requires expanded disclosures about discontinued operations that will provide financial statement users with more information about the assets, liabilities, income, and expenses of discontinued operations. The guidance is effective prospectively for fiscal years beginning after December 15, 2014 and interim periods within annual periods beginning on or after December 15, 2015. The adoption of this standard has the potential to impact the Company’s accounting for and disclosure of any future discontinued operations.
	In May 2014, the FASB issued an accounting standards update related to revenue from contracts with customers. The new standard provides a five-step approach to be applied to all contracts with customers. The accounting standards update also requires expanded disclosures about revenue recognition. The guidance is effective for fiscal years beginning after December 15, 2016 and interim periods within that reporting period. Early adoption is not permitted. The Company is currently evaluating the new guidance to determine the impact it may have to its consolidated financial statements.
	In June 2014, the FASB issued an accounting standards update related accounting for share-based payments. The standard requires that a performance target that affects vesting and that could be achieved after the requisite service period be treated as a performance condition. The guidance is effective for annual periods and interim periods within those annual periods, beginning after December 15, 2015. Early application is permitted. Adoption of this new guidance is not expected to have a material effect on the Company’s financial statements.
	In August 2014, the FASB issued an accounting standards update related to going concern disclosures. The standard requires an entity’s management to evaluate whether there are conditions or events that raise substantial doubt about the entity’s ability to continue as a going concern within one year after the date that the financial statements are issued. The guidance is effective for annual reporting periods ending after December 15, 2016, and interim periods thereafter. Early application is permitted. Adoption of this new guidance is not expected to have a material effect on the Company’s financial statements.

ORGANIZATION_AND_BASIS_OF_PRES2

ORGANIZATION AND BASIS OF PRESENTATION (Tables)	12 Months Ended
	Dec. 31, 2014
Schedule of Insurance Receivables Against Property and Business Interruption Insurance Policies	The activity in the corresponding insurance receivable was follows (in thousands):
		Year Ended
		December 31, 2014
	Balance, beginning of period	$	6,261
	Change in estimated losses		(1,617	)
	Business interruption		2,274
	Claim payments		(6,918	)
	Balance, end of period	$	—

SIGNIFICANT_ACCOUNTING_POLICIE1

SIGNIFICANT ACCOUNTING POLICIES (Tables)	12 Months Ended
	Dec. 31, 2014
Summary of Activity in our Warranty Reserves	A summary of the activity in our warranty reserves is as follows (in thousands):
		Year Ended December 31,
		2014			2013			2012
	Balance, beginning of year	$	1,847		$	1,488		$	1,756
	Amount charged to expense for estimated warranty costs		1,788			1,138			338
	Deductions for actual costs incurred		(1,693	)		(779	)		(606	)
	Balance, end of year	$	1,942		$	1,847		$	1,488

ACQUISITIONS_Tables

ACQUISITIONS (Tables)	12 Months Ended
	Dec. 31, 2014
Purchase Price for Acquisition Allocated to Fair Values of Net Tangible and Intangible Assets Acquired	The purchase price for each of these acquisitions was allocated to the fair values of the net tangible and intangible assets acquired as follows (in thousands):
	(in thousands):		Speetec			Blue Leaf		Vasyli		Exos
	Cash		$	489		$	—	$	—	$	1,282
	Accounts receivable			608			—		—		1,138
	Inventory			2,766			59		542		1,754
	Other current assets			154			—		31		105
	Property and equipment			379			—		12		584
	Other non-current assets			—			—		—		12
	Liabilities assumed			(1,642	)		—		—		(474	)
	Deferred tax liabilities			(1,003	)		—		—		(9,137	)
	Identifiable intangible assets (1):
	Customer relationships			2,861			90		308		—
	Technology			—			—		—		24,200
	Non-compete			569			111		930		1,900
	Trademarks and trade names			320			—		—		1,000
	Goodwill (2)			2,383			322		363		18,211
	Total purchase price		$	7,884		$	582	$	2,186	$	40,575
	-1	The fair value of customer relationships was assigned to relationships with major customers existing on the acquisition date based upon an estimate of the future discounted cash flows that would be derived from those customers, after deducting contributory asset charges.
	The fair value of technology was determined primarily by estimating the present value of future royalty costs that will be avoided due to our ownership of the patents and technology acquired.
	The fair value of non-compete agreements relate to non-compete agreements entered into with certain members of senior management. The values were determined by estimating the present value of the cash flows associated with having these agreements in place, less the present value of the cash flows assuming the non-compete agreements were not in place.
	The fair value of trademarks and trade names was determined primarily by estimating the present value of future royalty costs that will be avoided due to our ownership of the trade names and trademarks acquired.
	The useful lives of the intangible assets acquired were estimated based on the underlying agreements and/or the future economic benefit expected to be received from the assets.
	-2	Goodwill represents the excess purchase price over the fair value of the identifiable net assets acquired. Among the factors which resulted in the recognition of goodwill for the Speetec acquisition was the opportunity to expand our direct presences in the German market with our surgical products. Among the factors which resulted in the recognition of goodwill for the Blue Leaf and Vasyli assets was the opportunity to expand our direct presence in the local markets with our vascular products. Among the factors which resulted in the recognition of goodwill for Exos was improved our margins on the sale of Exos products and being able to control the rights to future products developed by Exos.

ACCOUNTS_RECEIVABLE_RESERVES_T

ACCOUNTS RECEIVABLE RESERVES (Tables)	12 Months Ended
	Dec. 31, 2014
Summary of Activity in Accounts Receivable Reserves for Doubtful Accounts and Sales Returns	A summary of activity in our accounts receivable reserves for doubtful accounts is presented below (in thousands):
		Year Ended December 31,
		2014			2013			2012
	Balance, beginning of year	$	32,957		$	25,211		$	35,649
	Provision for doubtful accounts		40,164			33,129			19,586
	Write-offs, net of recoveries		(31,719	)		(25,383	)		(30,024	)
	Balance, end of year	$	41,402		$	32,957		$	25,211

INVENTORIES_Tables

INVENTORIES (Tables)	12 Months Ended
	Dec. 31, 2014
Summary of Inventories	Inventories consist of the following (in thousands):
		December 31,2014			December 31,2013
	Components and raw materials	$	59,578		$	59,825
	Work in process		5,718			7,373
	Finished goods		103,042			83,502
	Inventory held on consignment		30,978			27,969
			199,316			178,669
	Inventory reserves		(23,976	)		(23,686	)
		$	175,340		$	154,983
Summary of Activity of Reserves in Inventory	A summary of the activity in our reserves for estimated slow moving, excess, obsolete and otherwise impaired inventory is presented below (in thousands):
		Year Ended December 31,
		2014			2013			2012
	Balance, beginning of year	$	23,686		$	17,313		$	14,146
	Provision charged to costs of sales		8,924			10,121			6,350
	Write-offs, net of recoveries		(8,634	)		(3,748	)		(3,183	)
	Balance, end of year	$	23,976		$	23,686		$	17,313

PROPERTY_AND_EQUIPMENT_NET_Tab

PROPERTY AND EQUIPMENT, NET (Tables)	12 Months Ended
	Dec. 31, 2014
Property and Equipment	Property and equipment consists of the following (in thousands):
		December 31,			December 31,			Depreciable lives
		2014			2013			(years)
	Land	$	266		$	266		Indefinite
	Buildings and improvements		28,967			27,229		3 to 25
	Equipment		137,468			132,688		2 to 7
	Software		38,627			33,817		3 to 10
	Furniture and fixtures		12,618			12,223		3 to 8
	Surgical implant instrumentation		78,275			55,841		5
	Construction in progress		12,027			7,919		N/A
			308,248			269,983
	Accumulated depreciation and amortization		(188,141	)		(162,154	)
	Property and equipment, net	$	120,107		$	107,829

LONGLIVED_ASSETS_Tables

LONG-LIVED ASSETS (Tables)	12 Months Ended
	Dec. 31, 2014
Schedule of Changes in Carrying Amount of Goodwill	Changes in the carrying amount of goodwill for the year ended December 31, 2014 are presented in the table below (in thousands):
		Bracing &		Recovery			Surgical			International			Total
		Vascular		Sciences			Implant
	Balance, beginning of period
	Goodwill	$	483,258	$	495,999		$	47,406		$	348,774		$	1,375,437
	Accumulated impairment losses		—		(178,700	)		(47,406	)		—			(226,106	)
			483,258		317,299			—			348,774			1,149,331
	Acquisitions (see Note 3)		—		—			—			2,383			2,383
	Foreign currency translation		—		—			—			(10,526	)		(10,526	)
	Balance, end of period
	Goodwill		483,258		495,999			47,406			340,631			1,367,294
	Accumulated impairment losses		—		(178,700	)		(47,406	)		—			(226,106	)
		$	483,258	$	317,299		$	—		$	340,631		$	1,141,188
Summary of Identifiable Intangible Assets	Identifiable intangible assets consisted of the following (in thousands):
	December 31, 2014	Gross Carrying		Accumulated			Intangible
		Amount		Amortization			Assets, Net
	Definite-lived intangible assets:
	Customer relationships	$	569,360	$	(341,353	)	$	228,007
	Patents and technology		486,466		(264,132	)		222,334
	Trademarks and trade names		25,970		(9,902	)		16,068
	Distributor contracts and relationships		4,771		(3,401	)		1,370
	Non-compete agreements		6,824		(4,723	)		2,101
		$	1,093,391	$	(623,511	)		469,880
	Indefinite-lived intangible assets:
	Trademarks and trade names							398,151
	Net identifiable intangible assets						$	868,031
	December 31, 2013	Gross Carrying		Accumulated			Intangible
		Amount		Amortization			Assets, Net
	Definite-lived intangible assets:
	Customer relationships	$	570,070	$	(290,359	)	$	279,711
	Patents and technology		486,246		(230,111	)		256,135
	Trademarks and trade names		25,820		(7,102	)		18,718
	Distributor contracts and relationships		5,054		(3,183	)		1,871
	Non-compete agreements		6,423		(3,149	)		3,274
		$	1,093,613	$	(533,904	)		559,709
	Indefinite-lived intangible assets:
	Trademarks and trade names							399,284
	Net identifiable intangible assets						$	958,993
Schedule of Estimated Amortization Expense	Based on our amortizable intangible asset balance as of December 31, 2014, we estimate that amortization expense will be as follows for the next five years and thereafter (in thousands):
	2015	$	88,405
	2016		83,874
	2017		72,712
	2018		62,552
	2019		51,742
	Thereafter		110,595
		$	469,880
Goodwill and Intangible Assets by Segments	Our goodwill and intangible assets by segment are as follows (in thousands):
	December 31, 2014	Goodwill		Intangible
				Assets, Net
	Bracing and Vascular	$	483,258	$	487,122
	Recovery Sciences		317,299		218,260
	International		340,631		150,128
	Surgical Implant		—		12,521
		$	1,141,188	$	868,031
	December 31, 2013	Goodwill		Intangible
				Assets, Net
	Bracing and Vascular	$	483,258	$	527,806
	Recovery Sciences		317,299		250,725
	International		348,774		165,569
	Surgical Implant		—		14,893
		$	1,149,331	$	958,993

OTHER_CURRENT_LIABILITIES_Tabl

OTHER CURRENT LIABILITIES (Tables)	12 Months Ended
	Dec. 31, 2014
Schedule of Other Current Liabilities	Other current liabilities consist of the following (in thousands):
		December 31,		December 31,
		2014		2013
	Accrued wages and related expenses	$	32,220	$	33,128
	Accrued commissions		16,611		16,489
	Accrued rebates		12,981		10,731
	Accrued other taxes		4,987		4,734
	Accrued professional expenses		2,682		3,372
	Income taxes payable		2,477		2,877
	Deferred tax liability		343		445
	Other accrued liabilities		26,844		37,696
		$	99,145	$	109,472

DERIVATIVE_INSTRUMENTS_Tables

DERIVATIVE INSTRUMENTS (Tables)	12 Months Ended
	Dec. 31, 2014
Schedule of Information Regarding Notional Amounts of Foreign Exchange Forward Contracts	Information regarding the notional amounts of our foreign exchange forward contracts is presented in the table below (in thousands):
		Notional Amount (MXN)								Notional Amount (USD)
		December 31,				December 31,				December 31,				December 31,
		2014				2013				2014				2013
	Foreign exchange contracts not designated as hedges		7,682				302,730			$	526			$	22,959
Summary of Location and Fair Value of Derivative Instruments in Condensed Consolidated Balance Sheets	The following table summarizes the fair value of derivative instruments in our Consolidated Balance Sheets (in thousands):
		Balance Sheet Location		December 31,				December 31,
				2014				2013
	Derivative Liabilities:
	Foreign exchange forward contracts not designated as hedges	Other current liabilities		$	4			$	44
Summary of Effect of Derivative Instruments on Condensed Consolidated Statements of Operations	The following table summarizes the effect our derivative instruments have on our Consolidated Statements of Operations (in thousands):
				Year Ended December 31,
		Location of gain (loss)		2014				2013				2012
	Foreign exchange forward contracts not designated as hedges	Other income (expense), net		$	40				(821	)			1,322
				$	40			$	(821	)		$	1,322

FAIR_VALUE_MEASUREMENTS_Tables

FAIR VALUE MEASUREMENTS (Tables)	12 Months Ended
	Dec. 31, 2014
Schedule of Assets and Liabilities Measured at Fair Value on Recurring Basis	The following tables present the balances of financial assets and liabilities measured at fair value on a recurring basis (in thousands):
	As of December 31, 2014	Quoted Prices			Significant		Significant		Recorded
		in Active			Other		Unobservable		Balance
		Markets for			Observable		Inputs
		Identical Assets			Inputs		(Level 3)
		(Level 1)			(Level 2)
	Liabilities:
	Foreign exchange forward contracts not designated as hedges	$	—		$	4	$	—	$	4
	As of December 31, 2013	Quoted Prices			Significant		Significant		Recorded
		in Active			Other		Unobservable		Balance
		Markets for			Observable		Inputs
		Identical Assets			Inputs		(Level 3)
		(Level 1)			(Level 2)
	Liabilities:
	Foreign exchange forward contracts not designated as hedges	$	—		$	44	$	—	$	44
	Contingent consideration	$	—		$	—	$	5,690	$	5,690
Reconciliation of All Financial Assets and Liabilities Measured at Fair Value on Recurring Basis Using Significant Unobservable Inputs (Level 3)	The table below presents reconciliation of all financial assets and liabilities measured at fair value on a recurring basis using significant unobservable inputs (Level 3) for the year ended December 31, 2014 (in thousands):
		Year Ended
		December 31, 2014
	Balance, beginning of period	$	5,690
	Acquisitions		1,627
	Payment of contingent consideration		(5,690	)
	Adjustment of contingent consideration included in SG&A		(1,482	)
	Foreign currency translation		(145	)
	Balance, end of period	$	—

DEBT_Tables

DEBT (Tables)	12 Months Ended
	Dec. 31, 2014
Schedule of Debt Obligations	Debt obligations consist of the following (in thousands):
		December 31,			December 31,
		2014			2013
	Senior secured credit facilities:
	Revolving credit facility	$	17,000		$	38,000
	Term Loan:
	$884.6 million New Tranche B term loans, net of unamortized original issuance discount of $5.1 million as of December 31, 2014		879,476			—
	$853.4 million Tranche B term loans, net of unamortized original issuance discount of $7.1 million as of December 31, 2013		—			846,297
	8.75% Second priority senior secured notes, including unamortized original issue premium of $4.4 million and $5.5 million as of December 31, 2014 and December 31, 2013, respectively		334,377			335,490
	9.875% Senior unsecured notes		440,000			440,000
	7.75% Senior unsecured notes		300,000			300,000
	9.75% Senior subordinated notes		300,000			300,000
	Other		63			—
	Total debt		2,270,916			2,259,787
	Current maturities		(8,975	)		(8,620	)
	Long-term debt	$	2,261,941		$	2,251,167
Aggregate Amounts of Annual Principal Maturities of Long-term Debt	At December 31, 2014, the aggregate amounts of annual principal maturities of long-term debt for the next five years and thereafter are as follows (in thousands):
	Years Ending December 31,
	2015	$	8,975
	2016		8,912
	2017		1,183,736
	2018		1,070,000
	2019		—
		$	2,271,623

STOCK_OPTION_PLANS_AND_STOCKBA1

STOCK OPTION PLANS AND STOCK-BASED COMPENSATION (Tables)	12 Months Ended
	Dec. 31, 2014
Summary of Assumptions Used to Estimate Fair Value of Time-Based Options, Vested Options and Director Service Options of Stock Options Granted	The following table summarizes certain assumptions we used to estimate the fair value of the Time-Based Options, the Vested Options and the Director Service Options of stock options granted during the years ended December 31, 2014, 2013, and 2012:
		Year Ended December 31,
		2014			2013			2012
	Expected volatility		31.7-33.4	%		33.4-35.1	%		35.3-37.7	%
	Risk-free interest rate		1.7-2.2	%		0.7-2.0	%		0.8-1.5	%
	Expected term until exercise		5.0-6.4			5.0-6.3			6.1-6.2
	Expected dividend yield		0	%		0	%		0	%
Schedule of Recorded Non-cash Stock-based Compensation Expense	We recorded non-cash stock-based compensation expense during the periods presented as follows (in thousands):
		Year Ended December 31,
		2014			2013			2012
	Cost of goods sold	$	82		$	52		$	78
	Operating expenses:
	Selling, general and administrative		1,782			2,049			2,206
	Research and development		5			54			55
		$	1,869		$	2,155		$	2,339
Summary of Option Activity	A summary of option activity under the 2007 Plan is presented below:
		Number of			Weighted-			Weighted-			Aggregate
		Shares			Average			Average			Intrinsic
					Exercise Price			Remaining			Value
								Contractual Term
								(Years)
	Outstanding at December 31, 2013		9,017,290		$	15.79			6.1		$	6,133,210
	Granted		1,747,268		$	16.46
	Exercised		(513,535	)	$	10.89
	Forfeited or expired		(1,011,857	)	$	16.44
	Outstanding at December 31, 2014		9,239,166		$	16.11			6.3		$	3,197,576
	Vested or expected to vest at December 31, 2014		5,793,957		$	15.91			5.5		$	3,197,576
	Exercisable at December 31, 2014		2,496,422		$	15.18			3.6		$	3,197,576
Exercise of Stock Options Using Net Exercise Method	The following table provides information regarding the use of the net exercise method during the periods presented:
		Year Ended December 31,
		2014			2013
	Options exercised		507,088			221,057
	Shares withheld		391,395			148,906
	Shares issued		115,693			72,151
	Average market value per share withheld	$	16.46		$	16.46
	Aggregate market value of shares withheld (in thousands)	$	6,442		$	2,451

INCOME_TAXES_Tables

INCOME TAXES (Tables)	12 Months Ended
	Dec. 31, 2014
Loss from Continuing Operations Before Income Tax Provision (Benefit)	The components of loss before income tax provision (benefit) consist of the following (in thousands):
		Year Ended December 31,
		2014			2013			2012
	U.S. operations	$	(94,111	)	$	(206,769	)	$	(137,268	)
	Foreign operations		17,439			17,323			13,996
		$	(76,672	)	$	(189,446	)	$	(123,272	)
Components of Income Tax Provision (Benefit)	The income tax provision (benefit) consists of the following (in thousands):
		Year Ended December 31,
		2014			2013			2012
	Current income taxes:
	U.S. federal	$	(309	)	$	1,135		$	(1,205	)
	U.S. state		852			870			1,347
	Foreign		5,989			6,373			6,330
	Total current income taxes		6,532			8,378			6,472
	Deferred income taxes:
	U.S. federal		8,676			7,460			(3,558	)
	U.S. state		(307	)		(2,154	)		(5,751	)
	Foreign		(2,011	)		(568	)		(2,067	)
	Total deferred income taxes		6,358			4,738			(11,376	)
	Total income tax provision (benefit)	$	12,890		$	13,116		$	(4,904	)
Difference Between Income Tax Benefit Derived by Applying U.S. Federal Statutory Income Tax Rate to Loss from Continuing Operations Before Income Tax and Income Tax Provision (Benefit) Recognized	The difference between the income tax provision (benefit) derived by applying the U.S. federal statutory income tax rate of 35% and the recognized income tax provision (benefit) is as follows (in thousands):
		Year Ended December 31,
		2014			2013			2012
	Income tax provision (benefit) derived by applying the U.S. federal statutory income tax rate to loss before income taxes	$	(26,835	)	$	(66,306	)	$	(43,145	)
	Add (deduct) the effect of:
	State tax benefit, net		(2,476	)		(3,323	)		(4,275	)
	Change in state effective tax rates		(722	)		(992	)		(639	)
	Foreign earnings repatriation		(1,646	)		2,678			3,199
	Unrecognized tax benefits		949			2,216			(7,723	)
	Goodwill impairment		—			33,687			—
	Prepaid tax asset impairment		(1	)		229			5,479
	Valuation allowance		40,692			50,516			38,845
	Research tax credit		(618	)		(1,249	)		—
	Equity compensation benefit		—			(2,864	)		—
	Permanent differences and other, net		3,547			(1,476	)		3,355
		$	12,890		$	13,116		$	(4,904	)
Components of Deferred Income Tax Assets and Liabilities	The components of deferred income tax assets and liabilities are as follows (in thousands):
		December 31,			December 31,
		2014			2013
	Deferred tax assets:
	Net operating loss carryforwards	$	214,319		$	202,387
	Receivables reserve		26,709			23,878
	Other		39,284			38,766
	Gross deferred tax assets		280,312			265,031
	Valuation allowance		(137,520	)		(94,741	)
	Net deferred tax assets		142,792			170,290
	Deferred tax liabilities:
	Intangible assets		(343,370	)		(362,950	)
	Foreign earnings repatriation		(13,012	)		(14,092	)
	Other		(3,987	)		(7,038	)
	Gross deferred tax liabilities		(360,369	)		(384,080	)
	Net deferred tax liabilities	$	(217,577	)	$	(213,790	)
Reconciliation of Beginning and Ending Amount of Gross Unrecognized Tax Benefits	A reconciliation of the beginning and ending amount of gross unrecognized tax benefits is as follows (in thousands):
		Year Ended December 31,
		2014			2013			2012
	Balance, beginning of year	$	14,469		$	12,342		$	19,443
	Additions based on tax positions related to current year		1,502			1,531			817
	Additions for tax positions related to prior years		354			975			892
	Reductions for tax positions of prior years		—			—			—
	Reduction due to lapse of statute of limitations		(709	)		(379	)		(990	)
	Reductions for settlements of tax positions		(1,711	)		—			(7,820	)
	Balance, end of year	$	13,905		$	14,469		$	12,342

COMMITMENTS_AND_CONTINGENCIES_

COMMITMENTS AND CONTINGENCIES (Tables)	12 Months Ended
	Dec. 31, 2014
Aggregate Minimum Rental Commitments Under Non-Cancelable Leases	The aggregate minimum rental commitments under non-cancelable leases for the next five years and thereafter, as of December 31, 2014, are as follows (in thousands):
	Years Ending December 31,
	2015	$	17,374
	2016		15,645
	2017		9,698
	2018		8,966
	2019		7,352
	Thereafter		14,219
		$	73,254

SEGMENT_AND_GEOGRAPHIC_INFORMA1

SEGMENT AND GEOGRAPHIC INFORMATION (Tables)	12 Months Ended
	Dec. 31, 2014
Information Regarding Reportable Business Segments	Information regarding our reportable business segments is presented below (in thousands). Segment results exclude the impact of amortization and impairment of goodwill and intangible assets, certain general corporate expenses, and charges related to various integration activities, as defined by management. The accounting policies of the reportable segments are the same as the accounting policies of the Company. We allocate resources and evaluate the performance of segments based on net sales, gross profit, operating income and other non-GAAP measures, as defined in the senior secured credit facilities. We do not allocate assets to reportable segments because a significant portion of our assets are shared by the segments.
		Year Ended December 31,
		2014			2013			2012
	Net sales:
	Bracing and Vascular	$	504,590		$	476,492		$	444,444
	Recovery Sciences		299,122			312,783			331,461
	Surgical Implant		100,139			87,088			72,980
	International		325,315			299,094			280,535
		$	1,229,166		$	1,175,457		$	1,129,420
	Operating income (loss):
	Bracing and Vascular	$	102,933		$	86,447		$	87,694
	Recovery Sciences		84,322			83,028			90,353
	Surgical Implant		12,712			8,669			6,747
	International		62,304			57,515			54,442
	Expenses not allocated to segments and eliminations		(158,520	)		(245,217	)		(146,318	)
		$	103,751		$	(9,558	)	$	92,918
Net Sales by Geographic Area	Following are our net sales by geographic area (in thousands):
		Year Ended December 31,
		2014			2013			2012
	United States	$	903,851		$	876,363		$	848,885
	Other Europe, Middle East, and Africa		156,339			139,252			135,030
	Germany		91,754			88,236			84,527
	Australia and Asia Pacific		39,990			35,025			26,786
	Canada		26,481			27,035			24,588
	Latin America		10,751			9,546			9,604
		$	1,229,166		$	1,175,457		$	1,129,420
Long-lived Assets by Geographic Area	Following are our long-lived assets by geographic area (in thousands):
		December 31,			December 31,
		2014			2013
	United States	$	136,490		$	130,498
	International		16,470			16,830
		$	152,960		$	147,328

UNAUDITED_QUARTERLY_CONSOLIDAT1

UNAUDITED QUARTERLY CONSOLIDATED FINANCIAL DATA (Tables)	12 Months Ended
	Dec. 31, 2014
Unaudited Quarterly Consolidated Financial Data	The following table presents our unaudited quarterly consolidated financial data (in thousands):
		Three months ended
		March 29,			June 28,			September 27,			December 31,
		2014			2014			2014			2014
	Net sales	$	282,744		$	313,867		$	305,501		$	327,054
	Operating income		10,202			25,521			26,861			41,167
	Net loss		(36,173	)		(25,207	)		(21,133	)		(7,049	)
	Net loss attributable to DJOFL		(36,522	)		(25,434	)		(21,206	)		(7,372	)
		Three months ended
		March 30,			June 29,			September 28,			December 31,
		2013			2013			2013			2013
	Net sales	$	279,077		$	294,745		$	288,049		$	313,586
	Operating income (loss)		19,793			26,423			25,375			(81,149	)
	Net loss		(32,126	)		(20,642	)		(18,375	)		(131,419	)
	Net loss attributable to DJOFL		(32,364	)		(20,814	)		(18,488	)		(131,786	)

SUPPLEMENTAL_GUARANTOR_CONDENS1

SUPPLEMENTAL GUARANTOR CONDENSED CONSOLIDATING FINANCIAL STATEMENTS (Tables)	12 Months Ended
	Dec. 31, 2014
Two Thousand And Fourteen
Schedule of Condensed Consolidating Balance Sheets	DJO Finance LLC
	Condensed Consolidating Balance Sheets
	As of December 31, 2014
	(in thousands)
		DJOFL			Guarantors			Non-Guarantors			Eliminations			Consolidated
	Assets
	Current assets:
	Cash and cash equivalents	$	12,958		$	3		$	18,183		$	—		$	31,144
	Accounts receivable, net		—			140,782			47,278			—			188,060
	Inventories, net		—			145,046			31,134			(840	)		175,340
	Deferred tax assets, net		—			24,351			247			—			24,598
	Prepaid expenses and other current assets		160			11,464			5,548			—			17,172
	Total current assets		13,118			321,646			102,390			(840	)		436,314
	Property and equipment, net		—			106,191			14,071			(155	)		120,107
	Goodwill		—			1,066,479			109,260			(34,551	)		1,141,188
	Intangible assets, net		—			853,023			15,008			—			868,031
	Investment in subsidiaries		1,297,699			1,686,557			56,572			(3,040,828	)		—
	Intercompany receivables		836,759			—			—			(836,759	)		—
	Other non-current assets		28,632			1,822			2,399			—			32,853
	Total assets	$	2,176,208		$	4,035,718		$	299,700		$	(3,913,133	)	$	2,598,493
	Liabilities and (Deficit) Equity
	Current liabilities:
	Accounts payable	$	—		$	50,590		$	12,370		$	—		$	62,960
	Current portion of debt obligations		8,912			—			63			—			8,975
	Other current liabilities		29,589			70,073			29,083			—			128,745
	Total current liabilities		38,501			120,663			41,516			—			200,680
	Long-term debt obligations		2,261,941			—			—			—			2,261,941
	Deferred tax liabilities, net		—			237,813			5,310			—			243,123
	Intercompany payables, net		—			552,612			135,833			(688,445	)		—
	Other long-term liabilities		—			12,243			2,122			—			14,365
	Total liabilities		2,300,442			923,331			184,781			(688,445	)		2,720,109
	Noncontrolling interests		—			—			2,618			—			2,618
	Total membership (deficit) equity		(124,234	)		3,112,387			112,301			(3,224,688	)		(124,234	)
	Total liabilities and (deficit) equity	$	2,176,208		$	4,035,718		$	299,700		$	(3,913,133	)	$	2,598,493
Schedule of Condensed Consolidating Statements of Operations	DJO Finance LLC
	Condensed Consolidating Statements of Operations
	For the Year Ended December 31, 2014
	(in thousands)
		DJOFL			Guarantors			Non-			Eliminations			Consolidated
								Guarantors
	Net sales	$	—		$	1,059,241		$	318,849		$	(148,924	)	$	1,229,166
	Costs and operating expenses:
	Cost of sales (exclusive of amortization of intangible assets of $34,368)		—			433,692			230,721			(169,016	)		495,397
	Selling, general and administrative		—			398,491			100,714			—			499,205
	Research and development		—			33,525			4,245			(28	)		37,742
	Amortization of intangible assets		—			89,172			3,899			—			93,071
			—			954,880			339,579			(169,044	)		1,125,415
	Operating (loss) income		—			104,361			(20,730	)		20,120			103,751
	Other (expense) income:
	Interest (expense) income, net		(174,309	)		128			(110	)		—			(174,291	)
	Loss on modification of debt		(938	)		—			—			—			(938	)
	Other income (expense), net		—			(277	)		(4,917	)		—			(5,194	)
	Intercompany income (expense), net		—			(14,848	)		24,037			(9,189	)		—
	Equity in loss of subsidiaries, net		84,713			—			—			(84,713	)		—
			(90,534	)		(14,997	)		19,010			(93,902	)		(180,423	)
	(Loss) income before income taxes		(90,534	)		89,364			(1,720	)		(73,782	)		(76,672	)
	Income tax benefit (provision)		—			(8,638	)		(4,252	)		—			(12,890	)
	Net (loss) income		(90,534	)		80,726			(5,972	)		(73,782	)		(89,562	)
	Net income attributable to noncontrolling interests		—			—			(972	)		—			(972	)
	Net (loss) income attributable to DJOFL	$	(90,534	)	$	80,726		$	(6,944	)	$	(73,782	)	$	(90,534	)
Schedule of Condensed Consolidating Statements of Comprehensive Loss	DJO Finance LLC
	Condensed Consolidating Statements of Comprehensive Loss
	For the Year Ended December 31, 2014
	(in thousands)
		DJOFL			Guarantors			Non-			Eliminations			Consolidated
								Guarantors
	Net (loss) income	$	(90,534	)	$	80,726		$	(5,972	)	$	(73,782	)	$	(89,562	)
	Other comprehensive income, net of taxes:
	Foreign currency translation adjustments, net of tax benefit of $3,871		—			—			(13,167	)		—			(13,167	)
	Other comprehensive income (loss)		—			—			(13,167	)		—			(13,167	)
	Comprehensive (loss) income		(90,534	)		80,726			(19,139	)		(73,782	)		(102,729	)
	Comprehensive income attributable to noncontrolling interests		—			—			(591	)		—			(591	)
	Comprehensive (loss) income attributable to DJO Finance LLC	$	(90,534	)	$	80,726		$	(19,730	)	$	(73,782	)	$	(103,320	)
Schedule of Condensed Consolidating Statements of Cash Flows	DJO Finance LLC
	Condensed Consolidating Statements of Cash Flows
	For the Year Ended December 31, 2014
	(in thousands)
		DJOFL			Guarantors			Non-			Eliminations			Consolidated
								Guarantors
	Cash Flows From Operating Activities:
	Net (loss) income	$	(90,534	)	$	80,726		$	(5,972	)	$	(73,782	)	$	(89,562	)
	Adjustments to reconcile net (loss) income to net cash (used in) provided by operating activities:
	Depreciation		—			29,653			6,265			(179	)		35,739
	Amortization of intangible assets		—			89,172			3,899			—			93,071
	Amortization of debt issuance costs and non-cash interest expense		8,692			—			—			—			8,692
	Loss on modification and extinguishment of debt		938			—			—			—			938
	Stock-based compensation expense		—			1,869			—			—			1,869
	(Gain) loss on disposal of assets, net		—			(948	)		105			—			(843	)
	Deferred income tax expense (benefit)		—			8,450			(1,104	)		(988	)		6,358
	Equity in loss of subsidiaries, net		(84,713	)		—			—			84,713			—
	Changes in operating assets and liabilities, net of acquired assets and liabilities:
	Accounts receivable		—			338			(7,609	)		—			(7,271	)
	Inventories		—			(13,212	)		12,746			(20,065	)		(20,531	)
	Prepaid expenses and other assets		—			6,504			4,851			(291	)		11,064
	Accounts payable and other current liabilities		(83	)		3,376			1,618			2,052			6,963
	Net cash (used in) provided by operating activities		(165,700	)		205,928			14,799			(8,540	)		46,487
	Cash Flows From Investing Activities:
	Cash paid in connection with acquisitions, net of cash acquired		—			—			(4,587	)		—			(4,587	)
	Purchases of property and equipment		—			(46,321	)		(6,597	)		125			(52,793	)
	Other investing activities, net		—			(676	)		(362	)		—			(1,038	)
	Net cash (used in) provided by investing activities		—			(46,997	)		(11,546	)		125			(58,418	)
	Cash Flows From Financing Activities:
	Intercompany		149,870			(153,596	)		(4,687	)		8,413			—
	Proceeds from issuance of debt		1,000,294			—			—			—			1,000,294
	Repayments of debt obligations		(990,085	)		—			(134	)		—			(990,219	)
	Payment of debt issuance, modification and extinguishment costs		(1,812	)		—			—			—			(1,812	)
	Investment by parent		22			—			—			—			22
	Payment of contingent consideration		—			(5,690	)		—			—			(5,690	)
	Cancellation of vested options		(2,001	)		—			—			—			(2,001	)
	Dividend paid by subsidiary to owners of noncontrolling interests		—			—			(617	)		—			(617	)
	Net cash provided by (used in) financing activities		156,288			(159,286	)		(5,438	)		8,413			(23	)
	Effect of exchange rate changes on cash and cash equivalents		—			—			(480	)		—			(480	)
	Net decrease in cash and cash equivalents		(9,412	)		(355	)		(2,665	)		(2	)		(12,434	)
	Cash and cash equivalents, beginning of year		22,370			358			20,848			2			43,578
	Cash and cash equivalents, end of year	$	12,958		$	3		$	18,183		$	—		$	31,144
Two Thousand And Thirteen
Schedule of Condensed Consolidating Balance Sheets	DJO Finance LLC
	Condensed Consolidating Balance Sheets
	As of December 31, 2013
	(in thousands)
		DJOFL			Guarantors			Non-Guarantors			Eliminations			Consolidated
	Assets
	Current assets:
	Cash and cash equivalents	$	22,370		$	358		$	20,848		$	2		$	43,578
	Accounts receivable, net		—			141,121			43,967			—			185,088
	Inventories, net		—			126,529			33,439			(4,985	)		154,983
	Deferred tax assets, net		—			27,286			241			—			27,527
	Prepaid expenses and other current assets		160			16,469			10,596			726			27,951
	Total current assets		22,530			311,763			109,091			(4,257	)		439,127
	Property and equipment, net		—			93,229			14,834			(234	)		107,829
	Goodwill		—			1,066,479			121,998			(39,146	)		1,149,331
	Intangible assets, net		—			941,550			17,443			—			958,993
	Investment in subsidiaries		1,297,699			1,686,557			62,344			(3,046,600	)		—
	Intercompany receivables		911,630			—			—			(911,630	)		—
	Other non-current assets		35,675			1,828			1,996			—			39,499
	Total assets	$	2,267,534		$	4,101,406		$	327,706		$	(4,001,867	)	$	2,694,779
	Liabilities and (Deficit) Equity
	Current liabilities:
	Accounts payable	$	—		$	45,639		$	10,736		$	(1	)	$	56,374
	Current portion of debt obligations		8,620			—			—			—			8,620
	Other current liabilities		29,673			77,220			31,564			697			139,154
	Total current liabilities		38,293			122,859			42,300			696			204,148
	Long-term debt obligations		2,251,167			—			—			—			2,251,167
	Deferred tax liabilities, net		—			236,230			5,798			—			242,028
	Intercompany payables, net		—			693,513			143,637			(837,150	)		—
	Other long-term liabilities		—			13,820			2,898			—			16,718
	Total liabilities		2,289,460			1,066,422			194,633			(836,454	)		2,714,061
	Noncontrolling interests		—			—			2,644			—			2,644
	Total membership (deficit) equity		(21,926	)		3,034,984			130,429			(3,165,413	)		(21,926	)
	Total liabilities and (deficit) equity	$	2,267,534		$	4,101,406		$	327,706		$	(4,001,867	)	$	2,694,779
Schedule of Condensed Consolidating Statements of Operations	DJO Finance LLC
	Condensed Consolidating Statements of Operations
	For the Year Ended December 31, 2013
	(in thousands)
		DJOFL			Guarantors			Non-Guarantors			Eliminations			Consolidated
	Net sales	$	—		$	1,026,249		$	282,317		$	(133,109	)	$	1,175,457
	Costs and operating expenses:
	Cost of sales (exclusive of amortization of intangible assets of $35,125)		—			426,889			191,135			(146,359	)		471,665
	Selling, general and administrative		—			383,961			94,022			7			477,990
	Research and development		—			29,621			3,577			23			33,221
	Amortization of intangible assets		—			90,170			5,369			—			95,539
	Impairment of goodwill		—			102,000			—			—			102,000
	Impairment of intangible assets		—			4,600			—			—			4,600
			—			1,037,241			294,103			(146,329	)		1,185,015
	Operating (loss) income		—			(10,992	)		(11,786	)		13,220			(9,558	)
	Other (expense) income:
	Interest (expense) income, net		(177,570	)		109			(81	)		—			(177,542	)
	Loss on modification and extinguishment of debt		(1,059	)		—			—			—			(1,059	)
	Other income (expense), net		—			(315	)		(10,684	)		9,712			(1,287	)
	Intercompany income (expense), net		—			4,379			17,799			(22,178	)		—
	Equity in (loss) income of subsidiaries, net		(24,823	)		—			—			24,823			—
			(203,452	)		4,173			7,034			12,357			(179,888	)
	(Loss) income before income taxes		(203,452	)		(6,819	)		(4,752	)		25,577			(189,446	)
	Income tax provision		—			(7,828	)		(5,288	)		—			(13,116	)
	Net (loss) income		(203,452	)		(14,647	)		(10,040	)		25,577			(202,562	)
	Net income attributable to noncontrolling interests		—			—			(890	)		—			(890	)
	Net (loss) income attributable to DJOFL	$	(203,452	)	$	(14,647	)	$	(10,930	)	$	25,577		$	(203,452	)
Schedule of Condensed Consolidating Statements of Comprehensive Loss	DJO Finance LLC
	Condensed Consolidating Statements of Comprehensive Loss
	For the Year Ended December 31, 2013
	(in thousands)
		DJOFL			Guarantors			Non-Guarantors			Eliminations			Consolidated
	Net (loss) income	$	(203,452	)	$	(14,647	)	$	(10,040	)	$	25,577		$	(202,562	)
	Other comprehensive income, net of taxes:
	Foreign currency translation adjustments, net of tax provision of $1,212		—			—			19			—			19
	Other comprehensive income		—			—			19			—			19
	Comprehensive (loss) income		(203,452	)		(14,647	)		(10,021	)		25,577			(202,543	)
	Comprehensive income attributable to noncontrolling interests		—			—			(1,010	)		—			(1,010	)
	Comprehensive (loss) income attributable to DJO Finance LLC	$	(203,452	)	$	(14,647	)	$	(11,031	)	$	25,577		$	(203,553	)
Schedule of Condensed Consolidating Statements of Cash Flows	DJO Finance LLC
	Condensed Consolidating Statements of Cash Flows
	For the Year Ended December 31, 2013
	(in thousands)
		DJOFL			Guarantors			Non-			Eliminations			Consolidated
								Guarantors
	Cash Flows from Operating Activities:
	Net (loss) income	$	(203,452	)	$	(14,647	)	$	(10,040	)	$	25,577		$	(202,562	)
	Adjustments to reconcile net (loss) income to net cash (used in) provided by operating activities:
	Depreciation		—			28,002			5,383			(258	)		33,127
	Amortization of intangible assets		—			90,170			5,369			—			95,539
	Amortization of debt issuance costs and non-cash interest expense		8,012			—			—			—			8,012
	Loss on modification and extinguishment of debt		1,059			—			—			—			1,059
	Stock-based compensation expense		—			2,155			—			—			2,155
	Impairment of goodwill		—			102,000			—			—			102,000
	Impairment of intangible assets		—			4,600			—			—			4,600
	Loss on disposal of assets, net		—			424			684			—			1,108
	Deferred income tax expense (benefit)		—			5,824			(1,233	)		147			4,738
	Equity in income of subsidiaries, net		24,823			—			—			(24,823	)		—
	Changes in operating assets and liabilities:
	Accounts receivable		—			(11,533	)		(6,332	)		—			(17,865	)
	Inventories		—			5,799			7,738			(9,064	)		4,473
	Prepaid expenses and other assets		—			(1,076	)		(7,368	)		(311	)		(8,755	)
	Accounts payable and other current liabilities		(1,839	)		(2,863	)		7,597			(744	)		2,151
	Net cash (used in) provided by operating activities		(171,397	)		208,855			1,798			(9,476	)		29,780
	Cash Flows from Investing Activities:
	Cash paid in connection with acquisitions, net of cash acquired		—			(192	)		(1,761	)		—			(1,953	)
	Purchases of property and equipment		—			(29,158	)		(8,310	)		(16	)		(37,484	)
	Other investing activities, net		—			(1,239	)		(387	)		—			(1,626	)
	Net cash used in investing activities		—			(30,589	)		(10,458	)		(16	)		(41,063	)
	Cash Flows from Financing Activities:
	Intercompany		156,598			(181,030	)		14,944			9,488			—
	Proceeds from issuance of debt		549,417			—			—			—			549,417
	Repayments of debt obligations		(523,037	)		—			—			—			(523,037	)
	Payment of debt issuance costs		(2,387	)		—			—			—			(2,387	)
	Dividend paid by subsidiary to owners of noncontrolling interest		—			—			(684	)		—			(684	)
	Net cash provided by (used in) financing activities		180,591			(181,030	)		14,260			9,488			23,309
	Effect of exchange rate changes on cash and cash equivalents		—			—			329			—			329
	Net increase (decrease) in cash and cash equivalents		9,194			(2,764	)		5,929			(4	)		12,355
	Cash and cash equivalents at beginning of period		13,176			3,122			14,919			6			31,223
	Cash and cash equivalents at end of period	$	22,370		$	358		$	20,848		$	2		$	43,578
Two Thousand And Twelve
Schedule of Condensed Consolidating Statements of Operations	DJO Finance LLC
	Condensed Consolidating Statements of Operations
	For the Year Ended December 31, 2012
	(in thousands)
		DJOFL			Guarantors			Non-			Eliminations			Consolidated
								Guarantors
	Net sales	$	—		$	976,874		$	265,137		$	(112,591	)	$	1,129,420
	Costs and operating expenses:
	Cost of sales (exclusive of amortization of intangible assets of $38,355)		—			392,369			178,626			(127,136	)		443,859
	Selling, general and administrative		—			377,086			83,021			4			460,111
	Research and development		—			23,600			4,292			—			27,892
	Amortization of intangible assets		—			93,038			4,205			—			97,243
	Impairment of intangible assets		—			—			7,397			—			7,397
			—			886,093			277,541			(127,132	)		1,036,502
	Operating income (loss)		—			90,781			(12,404	)		14,541			92,918
	Other (expense) income:
	Interest (expense) income, net		(182,909	)		93			(38	)		—			(182,854	)
	Loss on modification of debt		(36,889	)		—			—			—			(36,889	)
	Other income, net		—			2,453			1,100			—			3,553
	Intercompany (expense) income, net		—			(1,297	)		10,584			(9,287	)		—
	Equity in income of subsidiaries, net		100,648			—			—			(100,648	)		—
			(119,150	)		1,249			11,646			(109,935	)		(216,190	)
	(Loss) income before income taxes		(119,150	)		92,030			(758	)		(95,394	)		(123,272	)
	Income tax benefit (provision)		—			8,333			(3,429	)		—			4,904
	Net (loss) income		(119,150	)		100,363			(4,187	)		(95,394	)		(118,368	)
	Net income attributable to noncontrolling interests		—			—			(782	)		—			(782	)
	Net (loss) income attributable to DJOFL	$	(119,150	)	$	100,363		$	(4,969	)	$	(95,394	)	$	(119,150	)
Schedule of Condensed Consolidating Statements of Comprehensive Loss	DJO Finance LLC
	Condensed Consolidating Statements of Comprehensive Loss
	For the Year Ended December 31, 2012
	(in thousands)
		DJOFL			Guarantors			Non-Guarantors			Eliminations			Consolidated
	Net (loss) income	$	(119,150	)	$	100,363		$	(4,187	)	$	(95,394	)	$	(118,368	)
	Other comprehensive income, net of taxes:
	Foreign currency translation adjustments, net of tax provision of $1,386		—			—			1,108			—			1,108
	Other comprehensive income		—			—			1,108			—			1,108
	Comprehensive (loss) income		(119,150	)		100,363			(3,079	)		(95,394	)		(117,260	)
	Comprehensive income attributable to noncontrolling interests		—			—			(824	)		—			(824	)
	Comprehensive (loss) income attributable to DJO Finance LLC	$	(119,150	)	$	100,363		$	(3,903	)	$	(95,394	)	$	(118,084	)
Schedule of Condensed Consolidating Statements of Cash Flows	DJO Finance LLC
	Condensed Consolidating Statements of Cash Flows
	For the Year Ended December 31, 2012
	(in thousands)
		DJOFL			Guarantors			Non-Guarantors			Eliminations			Consolidated
	Cash Flows From Operating Activities:
	Net (loss) income	$	(119,150	)	$	100,363		$	(4,187	)	$	(95,394	)	$	(118,368	)
	Adjustments to reconcile net (loss) income to net cash (used in) provided by operating activities:
	Depreciation		—			25,529			5,049			(362	)		30,216
	Amortization of intangible assets		—			93,038			4,205			—			97,243
	Amortization of debt issuance costs and non-cash interest expense		9,732			—			—			—			9,732
	Stock-based compensation expense		—			2,339			—			—			2,339
	Loss on disposal of assets, net		—			1,098			588			—			1,686
	Impairment of intangible assets		—			—			7,397			—			7,397
	Deferred income benefit		—			(8,493	)		(3,088	)		—			(11,581	)
	Equity in (income) loss of subsidiaries, net		(100,648	)		—			—			100,648			—
	Loss on modification and extinguishment of debt		36,889			—			—			—			36,889
	Changes in operating assets and liabilities, net of acquired assets and liabilities:
	Accounts receivable		—			(4,491	)		(2,773	)		—			(7,264	)
	Inventories		—			(18,687	)		9,725			(12,975	)		(21,937	)
	Prepaid expenses and other assets		—			1,108			169			36			1,313
	Accounts payable and other current liabilities		10,648			9,675			(5,420	)		2,051			16,954
	Net cash (used in) provided by operating activities		(162,529	)		201,479			11,665			(5,996	)		44,619
	Cash Flows From Investing Activities:
	Cash paid in connection with acquisitions, net of cash acquired		—			(29,909	)		—			—			(29,909	)
	Purchases of property and equipment		—			(27,929	)		(5,008	)		(13	)		(32,950	)
	Other investing activities, net		—			(1,106	)		—			—			(1,106	)
	Net cash used in investing activities		—			(58,944	)		(5,008	)		(13	)		(63,965	)
	Cash Flows From Financing Activities:
	Intercompany		149,292			(141,153	)		(14,153	)		6,014			—
	Proceeds from issuance of debt		1,342,450			—			—			—			1,342,450
	Repayments of debt obligations		(1,276,007	)		(38	)		—			—			(1,276,045	)
	Payment of debt issuance, modification and extinguishment costs		(55,827	)		—			—			—			(55,827	)
	Investment by parent		2,000			—			—			—			2,000
	Exercise of indirect parent stock options		24			—			—			—			24
	Dividend paid by subsidiary to owners of noncontrolling interests		—			—			(649	)		—			(649	)
	Net cash provided by (used in) financing activities		161,932			(141,191	)		(14,802	)		6,014			11,953
	Effect of exchange rate changes on cash and cash equivalents		—			—			447			—			447
	Net (decrease) increase in cash and cash equivalents		(597	)		1,344			(7,698	)		5			(6,946	)
	Cash and cash equivalents, beginning of year		13,773			1,778			22,617			1			38,169
	Cash and cash equivalents, end of year	$	13,176		$	3,122		$	14,919		$	6		$	31,223

Recovered_Sheet1

Organization and Basis of Presentation - Additional Information (Detail) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
	Segment	Segment	Segment
Organization And Basis Of Presentation [Line Items]
Number of operating segments	4	4	4
Percentage of ownership interest in subsidiary Medireha GmbH	50.00%
Tunisia
Organization And Basis Of Presentation [Line Items]
Description of infrequent event	In September 2013, a fire occurred at our factory in Tunisia. As a result of the fire, certain inventory and fixed assets were destroyed and the leased facility became inoperable.
Estimated losses for destroyed inventory and fixed assets, excess expenses incurred and building reconstruction	3,300,000	5,000,000
Revenue from business interruption insurance proceeds	2,274,000	1,300,000

Schedule_of_Insurance_Receivab

Schedule of Insurance Receivables Against Property and Business Interruption Insurance Policies (Detail) (Tunisia, USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Tunisia
Unusual or Infrequent Item [Line Items]
Balance, beginning of period	$6,261
Change in estimated losses	-1,617
Business interruption	2,274	1,300
Claim payments	-6,918
Balance, end of period		$6,261

Recovered_Sheet2

Significant Accounting Policies - Additional Information (Detail) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
	Customer	Customer	Customer
Accounting Policies [Line Items]
Amortization expense	$93,071,000	$95,539,000	$97,243,000
Unamortized internally developed software costs	8,500,000	10,500,000
Product warranty, description	We provide expressed warranties on certain products for periods typically ranging from one to three years. We estimate our warranty obligations at the time of sale based upon historical experience and known product issues, if any.
Advertising cost	4,700,000	6,400,000	6,500,000
Foreign transaction (losses) gains	-5,300,000	-1,500,000	3,600,000
Disclosure of major customers	0	0	0
Software Developed For Internal Use
Accounting Policies [Line Items]
Amortization expense	$2,000,000	$1,900,000	$1,900,000
Geographic Concentration Risk | Sales Revenue, Net | International
Accounting Policies [Line Items]
Percentage of net sales	26.50%	25.50%	24.80%
Minimum
Accounting Policies [Line Items]
Estimated useful lives of property and equipment	3 years
Product warranty period	1 year
Minimum | Software Developed For Internal Use
Accounting Policies [Line Items]
Estimated useful lives	3 years
Maximum
Accounting Policies [Line Items]
Estimated useful lives of property and equipment	25 years
Product warranty period	3 years
Maximum | Software Developed For Internal Use
Accounting Policies [Line Items]
Estimated useful lives	10 years

Summary_of_Activity_in_Warrant

Summary of Activity in Warranty Reserves (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Warranty Liability [Line Items]
Balance, beginning of year	$1,847	$1,488	$1,756
Amount charged to expense for estimated warranty costs	1,788	1,138	338
Deductions for actual costs incurred	-1,693	-779	-606
Balance, end of year	$1,942	$1,847	$1,488

Acquisitions_Additional_Inform

Acquisitions - Additional Information (Detail) (USD $)	0 Months Ended	12 Months Ended	0 Months Ended		1 Months Ended
	Dec. 28, 2012	Dec. 31, 2014	Jan. 23, 2014	Mar. 07, 2013	Jul. 01, 2013	Dec. 31, 2013	Dec. 31, 2012
Business Acquisition [Line Items]
Business acquisition, contingent consideration fair value						$5,690,000
Indemnification Asset		The indemnity holdback accrues interest at the Euribor rate plus 100 basis points and is 50% payable in March 2015 and March 2016, respectively, if not used for indemnification claims.
Proceeds from new senior notes issued	25,000,000
Significant Unobservable Inputs (Level 3)
Business Acquisition [Line Items]
Business acquisition, contingent consideration fair value						5,690,000
Period 1
Business Acquisition [Line Items]
Business Acquisition, Payment Date of Contingent Consideration		2015-03
Period 2
Business Acquisition [Line Items]
Business Acquisition, Payment Date of Contingent Consideration		2016-03
Speetec
Business Acquisition [Line Items]
Business acquisition, cash payment			5,000,000
Business acquisition, consideration held for potential indemnity claims			1,300,000
Business acquisition, contingent consideration fair value			1,600,000
Business acquisition, contingent consideration amount total			7,300,000
Business acquisition, Contingent consideration percentage			25.00%
Business acquisition, total purchase price			7,884,000
Business acquisition, inventory payment			2,766,000
Speetec | Significant Unobservable Inputs (Level 3)
Business Acquisition [Line Items]
Business acquisition, contingent consideration fair value		0
Business acquisition, contingent consideration amount total		7,300,000
Business acquisition, Contingent consideration percentage		25.00%
Speetec | Period 1 | Significant Unobservable Inputs (Level 3)
Business Acquisition [Line Items]
Business Acquisition, Payment Date of Contingent Consideration		2015-03
Speetec | Period 2 | Significant Unobservable Inputs (Level 3)
Business Acquisition [Line Items]
Business Acquisition, Payment Date of Contingent Consideration		2016-03
Vasyli
Business Acquisition [Line Items]
Business acquisition, cash payment				1,300,000
Business acquisition, consideration held for potential indemnity claims				400,000
Business acquisition, contingent consideration fair value				300,000		0
Business acquisition, total purchase price				2,186,000
Business acquisition, inventory payment				542,000
Exos
Business Acquisition [Line Items]
Business acquisition, cash payment	31,200,000
Business acquisition, consideration held for potential indemnity claims	3,000,000
Business acquisition, contingent consideration fair value	8,200,000
Business acquisition, total purchase price	40,575,000
Business acquisition, inventory payment	1,754,000
Business acquisition settlement of existing contingent consideration	1,200,000
Direct acquisition costs incurred		1,300,000
Legal fees		500,000
Transaction and advisory fees		800,000
Exos | Significant Unobservable Inputs (Level 3)
Business Acquisition [Line Items]
Business acquisition, contingent consideration fair value	8,200,000						8,200,000
Business acquisition, contingent consideration amount total	10,000,000
Business acquisition, Contingent consideration percentage	95.00%						95.00%
Blue Leaf
Business Acquisition [Line Items]
Business acquisition, cash payment					400,000
Business acquisition, consideration held for potential indemnity claims					100,000
Business acquisition, total purchase price					582,000
Business acquisition, inventory payment					$59,000

Purchase_Price_for_Acquisition

Purchase Price for Acquisition Allocated to Fair Values of Net Tangible and Intangible Assets Acquired (Detail) (USD $)	Dec. 31, 2014	Dec. 31, 2013	Jan. 23, 2014		Mar. 07, 2013		Dec. 28, 2012		Jul. 01, 2013
In Thousands, unless otherwise specified
Business Acquisition [Line Items]
Goodwill	$1,141,188	$1,149,331
Speetec
Business Acquisition [Line Items]
Cash			489
Accounts receivable			608
Inventory			2,766
Other current assets			154
Property and equipment			379
Liabilities assumed			-1,642
Deferred tax liabilities			-1,003
Goodwill			2,383	[1]
Total purchase price			7,884
Speetec | Customer Relationships
Business Acquisition [Line Items]
Identifiable intangible assets			2,861	[2]
Speetec | Non-compete
Business Acquisition [Line Items]
Identifiable intangible assets			569	[2]
Speetec | Trademarks and Trade Names
Business Acquisition [Line Items]
Identifiable intangible assets			320	[2]
Vasyli
Business Acquisition [Line Items]
Inventory					542
Other current assets					31
Property and equipment					12
Goodwill					363	[1]
Total purchase price					2,186
Vasyli | Customer Relationships
Business Acquisition [Line Items]
Identifiable intangible assets					308	[2]
Vasyli | Non-compete
Business Acquisition [Line Items]
Identifiable intangible assets					930	[2]
Exos
Business Acquisition [Line Items]
Cash							1,282
Accounts receivable							1,138
Inventory							1,754
Other current assets							105
Property and equipment							584
Other non-current assets							12
Liabilities assumed							-474
Deferred tax liabilities							-9,137
Goodwill							18,211	[1]
Total purchase price							40,575
Exos | Technology
Business Acquisition [Line Items]
Identifiable intangible assets							24,200	[2]
Exos | Non-compete
Business Acquisition [Line Items]
Identifiable intangible assets							1,900	[2]
Exos | Trademarks and Trade Names
Business Acquisition [Line Items]
Identifiable intangible assets							1,000	[2]
Blue Leaf
Business Acquisition [Line Items]
Inventory									59
Goodwill									322	[1]
Total purchase price									582
Blue Leaf | Customer Relationships
Business Acquisition [Line Items]
Identifiable intangible assets									90	[2]
Blue Leaf | Non-compete
Business Acquisition [Line Items]
Identifiable intangible assets									$111	[2]
[1]	Goodwill represents the excess purchase price over the fair value of the identifiable net assets acquired. Among the factors which resulted in the recognition of goodwill for the Speetec acquisition was the opportunity to expand our direct presences in the German market with our surgical products. Among the factors which resulted in the recognition of goodwill for the Blue Leaf and Vasyli assets was the opportunity to expand our direct presence in the local markets with our vascular products. Among the factors which resulted in the recognition of goodwill for Exos was improved our margins on the sale of Exos products and being able to control the rights to future products developed by Exos.
[2]	The fair value of customer relationships was assigned to relationships with major customers existing on the acquisition date based upon an estimate of the future discounted cash flows that would be derived from those customers, after deducting contributory asset charges. The fair value of technology was determined primarily by estimating the present value of future royalty costs that will be avoided due to our ownership of the patents and technology acquired. The fair value of non-compete agreements relate to non-compete agreements entered into with certain members of senior management. The values were determined by estimating the present value of the cash flows associated with having these agreements in place, less the present value of the cash flows assuming the non-compete agreements were not in place. The fair value of trademarks and trade names was determined primarily by estimating the present value of future royalty costs that will be avoided due to our ownership of the trade names and trademarks acquired. The useful lives of the intangible assets acquired were estimated based on the underlying agreements and/or the future economic benefit expected to be received from the assets.

Summary_of_Activity_in_Account

Summary of Activity in Accounts Receivable Reserves for Doubtful Accounts and Sales Returns (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Accounts, Notes, Loans and Financing Receivable [Line Items]
Balance, beginning of year	$32,957	$25,211	$35,649
Provision for doubtful accounts	40,164	33,129	19,586
Write-offs, net of recoveries	-31,719	-25,383	-30,024
Balance, end of year	$41,402	$32,957	$25,211

Accounts_Receivable_Reserves_A

Accounts Receivable Reserves - Additional Information (Detail) (USD $)	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
In Millions, unless otherwise specified
Accounts, Notes, Loans and Financing Receivable [Line Items]
Provision for sales returns	$3.60	$3.90	$4

Summary_of_Inventories_Detail

Summary of Inventories (Detail) (USD $)	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
In Thousands, unless otherwise specified
Inventory [Line Items]
Components and raw materials	$59,578	$59,825
Work in process	5,718	7,373
Finished goods	103,042	83,502
Inventory held on consignment	30,978	27,969
Inventory, Gross, Total	199,316	178,669
Inventory reserves	-23,976	-23,686	-17,313	-14,146
Inventories, net	$175,340	$154,983

Summary_of_Activity_of_Reserve

Summary of Activity of Reserves in Inventory (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Inventory [Line Items]
Balance, beginning of year	$23,686	$17,313	$14,146
Provision charged to costs of sales	8,924	10,121	6,350
Write-offs, net of recoveries	-8,634	-3,748	-3,183
Balance, end of year	$23,976	$23,686	$17,313

Components_of_Property_and_Equ

Components of Property and Equipment (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$308,248	$269,983
Accumulated depreciation and amortization	-188,141	-162,154
Property and equipment, net	120,107	107,829
Minimum
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment useful life	3 years
Maximum
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment useful life	25 years
Land
Property, Plant and Equipment [Line Items]
Property and equipment, gross	266	266
Property, Plant and Equipment useful life	Indefinite
Building and Improvements
Property, Plant and Equipment [Line Items]
Property and equipment, gross	28,967	27,229
Building and Improvements | Minimum
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment useful life	3 years
Building and Improvements | Maximum
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment useful life	25 years
Equipment
Property, Plant and Equipment [Line Items]
Property and equipment, gross	137,468	132,688
Equipment | Minimum
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment useful life	2 years
Equipment | Maximum
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment useful life	7 years
Software
Property, Plant and Equipment [Line Items]
Property and equipment, gross	38,627	33,817
Software | Minimum
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment useful life	3 years
Software | Maximum
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment useful life	10 years
Furniture and Fixtures
Property, Plant and Equipment [Line Items]
Property and equipment, gross	12,618	12,223
Furniture and Fixtures | Minimum
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment useful life	3 years
Furniture and Fixtures | Maximum
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment useful life	8 years
Surgical Implant Instrumentation
Property, Plant and Equipment [Line Items]
Property and equipment, gross	78,275	55,841
Property, Plant and Equipment useful life	5 years
Construction in Progress
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$12,027	$7,919
Property, Plant and Equipment useful life	N/A

Property_and_Equipment_Net_Add

Property and Equipment, Net - Additional Information (Detail) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Property, Plant and Equipment [Line Items]
Depreciation and amortization expense	$35.70	$33.10	$30.20

Schedule_of_Changes_in_Carryin

Schedule of Changes in Carrying Amount of Goodwill (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Goodwill [Line Items]
Goodwill, balance, beginning of period	$1,375,437
Accumulated impairment losses, balance, beginning of period	-226,106
Balance, beginning of period	1,149,331
Acquisitions (see Note 3)	2,383
Foreign currency translation	-10,526
Goodwill, balance, end of period	1,367,294
Accumulated impairment losses, balance, end of period	-226,106
Balance, end of period	1,141,188
Bracing and Vascular
Goodwill [Line Items]
Goodwill, balance, beginning of period		483,258
Balance, beginning of period		483,258
Goodwill, balance, end of period	483,258	483,258
Balance, end of period	483,258	483,258
Recovery Sciences
Goodwill [Line Items]
Goodwill, balance, beginning of period		495,999
Accumulated impairment losses, balance, beginning of period		-178,700
Balance, beginning of period		317,299
Goodwill, balance, end of period	495,999	495,999
Accumulated impairment losses, balance, end of period	-178,700	-178,700
Balance, end of period	317,299	317,299
Surgical Implant
Goodwill [Line Items]
Goodwill, balance, beginning of period		47,406
Accumulated impairment losses, balance, beginning of period		-47,406
Goodwill, balance, end of period	47,406	47,406
Accumulated impairment losses, balance, end of period	-47,406	-47,406
International
Goodwill [Line Items]
Goodwill, balance, beginning of period	348,774
Balance, beginning of period	348,774
Acquisitions (see Note 3)	2,383
Foreign currency translation	-10,526
Goodwill, balance, end of period	340,631
Balance, end of period	$340,631

Long_Lived_Assets_Additional_I

Long Lived Assets - Additional Information (Detail) (USD $)	12 Months Ended			3 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2014	Dec. 31, 2013
Acquired Finite-Lived Intangible Assets [Line Items]
Number of reporting units without impairment			6
Goodwill impairment charges	$102,000
Impairment charge of intangible assets	4,600	7,397
Minimum
Acquired Finite-Lived Intangible Assets [Line Items]
Percentage by which the fair value exceeds the carrying value			30.90%
Maximum
Acquired Finite-Lived Intangible Assets [Line Items]
Percentage by which the fair value exceeds the carrying value			126.10%
Significant Unobservable Inputs (Level 3) | Minimum
Acquired Finite-Lived Intangible Assets [Line Items]
Estimated revenue growth rate			1.00%
Discount rates			9.60%
Terminal value growth rate			1.40%
Significant Unobservable Inputs (Level 3) | Maximum
Acquired Finite-Lived Intangible Assets [Line Items]
Estimated revenue growth rate			6.00%
Discount rates			11.30%
Terminal value growth rate			3.00%
Chattanooga
Acquired Finite-Lived Intangible Assets [Line Items]
Goodwill impairment charges				49,500
Empi
Acquired Finite-Lived Intangible Assets [Line Items]
Goodwill impairment charges				52,500
Customer Relationships
Acquired Finite-Lived Intangible Assets [Line Items]
Definite-lived intangible assets, weighted average useful lives			5 years 1 month 6 days
Patents and Technology
Acquired Finite-Lived Intangible Assets [Line Items]
Definite-lived intangible assets, weighted average useful lives			8 years 3 months 18 days
Distributor Contracts And Relationships
Acquired Finite-Lived Intangible Assets [Line Items]
Definite-lived intangible assets, weighted average useful lives			2 years 8 months 12 days
Trademarks and Trade Names
Acquired Finite-Lived Intangible Assets [Line Items]
Definite-lived intangible assets, weighted average useful lives			6 years 2 months 12 days
Non-compete
Acquired Finite-Lived Intangible Assets [Line Items]
Definite-lived intangible assets, weighted average useful lives			2 years 2 months 12 days
Trade Names | Minimum
Acquired Finite-Lived Intangible Assets [Line Items]
Discount rates			9.60%
Terminal value growth rate			1.40%
Percentage by which the fair value exceeds the carrying value			10.50%
Market average royalty rates			0.50%
Trade Names | Maximum
Acquired Finite-Lived Intangible Assets [Line Items]
Discount rates			11.30%
Terminal value growth rate			3.00%
Percentage by which the fair value exceeds the carrying value			89.60%
Market average royalty rates			5.00%
Trade Names | Empi
Acquired Finite-Lived Intangible Assets [Line Items]
Impairment charge of intangible assets				$4,500

Summary_of_Identifiable_Intang

Summary of Identifiable Intangible Assets (Detail) (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Finite-Lived Intangible Assets [Line Items]
Net identifiable intangible assets	$868,031	$958,993
Gross Carrying Amount	1,093,391	1,093,613
Accumulated Amortization	-623,511	-533,904
Intangible Assets, Net	469,880	559,709
Customer Relationships
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	569,360	570,070
Accumulated Amortization	-341,353	-290,359
Intangible Assets, Net	228,007	279,711
Patents and Technology
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	486,466	486,246
Accumulated Amortization	-264,132	-230,111
Intangible Assets, Net	222,334	256,135
Trademarks and Trade Names
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	25,970	25,820
Accumulated Amortization	-9,902	-7,102
Intangible Assets, Net	16,068	18,718
Indefinite lived intangible assets	398,151	399,284
Distributor Contracts And Relationships
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	4,771	5,054
Accumulated Amortization	-3,401	-3,183
Intangible Assets, Net	1,370	1,871
Non-compete
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	6,824	6,423
Accumulated Amortization	-4,723	-3,149
Intangible Assets, Net	$2,101	$3,274

Schedule_of_Estimated_Amortiza

Schedule of Estimated Amortization Expense (Detail) (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Finite Lived Intangible Assets Future Amortization Expense [Line Items]
2015	$88,405
2016	83,874
2017	72,712
2018	62,552
2019	51,742
Thereafter	110,595
Intangible Assets, Net	$469,880	$559,709

Goodwill_and_Intangible_Assets

Goodwill and Intangible Assets by Segment (Detail) (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Goodwill And Intangible Assets [Line Items]
Goodwill	$1,141,188	$1,149,331
Intangible assets, net	868,031	958,993
Bracing and Vascular
Goodwill And Intangible Assets [Line Items]
Goodwill	483,258	483,258
Intangible assets, net	487,122	527,806
Recovery Sciences
Goodwill And Intangible Assets [Line Items]
Goodwill	317,299	317,299
Intangible assets, net	218,260	250,725
International
Goodwill And Intangible Assets [Line Items]
Goodwill	340,631	348,774
Intangible assets, net	150,128	165,569
Surgical Implant
Goodwill And Intangible Assets [Line Items]
Intangible assets, net	$12,521	$14,893

Schedule_of_Other_Current_Liab

Schedule of Other Current Liabilities (Detail) (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Other Current Liabilities [Line Items]
Accrued wages and related expenses	$32,220	$33,128
Accrued commissions	16,611	16,489
Accrued rebates	12,981	10,731
Accrued other taxes	4,987	4,734
Accrued professional expenses	2,682	3,372
Income taxes payable	2,477	2,877
Deferred tax liability	343	445
Other accrued liabilities	26,844	37,696
Other current liabilities	$99,145	$109,472

Employee_Benefit_Plans_Additio

Employee Benefit Plans - Additional Information (Detail) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Employee Benefit And Retirement Plans [Line Items]
Contributions made according to the plans	$4.10	$4.20	$4
Contributions towards international contribution plans	$1.70	$1.10	$1.30
The first 1%
Employee Benefit And Retirement Plans [Line Items]
Matching contributions made as a percentage of employee contribution	100.00%	100.00%	100.00%
The next 5%
Employee Benefit And Retirement Plans [Line Items]
Matching contributions made as a percentage of employee contribution	50.00%	50.00%	50.00%

Schedule_of_Information_Regard

Schedule of Information Regarding Notional Amounts of Foreign Exchange Forward Contracts (Detail) (Foreign Exchange Contract, Not Designated as Hedging Instrument)	Dec. 31, 2014	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2013
In Thousands, unless otherwise specified	USD ($)	MXN	USD ($)	MXN
Derivatives, Fair Value [Line Items]
Foreign exchange contracts not designated as hedges	$526	7,682	$22,959	302,730

Summary_of_Location_and_Fair_V

Summary of Location and Fair Value of Derivative Instruments in Condensed Consolidated Balance Sheets (Detail) (Not Designated as Hedging Instrument, Foreign Exchange Forward, Other Current Liabilities, USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Not Designated as Hedging Instrument | Foreign Exchange Forward | Other Current Liabilities
Derivatives, Fair Value [Line Items]
Derivative Liabilities	$4	$44

Summary_of_Effect_of_Derivativ

Summary of Effect of Derivative Instruments on Condensed Consolidated Statements of Operations (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Derivative Instruments, Gain (Loss) [Line Items]
Effect of derivative instruments	$40	($821)	$1,322
Foreign Exchange Forward | Other income (expense), net | Not Designated as Hedging Instrument
Derivative Instruments, Gain (Loss) [Line Items]
Effect of derivative instruments	$40	($821)	$1,322

Fair_Value_Measurements_Additi

Fair Value Measurements - Additional Information (Detail) (USD $)	12 Months Ended	1 Months Ended	0 Months Ended	12 Months Ended	0 Months Ended
	Dec. 31, 2014	Apr. 30, 2014	Dec. 28, 2012	Dec. 31, 2013	Jan. 23, 2014	Dec. 31, 2012
Fair Value Measurements Disclosure [Line Items]
Business acquisition, contingent consideration fair value				$5,690,000
Period 1
Fair Value Measurements Disclosure [Line Items]
Business Acquisition, Payment Date of Contingent Consideration	2015-03
Period 2
Fair Value Measurements Disclosure [Line Items]
Business Acquisition, Payment Date of Contingent Consideration	2016-03
Significant Unobservable Inputs (Level 3)
Fair Value Measurements Disclosure [Line Items]
Business acquisition, contingent consideration fair value				5,690,000
Exos
Fair Value Measurements Disclosure [Line Items]
Business acquisition, contingent consideration fair value			8,200,000
Business acquisition, payment of contingent consideration		5,700,000
Exos | Significant Unobservable Inputs (Level 3)
Fair Value Measurements Disclosure [Line Items]
Business acquisition, contingent consideration amount total			10,000,000
Business acquisition, Contingent consideration percentage			95.00%			95.00%
Business acquisition, contingent consideration fair value			8,200,000			8,200,000
Business acquisition, reduction in fair Value of contingent consideration				2,500,000
Speetec
Fair Value Measurements Disclosure [Line Items]
Business acquisition, contingent consideration amount total					7,300,000
Business acquisition, Contingent consideration percentage					25.00%
Business acquisition, contingent consideration fair value					1,600,000
Speetec | Significant Unobservable Inputs (Level 3)
Fair Value Measurements Disclosure [Line Items]
Business acquisition, contingent consideration amount total	7,300,000
Business acquisition, Contingent consideration percentage	25.00%
Business acquisition, contingent consideration expected discount rate	9.90%
Business acquisition, contingent consideration fair value	0
Speetec | Significant Unobservable Inputs (Level 3) | Period 1
Fair Value Measurements Disclosure [Line Items]
Business Acquisition, Payment Date of Contingent Consideration	2015-03
Speetec | Significant Unobservable Inputs (Level 3) | Period 2
Fair Value Measurements Disclosure [Line Items]
Business Acquisition, Payment Date of Contingent Consideration	2016-03

Schedule_of_Assets_and_Liabili

Schedule of Assets and Liabilities Measured at Fair Value on Recurring Basis (Detail) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Foreign exchange forward contracts not designated as hedges	$4,000	$44,000
Contingent consideration		5,690,000
Significant Other Observable Inputs (Level 2)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Foreign exchange forward contracts not designated as hedges	4,000	44,000
Significant Unobservable Inputs (Level 3)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent consideration		$5,690,000

Reconciliation_of_All_Financia

Reconciliation of All Financial Assets and Liabilities Measured at Fair Value on Recurring Basis Using Significant Unobservable Inputs (Level 3) (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Balance, beginning of period	$5,690
Acquisitions	1,627
Payment of contingent consideration	-5,690
Adjustment of contingent consideration included in SG&A	-1,482
Foreign currency translation	($145)

Schedule_of_Debt_Obligations_D

Schedule of Debt Obligations (Detail) (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Debt Instrument [Line Items]
Other	$63
Debt	2,270,916	2,259,787
Current maturities	-8,975	-8,620
Long-term debt	2,261,941	2,251,167
Revolving Credit Facility | Senior Secured Credit Facility
Debt Instrument [Line Items]
Debt	17,000	38,000
New Tranche B Term Loan | Senior Secured Credit Facility
Debt Instrument [Line Items]
Debt	879,476
Tranche B Term Loan Facility | Senior Secured Credit Facility
Debt Instrument [Line Items]
Debt		846,297
8.75% Second Priority Senior Secured Notes
Debt Instrument [Line Items]
Debt	334,377	335,490
9.875% Senior unsecured notes
Debt Instrument [Line Items]
Debt	440,000	440,000
7.75% Senior Unsecured Notes
Debt Instrument [Line Items]
Debt	300,000	300,000
9.75% Senior subordinated notes
Debt Instrument [Line Items]
Debt	$300,000	$300,000

Schedule_of_Debt_Obligations_P

Schedule of Debt Obligations (Parenthetical) (Detail) (USD $)	Dec. 31, 2014	Dec. 31, 2013	Sep. 30, 2012	Mar. 20, 2012	Oct. 01, 2012	Apr. 07, 2011	Oct. 18, 2010
In Millions, unless otherwise specified
8.75% Second Priority Senior Secured Notes
Debt Instrument [Line Items]
Term loan facility, face amount net			$330	$330
Stated percentage rate	8.75%		8.75%	8.75%
Unamortized original issue premium	4.4	5.5
9.875% Senior unsecured notes
Debt Instrument [Line Items]
Term loan facility, face amount net					440
Stated percentage rate	9.88%				9.88%
7.75% Senior Unsecured Notes
Debt Instrument [Line Items]
Term loan facility, face amount net						300
Stated percentage rate	7.75%
9.75% Senior subordinated notes
Debt Instrument [Line Items]
Term loan facility, face amount net							300
Stated percentage rate	9.75%
Senior Secured Credit Facility | New Tranche B Term Loan
Debt Instrument [Line Items]
Term loan facility, face amount net	884.6
Term loan facility, unamortized original issue discount	5.1
Senior Secured Credit Facility | Tranche B Term Loan Facility
Debt Instrument [Line Items]
Term loan facility, face amount net		853.4
Term loan facility, unamortized original issue discount		$7.10

Debt_Additional_Information_De

Debt - Additional Information (Detail) (USD $)	0 Months Ended	12 Months Ended	0 Months Ended
In Millions, unless otherwise specified	Dec. 28, 2012	Dec. 31, 2014	Mar. 21, 2013	Apr. 08, 2014	Nov. 20, 2007
Debt Instrument [Line Items]
Issuance of term loans	$25
Leverage ratio of consolidated senior secured first lien to adjusted EBITDA		475.00%
Revolving Credit Facility
Debt Instrument [Line Items]
Market Values of credit facility		15.6
New Term Loans
Debt Instrument [Line Items]
Percentage of annual payments quarterly installments		1.00%
Original Senior Secured Credit Facility | Revolving Credit Facility
Debt Instrument [Line Items]
Senior Secured Credit Facility, face amount					100
Amended Senior Secured Credit Facility
Debt Instrument [Line Items]
Commitment Fees Rate		0.50%
Amended Senior Secured Credit Facility | Original Term Loans
Debt Instrument [Line Items]
Issuance of term loans			421.4
Debt instrument maturity date			15-Sep-17
Leverage ratio			425.00%	475.00%
Amended Senior Secured Credit Facility | Refinancing Term Loans
Debt Instrument [Line Items]
Issuance of term loans				851.2
Amended Senior Secured Credit Facility | Incremental Term Loans
Debt Instrument [Line Items]
Issuance of term loans				40
Senior Secured Credit Facility
Debt Instrument [Line Items]
Weighted Average Interest Rate		4.23%
Percentage of prepay outstanding term loans of annual excess cash flow		50.00%
Percentage of prepay outstanding term loans of non-ordinary course asset sales		100.00%
Annual amount from non-ordinary course asset sales		25
Reinvestment right on-non ordinary course asset, percentage		100.00%
Percentage of cash proceeds from issuance of debt		100.00%
Soft call premium, percentage		1.00%
Senior Secured Credit Facility secured by pledges, capital stock		100.00%
Leverage ratio of consolidated senior secured first lien to adjusted EBITDA		308.00%
Senior Secured Credit Facility | Domestic Subsidiaries
Debt Instrument [Line Items]
Senior Secured Credit Facility secured by pledges, capital stock		100.00%
Senior Secured Credit Facility | Foreign Subsidiaries
Debt Instrument [Line Items]
Senior Secured Credit Facility secured by pledges, capital stock		65.00%
Senior Secured Credit Facility | Minimum
Debt Instrument [Line Items]
Percentage of prepay outstanding term loans of annual excess cash flow		25.00%
Senior Secured Credit Facility | Maximum
Debt Instrument [Line Items]
Percentage of prepay outstanding term loans of annual excess cash flow		0.00%
Senior Secured Credit Facility | Eurodollar Rate Plus
Debt Instrument [Line Items]
Revolving Credit Facility, percentage points added to the reference rate		3.25%
Senior Secured Credit Facility | Federal Funds Rate Plus
Debt Instrument [Line Items]
Revolving Credit Facility, percentage points added to the reference rate		0.50%
Senior Secured Credit Facility | One Month Eurodollar Rate
Debt Instrument [Line Items]
Revolving Credit Facility, percentage points added to the reference rate		3.25%
Tranche B Term Loan Facility
Debt Instrument [Line Items]
Market Values of credit facility		862.4
New Tranche B Term Loan | Base Rate Borrowings
Debt Instrument [Line Items]
Revolving Credit Facility, percentage points added to the reference rate		3.25%
New Tranche B Term Loan | LIBOR
Debt Instrument [Line Items]
Revolving Credit Facility, percentage points added to the reference rate		1.00%
New Tranche B Term Loan | Eurodollar Rate Plus
Debt Instrument [Line Items]
Revolving Credit Facility, percentage points added to the reference rate		3.25%

Debt_Senior_Notes_Debt_Issuanc

Debt (Senior Notes, Debt Issuance Costs and Loss on Modification and Extinguishment of Debt) - Additional Information (Detail) (USD $)	12 Months Ended			0 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Oct. 01, 2012	Sep. 30, 2012	Mar. 20, 2012	Apr. 07, 2011	Oct. 18, 2010
Debt Instrument [Line Items]
Loss on modification and extinguishment of debt	($938,000)	($1,059,000)	($36,889,000)
Arrangement, amendment and other fees of debt	300,000	900,000
Non-cash write off of unamortized debt issuance costs	600,000	200,000
Unamortized debt issuance costs	28,600,000	35,700,000
Amortization of debt issuance costs	8,100,000	7,300,000	8,900,000
Amended Senior Secured Credit Facility
Debt Instrument [Line Items]
Capitalized debt issuance costs	1,500,000	1,500,000
8.75% Second Priority Senior Secured Notes
Debt Instrument [Line Items]
Aggregate principal amount of debt issued					330,000,000	330,000,000
Debt instrument, stated percentage rate	8.75%				8.75%	8.75%
Debt instrument maturity date	15-Mar-18
Percentage of aggregate principal amount of notes to be outstanding	65.00%
Repurchase price percentage	101.00%
8.75% Second Priority Senior Secured Notes | 8.75 % Second Priority Senior Secured Notes Optional Redemption on March 15, 2015
Debt Instrument [Line Items]
Redemption price	104.38%
8.75% Second Priority Senior Secured Notes | 8.75 % Second Priority Senior Secured Notes Optional Redemption On March 15, 2016
Debt Instrument [Line Items]
Redemption price	102.19%
8.75% Second Priority Senior Secured Notes | 8.75 % Second Priority Senior Secured Notes Optional Redemption on March 15, 2017
Debt Instrument [Line Items]
Redemption price	100.00%
8.75% Second Priority Senior Secured Notes | 8.75 % Second Priority Senior Secured Notes Optional Redemption prior to March 15, 2015
Debt Instrument [Line Items]
Redemption price	108.75%
Percentage of debt redeemed	35.00%
9.875% Senior unsecured notes
Debt Instrument [Line Items]
Aggregate principal amount of debt issued				440,000,000
Debt instrument, stated percentage rate	9.88%			9.88%
Debt instrument maturity date				15-Apr-18
Percentage of aggregate principal amount of notes to be outstanding	65.00%
Repurchase price percentage	101.00%
9.875% Senior unsecured notes | Nine Point Eight Seven Five Percentage Senior Notes Optional Redemption On April Fifteen Two Thousand Fifteen
Debt Instrument [Line Items]
Redemption price	104.94%
9.875% Senior unsecured notes | Nine Point Eight Seven Five Percentage Senior Notes Optional Redemption On April Fifteen Two Thousand Sixteen
Debt Instrument [Line Items]
Redemption price	102.47%
9.875% Senior unsecured notes | Nine Point Eight Seven Five Percentage Senior Notes Optional Redemption On April Fifteen Two Thousand Seventeen
Debt Instrument [Line Items]
Redemption price	100.00%
9.875% Senior unsecured notes | Senior Notes Redeemable Prior to April 15th 2015
Debt Instrument [Line Items]
Redemption price	109.88%
Percentage of debt redeemed	35.00%
7.75% Senior Unsecured Notes
Debt Instrument [Line Items]
Aggregate principal amount of debt issued							300,000,000
Debt instrument, stated percentage rate	7.75%
Debt instrument maturity date	15-Apr-18
Repurchase price percentage	101.00%
7.75% Senior Unsecured Notes | 7.75 % Senior Notes Optional Redemption On April 15, 2014
Debt Instrument [Line Items]
Redemption price	105.81%
7.75% Senior Unsecured Notes | 7.75 % Senior Notes Optional Redemption On April 15, 2015
Debt Instrument [Line Items]
Redemption price	103.88%
7.75% Senior Unsecured Notes | 7.75 % Senior Notes Optional Redemption On April 15, 2016
Debt Instrument [Line Items]
Redemption price	101.94%
7.75% Senior Unsecured Notes | 7.75 % Senior Notes Optional Redemption On April 15, 2017
Debt Instrument [Line Items]
Redemption price	100.00%
9.75% Senior subordinated notes
Debt Instrument [Line Items]
Aggregate principal amount of debt issued								300,000,000
Debt instrument, stated percentage rate	9.75%
Debt instrument maturity date	15-Oct-17
Repurchase price percentage	101.00%
9.75% Senior subordinated notes | 9.75 % Senior Subordinated Notes Optional Redemption On October 15, 2014
Debt Instrument [Line Items]
Redemption price	104.88%
9.75% Senior subordinated notes | 9.75 % Senior Subordinated Notes Optional Redemption On October 15, 2015
Debt Instrument [Line Items]
Redemption price	102.44%
9.75% Senior subordinated notes | 9.75 % Senior Subordinated Notes Optional Redemption On October 15, 2016
Debt Instrument [Line Items]
Redemption price	100.00%
Significant Other Observable Inputs (Level 2) | 8.75% Second Priority Senior Secured Notes
Debt Instrument [Line Items]
Debt instrument, stated percentage rate	8.75%
Market value	344,000,000
Significant Other Observable Inputs (Level 2) | 9.875% Senior unsecured notes
Debt Instrument [Line Items]
Market value	442,200,000
Significant Other Observable Inputs (Level 2) | 7.75% Senior Unsecured Notes
Debt Instrument [Line Items]
Market value	286,500,000
Significant Other Observable Inputs (Level 2) | 9.75% Senior subordinated notes
Debt Instrument [Line Items]
Market value	$294,000,000

Principal_Maturities_of_LongTe

Principal Maturities of Long-Term Debt and Capital Leases (Detail) (USD $)	Dec. 31, 2014
In Thousands, unless otherwise specified
Debt and Capital Lease Obligations [Line Items]
2015	$8,975
2016	8,912
2017	1,183,736
2018	1,070,000
2019	0
Long-term Debt, Gross, Total	$2,271,623

Membership_Deficit_Additional_

Membership Deficit - Additional Information (Detail) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Class of Stock [Line Items]
Shares issued	115,693	72,151
Options exercised	507,088	221,057
Shares withheld	391,395	148,906
Aggregate market value of shares withheld	$6,500,000	$2,500,000
Remaining common stock issued, shares	115,693	72,151
Common stock issued, shares	6,447		121,506
Cash paid upon retirement to former chief executive officer	2,001,000	2,000,000
Common stock, value per share			$16.46
Stock option exercised	513,535		18,622
Net proceeds from stock purchases			$2,000,000
Chief Executive Officer
Class of Stock [Line Items]
Common stock issued, shares			60,753
New Board Member
Class of Stock [Line Items]
Common stock issued, shares			60,753
Rollover Options
Class of Stock [Line Items]
Shares of vested rollover options canceled		313,681

Recovered_Sheet3

Stock Option Plans and Stock-Based Compensation - Additional Information (Detail) (USD $)	1 Months Ended	12 Months Ended
In Millions, except Share data, unless otherwise specified	Feb. 28, 2013	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares available to grant		10,575,529
Exercise price as a percentage of the fair market value of underlying shares on the date of grant		100.00%
Stock option vest		33.33%
Granted stock options		1,747,268
Stock options granted, total unrecognized stock-based compensation expense		2
Unrecognized stock-based compensation expense, weighted-average period		4 years
Employee Stock Option
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted stock options modified	310,000
Granted stock options		1,747,268	1,082,397	303,767
2013 Vested Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted shares expiration period			10 years
Granted stock options			70,397
Option granted, weighted average grant date fair value			5.23
2014 Vested Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted shares expiration period		10 years
Granted stock options		27,768
Option granted, weighted average grant date fair value		5.28
Performance Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted stock options		1,221,162	768,677	2,482,100
Option granted, weighted average grant date fair value				6.09
Time-Based Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted stock options		498,338	243,323
Option granted, weighted average grant date fair value		6.05	5.99
Board member
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted stock options			100,000
Director
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted stock options			13,800	18,400
Option granted, weighted average grant date fair value			6.02	6.09
Chairman of the Board
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted stock options				100,000
Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted shares expiration period		10 years

Summary_of_Assumptions_Used_to

Summary of Assumptions Used to Estimate Fair Value of Time-Based Options, Vested Options and Director Service Options of Stock Options Granted (Detail)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected volatility, minimum	31.70%	33.40%	35.30%
Expected volatility, maximum	33.40%	35.10%	37.70%
Risk-free interest rate, minimum	1.70%	0.70%	0.80%
Risk-free interest rate, maximum	2.20%	2.00%	1.50%
Expected dividend yield	0.00%	0.00%	0.00%
Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected term until exercise	5 years	5 years	6 years 1 month 6 days
Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected term until exercise	6 years 4 months 24 days	6 years 3 months 18 days	6 years 2 months 12 days

Schedule_of_Recorded_Noncash_S

Schedule of Recorded Non-cash Stock-based Compensation Expense (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Non-cash stock-based compensation expense	$1,869	$2,155	$2,339
Cost of Goods Sold
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Non-cash stock-based compensation expense	82	52	78
Selling, General and Administrative Expenses
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Non-cash stock-based compensation expense	1,782	2,049	2,206
Research and Development Expense
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Non-cash stock-based compensation expense	$5	$54	$55

Summary_of_Option_Activity_Det

Summary of Option Activity (Detail) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Number of Shares
Outstanding at beginning of period	9,017,290
Granted	1,747,268
Exercised	-513,535		-18,622
Forfeited or expired	-1,011,857
Outstanding at end of period	9,239,166	9,017,290
Vested or expected to vest at end of period	5,793,957
Exercisable at end of period	2,496,422
Weighted-Average Exercise Price per Share
Outstanding at beginning of period	$15.79
Granted	$16.46	$16.46
Exercised	$10.89
Forfeited or expired	$16.44
Outstanding at end of period	$16.11	$15.79
Vested or expected to vest at end of period	$15.91
Exercisable at end of period	$15.18
Weighted-Average Remaining Contractual Term (Years)
Outstanding at end of period	6 years 3 months 18 days	6 years 1 month 6 days
Vested or expected to vest at end of period	5 years 6 months
Exercisable at end of period	3 years 7 months 6 days
Aggregate Intrinsic Value
Outstanding at beginning of period	$6,133,210
Outstanding at end of period	3,197,576	6,133,210
Vested or expected to vest at end of period	3,197,576
Exercisable at end of period	$3,197,576

Exercise_of_Stock_Option_Using

Exercise of Stock Option Using Net Exercise Method (Detail) (USD $)	12 Months Ended
In Thousands, except Share data, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Share Based Compensation Arrangements By Share Based Payment Award Options [Line Items]
Options exercised	507,088	221,057
Shares withheld	391,395	148,906
Shares issued	115,693	72,151
Average market value per share withheld	$16.46	$16.46
Aggregate market value of shares withheld (in thousands)	$6,442	$2,451

Components_of_Loss_from_Contin

Components of Loss from Continuing Operations (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Schedule of Components of Income Before Income Tax Expense (Benefit) [Line Items]
U.S. operations	($94,111)	($206,769)	($137,268)
Foreign operations	17,439	17,323	13,996
Loss before income taxes	($76,672)	($189,446)	($123,272)

Components_of_Income_Tax_Provi

Components of Income Tax Provision (Benefit) (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Current income taxes:
U.S. federal	($309)	$1,135	($1,205)
U.S. state	852	870	1,347
Foreign	5,989	6,373	6,330
Total current income taxes	6,532	8,378	6,472
Deferred income taxes:
U.S. federal	8,676	7,460	-3,558
U.S. state	-307	-2,154	-5,751
Foreign	-2,011	-568	-2,067
Total deferred income taxes	6,358	4,738	-11,376
Total income tax provision (benefit)	$12,890	$13,116	($4,904)

Income_Taxes_Additional_Inform

Income Taxes - Additional Information (Detail) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Income Taxes [Line Items]
Gross deferred tax assets	$280,312,000	$265,031,000
Valuation allowances	137,520,000	94,741,000
Deferred tax (income) expense for unrepatriated foreign earnings	-600,000	1,800,000	2,500,000
Expected decrease in unrecognized tax benefits in the next twelve months	-600,000
Unrecognized tax benefits impacting effective tax rate	5,200,000
Interest and penalties included as a component of income tax benefit	400,000	500,000	300,000
Accrued Interest Or Penalties Related To Tax Amounts	2,300,000	2,600,000
Federal
Income Taxes [Line Items]
Net operating loss carryforwards	563,100,000
United States
Income Taxes [Line Items]
Federal statutory income tax rate	35.00%
United States | Minimum
Income Taxes [Line Items]
Operating loss carryforwards, expiration dates	1 year
United States | Maximum
Income Taxes [Line Items]
Operating loss carryforwards, expiration dates	20 years
State
Income Taxes [Line Items]
Net operating loss carryforwards	336,500,000
Foreign
Income Taxes [Line Items]
Net operating loss carryforwards	$2,800,000

Difference_Between_Income_Tax_

Difference Between Income Tax Provision (Benefit) Derived by Applying U.S. Federal Statutory Income Tax Rate to Loss from Continuing Operations Before Income Tax and Income Tax Provision (Benefit) Recognized (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Income Tax Rate Reconciliation [Line Items]
Income tax provision (benefit) derived by applying the U.S. federal statutory income tax rate to loss before income taxes	($26,835)	($66,306)	($43,145)
State tax benefit, net	-2,476	-3,323	-4,275
Change in state effective tax rates	-722	-992	-639
Foreign earnings repatriation	-1,646	2,678	3,199
Unrecognized tax benefits	949	2,216	-7,723
Goodwill impairment		33,687
Prepaid tax asset impairment	-1	229	5,479
Valuation allowance	40,692	50,516	38,845
Research tax credit	-618	-1,249
Equity compensation benefit		-2,864
Permanent differences and other, net	3,547	-1,476	3,355
Total income tax provision (benefit)	$12,890	$13,116	($4,904)

Component_of_Deferred_Tax_Asse

Component of Deferred Tax Asset and Liabilities (Detail) (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Deferred tax assets:
Net operating loss carryforwards	$214,319	$202,387
Receivables reserve	26,709	23,878
Other	39,284	38,766
Gross deferred tax assets	280,312	265,031
Valuation allowance	-137,520	-94,741
Net deferred tax assets	142,792	170,290
Deferred tax liabilities:
Intangible assets	-343,370	-362,950
Foreign earnings repatriation	-13,012	-14,092
Other	-3,987	-7,038
Gross deferred tax liabilities	-360,369	-384,080
Net deferred tax liabilities	($217,577)	($213,790)

Reconciliation_of_Beginning_an

Reconciliation of Beginning and Ending Amount of Gross Unrecognized Tax Benefits (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Income Tax Contingency [Line Items]
Balance, beginning of year	$14,469	$12,342	$19,443
Additions based on tax positions related to current year	1,502	1,531	817
Additions for tax positions related to prior years	354	975	892
Reductions for tax positions of prior years	0	0	0
Reduction due to lapse of statute of limitations	-709	-379	-990
Reductions for settlements of tax positions	-1,711		-7,820
Balance, end of year	$13,905	$14,469	$12,342

Aggregate_Minimum_Rental_Commi

Aggregate Minimum Rental Commitments Under Non-Cancelable Leases (Detail) (USD $)	Dec. 31, 2014
In Thousands, unless otherwise specified
Years Ending December 31,
2015	$17,374
2016	15,645
2017	9,698
2018	8,966
2019	7,352
Thereafter	14,219
Operating Leases, Future Minimum Payments Due, Total	$73,254

Recovered_Sheet4

Commitments And Contingencies - Additional Information (Detail) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
	LegalMatter
Commitments and Contingencies Disclosure [Line Items]
Rental expense under operating leases	$17.40	$17.60	$16.40
Number of pending cases	2
Accrued unpaid settlement	0.7
Canada
Commitments and Contingencies Disclosure [Line Items]
Number of plaintiffs	45
Cold Therapy Litigation
Commitments and Contingencies Disclosure [Line Items]
Number of plaintiffs	172
Number of lawsuits	9
Lawsuit by Insurance Carrier
Commitments and Contingencies Disclosure [Line Items]
Damages sought value	$10

Related_Party_Transactions_Add

Related Party Transactions - Additional Information (Detail) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2014
Related Party Transaction [Line Items]
Maximum annual monitoring fee under advisory and consulting services	$7
Annual monitoring fee maximum under advisory and consulting services, percentage	2.00%
Annual monitoring fee recorded as component of selling, general and administrative expense	$7

Recovered_Sheet5

Segment and Geographic Information - Additional Information (Detail)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
	Customer	Customer	Segment
	Segment	Segment	Customer
Segment Reporting Information [Line Items]
Number of operating segments	4	4	4
Number of individual customer or distributor accounted for 10% or more of total annual net sales	0	0	0

Information_Regarding_Reportab

Information Regarding Reportable Business Segments (Detail) (USD $)	3 Months Ended								12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Sep. 27, 2014	Jun. 28, 2014	Mar. 29, 2014	Dec. 31, 2013	Sep. 28, 2013	Jun. 29, 2013	Mar. 30, 2013	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Net sales:
Net sales	$327,054	$305,501	$313,867	$282,744	$313,586	$288,049	$294,745	$279,077	$1,229,166	$1,175,457	$1,129,420
Operating income (loss):
Operating income (loss)	41,167	26,861	25,521	10,202	-81,149	25,375	26,423	19,793	103,751	-9,558	92,918
Operating Segments | Bracing and Vascular
Net sales:
Net sales									504,590	476,492	444,444
Operating income (loss):
Operating income (loss)									102,933	86,447	87,694
Operating Segments | Recovery Sciences
Net sales:
Net sales									299,122	312,783	331,461
Operating income (loss):
Operating income (loss)									84,322	83,028	90,353
Operating Segments | Surgical Implant
Net sales:
Net sales									100,139	87,088	72,980
Operating income (loss):
Operating income (loss)									12,712	8,669	6,747
Operating Segments | International
Net sales:
Net sales									325,315	299,094	280,535
Operating income (loss):
Operating income (loss)									62,304	57,515	54,442
Expenses not allocated to segments and eliminations
Operating income (loss):
Operating income (loss)									($158,520)	($245,217)	($146,318)

Net_Sales_by_Geographic_Area_D

Net Sales by Geographic Area (Detail) (USD $)	3 Months Ended								12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Sep. 27, 2014	Jun. 28, 2014	Mar. 29, 2014	Dec. 31, 2013	Sep. 28, 2013	Jun. 29, 2013	Mar. 30, 2013	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Net sales
Sales revenue goods net	$327,054	$305,501	$313,867	$282,744	$313,586	$288,049	$294,745	$279,077	$1,229,166	$1,175,457	$1,129,420
United States
Net sales
Sales revenue goods net									903,851	876,363	848,885
Other Europe, Middle East, and Africa
Net sales
Sales revenue goods net									156,339	139,252	135,030
Germany
Net sales
Sales revenue goods net									91,754	88,236	84,527
Australia And Asia Pacific
Net sales
Sales revenue goods net									39,990	35,025	26,786
Canada
Net sales
Sales revenue goods net									26,481	27,035	24,588
Latin America
Net sales
Sales revenue goods net									$10,751	$9,546	$9,604

LongLived_Assets_by_Geographic

Long-Lived Assets by Geographic Area (Detail) (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Long-Lived Assets by Geographic Area:
Long-lived assets	$152,960	$147,328
United States
Long-Lived Assets by Geographic Area:
Long-lived assets	136,490	130,498
International
Long-Lived Assets by Geographic Area:
Long-lived assets	$16,470	$16,830

Recovered_Sheet6

Unaudited Quarterly Consolidated Financial Data (Detail) (USD $)	3 Months Ended								12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Sep. 27, 2014	Jun. 28, 2014	Mar. 29, 2014	Dec. 31, 2013	Sep. 28, 2013	Jun. 29, 2013	Mar. 30, 2013	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Unaudited Quarterly Consolidated Financial Data:
Net sales	$327,054	$305,501	$313,867	$282,744	$313,586	$288,049	$294,745	$279,077	$1,229,166	$1,175,457	$1,129,420
Operating income (loss)	41,167	26,861	25,521	10,202	-81,149	25,375	26,423	19,793	103,751	-9,558	92,918
Net loss	-7,049	-21,133	-25,207	-36,173	-131,419	-18,375	-20,642	-32,126	-89,562	-202,562	-118,368
Net loss attributable to DJOFL	($7,372)	($21,206)	($25,434)	($36,522)	($131,786)	($18,488)	($20,814)	($32,364)	($90,534)	($203,452)	($119,150)

Recovered_Sheet7

Supplemental Guarantor Condensed Consolidating Financial Statements - Additional Information (Detail)	Dec. 31, 2014	Sep. 30, 2012	Mar. 20, 2012	Oct. 01, 2012
8.75% Second Priority Senior Secured Notes
Debt Instrument [Line Items]
Stated percentage rate	8.75%	8.75%	8.75%
9.875% Senior unsecured notes
Debt Instrument [Line Items]
Stated percentage rate	9.88%			9.88%
7.75% Senior Unsecured Notes
Debt Instrument [Line Items]
Stated percentage rate	7.75%
9.75% Senior subordinated notes
Debt Instrument [Line Items]
Stated percentage rate	9.75%
DJO Finco
Debt Instrument [Line Items]
Subsidiaries owned	100.00%
DJO Finco | 8.75% Second Priority Senior Secured Notes
Debt Instrument [Line Items]
Stated percentage rate	8.75%
DJO Finco | 9.875% Senior unsecured notes
Debt Instrument [Line Items]
Stated percentage rate	9.88%
DJO Finco | 7.75% Senior Unsecured Notes
Debt Instrument [Line Items]
Stated percentage rate	7.75%
DJO Finco | 9.75% Senior subordinated notes
Debt Instrument [Line Items]
Stated percentage rate	9.75%

Schedule_of_Condensed_Consolid

Schedule of Condensed Consolidating Balance Sheets (Detail) (USD $)	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
In Thousands, unless otherwise specified
Current assets:
Cash and cash equivalents	$31,144	$43,578	$31,223	$38,169
Accounts receivable, net	188,060	185,088
Inventories, net	175,340	154,983
Deferred tax assets, net	24,598	27,527
Prepaid expenses and other current assets	17,172	27,951
Total current assets	436,314	439,127
Property and equipment, net	120,107	107,829
Goodwill	1,141,188	1,149,331
Intangible assets, net	868,031	958,993
Other non-current assets	32,853	39,499
Total assets	2,598,493	2,694,779
Current liabilities:
Accounts payable	62,960	56,374
Current portion of debt obligations	8,975	8,620
Other current liabilities	128,745	139,154
Total current liabilities	200,680	204,148
Long-term debt obligations	2,261,941	2,251,167
Deferred tax liabilities, net	243,123	242,028
Other long-term liabilities	14,365	16,718
Total liabilities	2,720,109	2,714,061
Noncontrolling interests	2,618	2,644
Total membership (deficit) equity	-124,234	-21,926
Total liabilities and (deficit) equity	2,598,493	2,694,779
DJOFL
Current assets:
Cash and cash equivalents	12,958	22,370	13,176	13,773
Prepaid expenses and other current assets	160	160
Total current assets	13,118	22,530
Investment in subsidiaries	1,297,699	1,297,699
Intercompany receivables	836,759	911,630
Other non-current assets	28,632	35,675
Total assets	2,176,208	2,267,534
Current liabilities:
Current portion of debt obligations	8,912	8,620
Other current liabilities	29,589	29,673
Total current liabilities	38,501	38,293
Long-term debt obligations	2,261,941	2,251,167
Total liabilities	2,300,442	2,289,460
Total membership (deficit) equity	-124,234	-21,926
Total liabilities and (deficit) equity	2,176,208	2,267,534
Guarantors
Current assets:
Cash and cash equivalents	3	358	3,122	1,778
Accounts receivable, net	140,782	141,121
Inventories, net	145,046	126,529
Deferred tax assets, net	24,351	27,286
Prepaid expenses and other current assets	11,464	16,469
Total current assets	321,646	311,763
Property and equipment, net	106,191	93,229
Goodwill	1,066,479	1,066,479
Intangible assets, net	853,023	941,550
Investment in subsidiaries	1,686,557	1,686,557
Other non-current assets	1,822	1,828
Total assets	4,035,718	4,101,406
Current liabilities:
Accounts payable	50,590	45,639
Other current liabilities	70,073	77,220
Total current liabilities	120,663	122,859
Deferred tax liabilities, net	237,813	236,230
Intercompany payables, net	552,612	693,513
Other long-term liabilities	12,243	13,820
Total liabilities	923,331	1,066,422
Total membership (deficit) equity	3,112,387	3,034,984
Total liabilities and (deficit) equity	4,035,718	4,101,406
Non-Guarantors
Current assets:
Cash and cash equivalents	18,183	20,848	14,919	22,617
Accounts receivable, net	47,278	43,967
Inventories, net	31,134	33,439
Deferred tax assets, net	247	241
Prepaid expenses and other current assets	5,548	10,596
Total current assets	102,390	109,091
Property and equipment, net	14,071	14,834
Goodwill	109,260	121,998
Intangible assets, net	15,008	17,443
Investment in subsidiaries	56,572	62,344
Other non-current assets	2,399	1,996
Total assets	299,700	327,706
Current liabilities:
Accounts payable	12,370	10,736
Current portion of debt obligations	63
Other current liabilities	29,083	31,564
Total current liabilities	41,516	42,300
Deferred tax liabilities, net	5,310	5,798
Intercompany payables, net	135,833	143,637
Other long-term liabilities	2,122	2,898
Total liabilities	184,781	194,633
Noncontrolling interests	2,618	2,644
Total membership (deficit) equity	112,301	130,429
Total liabilities and (deficit) equity	299,700	327,706
Eliminations
Current assets:
Cash and cash equivalents		2	6	1
Inventories, net	-840	-4,985
Prepaid expenses and other current assets		726
Total current assets	-840	-4,257
Property and equipment, net	-155	-234
Goodwill	-34,551	-39,146
Investment in subsidiaries	-3,040,828	-3,046,600
Intercompany receivables	-836,759	-911,630
Total assets	-3,913,133	-4,001,867
Current liabilities:
Accounts payable		-1
Other current liabilities		697
Total current liabilities		696
Intercompany payables, net	-688,445	-837,150
Total liabilities	-688,445	-836,454
Total membership (deficit) equity	-3,224,688	-3,165,413
Total liabilities and (deficit) equity	($3,913,133)	($4,001,867)

Schedule_of_Condensed_Consolid1

Schedule of Condensed Consolidating Statements of Operations (Detail) (USD $)	3 Months Ended								12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Sep. 27, 2014	Jun. 28, 2014	Mar. 29, 2014	Dec. 31, 2013	Sep. 28, 2013	Jun. 29, 2013	Mar. 30, 2013	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Net sales	$327,054	$305,501	$313,867	$282,744	$313,586	$288,049	$294,745	$279,077	$1,229,166	$1,175,457	$1,129,420
Cost of sales (exclusive of amortization of intangible assets)									495,397	471,665	443,859
Selling, general and administrative									499,205	477,990	460,111
Research and development									37,742	33,221	27,892
Amortization of intangible assets									93,071	95,539	97,243
Impairment of goodwill										102,000
Impairment of intangible assets										4,600	7,397
Operating Expenses									1,125,415	1,185,015	1,036,502
Operating (loss) income	41,167	26,861	25,521	10,202	-81,149	25,375	26,423	19,793	103,751	-9,558	92,918
Other (expense) income:
Interest (expense) income, net									-174,291	-177,542	-182,854
Loss on modification and extinguishment of debt									-938	-1,059	-36,889
Other income (expense), net									-5,194	-1,287	3,553
Nonoperating Income (Expense), Total									-180,423	-179,888	-216,190
(Loss) income before income taxes									-76,672	-189,446	-123,272
Income tax benefit (provision)									-12,890	-13,116	4,904
Net (loss) income	-7,049	-21,133	-25,207	-36,173	-131,419	-18,375	-20,642	-32,126	-89,562	-202,562	-118,368
Net income attributable to noncontrolling interests									-972	-890	-782
Net (loss) income attributable to DJOFL	-7,372	-21,206	-25,434	-36,522	-131,786	-18,488	-20,814	-32,364	-90,534	-203,452	-119,150
DJOFL
Other (expense) income:
Interest (expense) income, net									-174,309	-177,570	-182,909
Loss on modification and extinguishment of debt									-938	-1,059	-36,889
Equity in (loss) income of subsidiaries, net									84,713	-24,823	100,648
Nonoperating Income (Expense), Total									-90,534	-203,452	-119,150
(Loss) income before income taxes									-90,534	-203,452	-119,150
Net (loss) income									-90,534	-203,452	-119,150
Net (loss) income attributable to DJOFL									-90,534	-203,452	-119,150
Guarantors
Net sales									1,059,241	1,026,249	976,874
Cost of sales (exclusive of amortization of intangible assets)									433,692	426,889	392,369
Selling, general and administrative									398,491	383,961	377,086
Research and development									33,525	29,621	23,600
Amortization of intangible assets									89,172	90,170	93,038
Impairment of goodwill										102,000
Impairment of intangible assets										4,600
Operating Expenses									954,880	1,037,241	886,093
Operating (loss) income									104,361	-10,992	90,781
Other (expense) income:
Interest (expense) income, net									128	109	93
Other income (expense), net									-277	-315	2,453
Intercompany (expense) income, net									-14,848	4,379	-1,297
Nonoperating Income (Expense), Total									-14,997	4,173	1,249
(Loss) income before income taxes									89,364	-6,819	92,030
Income tax benefit (provision)									-8,638	-7,828	8,333
Net (loss) income									80,726	-14,647	100,363
Net (loss) income attributable to DJOFL									80,726	-14,647	100,363
Non-Guarantors
Net sales									318,849	282,317	265,137
Cost of sales (exclusive of amortization of intangible assets)									230,721	191,135	178,626
Selling, general and administrative									100,714	94,022	83,021
Research and development									4,245	3,577	4,292
Amortization of intangible assets									3,899	5,369	4,205
Impairment of intangible assets											7,397
Operating Expenses									339,579	294,103	277,541
Operating (loss) income									-20,730	-11,786	-12,404
Other (expense) income:
Interest (expense) income, net									-110	-81	-38
Other income (expense), net									-4,917	-10,684	1,100
Intercompany (expense) income, net									24,037	17,799	10,584
Nonoperating Income (Expense), Total									19,010	7,034	11,646
(Loss) income before income taxes									-1,720	-4,752	-758
Income tax benefit (provision)									-4,252	-5,288	-3,429
Net (loss) income									-5,972	-10,040	-4,187
Net income attributable to noncontrolling interests									-972	-890	-782
Net (loss) income attributable to DJOFL									-6,944	-10,930	-4,969
Eliminations
Net sales									-148,924	-133,109	-112,591
Cost of sales (exclusive of amortization of intangible assets)									-169,016	-146,359	-127,136
Selling, general and administrative										7	4
Research and development									-28	23
Operating Expenses									-169,044	-146,329	-127,132
Operating (loss) income									20,120	13,220	14,541
Other (expense) income:
Other income (expense), net										9,712
Intercompany (expense) income, net									-9,189	-22,178	-9,287
Equity in (loss) income of subsidiaries, net									-84,713	24,823	-100,648
Nonoperating Income (Expense), Total									-93,902	12,357	-109,935
(Loss) income before income taxes									-73,782	25,577	-95,394
Net (loss) income									-73,782	25,577	-95,394
Net (loss) income attributable to DJOFL									($73,782)	$25,577	($95,394)

Schedule_of_Condensed_Consolid2

Schedule of Condensed Consolidating Statements of Operations (Parenthetical) (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Amortization of intangible assets	$34,368	$35,125	$38,355

Schedule_of_Condensed_Consolid3

Schedule of Condensed Consolidating Statements of Comprehensive Loss (Detail) (USD $)	3 Months Ended								12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Sep. 27, 2014	Jun. 28, 2014	Mar. 29, 2014	Dec. 31, 2013	Sep. 28, 2013	Jun. 29, 2013	Mar. 30, 2013	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Net (loss) income	($7,049)	($21,133)	($25,207)	($36,173)	($131,419)	($18,375)	($20,642)	($32,126)	($89,562)	($202,562)	($118,368)
Other comprehensive income, net of taxes:
Foreign currency translation adjustments, net of tax provision (benefit)									-13,167	19	1,108
Other comprehensive income (loss)									-13,167	19	1,108
Comprehensive (loss) income									-102,729	-202,543	-117,260
Comprehensive income attributable to noncontrolling interests									-591	-1,010	-824
Comprehensive (loss) income attributable to DJO Finance LLC									-103,320	-203,553	-118,084
DJOFL
Net (loss) income									-90,534	-203,452	-119,150
Other comprehensive income, net of taxes:
Comprehensive (loss) income									-90,534	-203,452	-119,150
Comprehensive (loss) income attributable to DJO Finance LLC									-90,534	-203,452	-119,150
Guarantors
Net (loss) income									80,726	-14,647	100,363
Other comprehensive income, net of taxes:
Comprehensive (loss) income									80,726	-14,647	100,363
Comprehensive (loss) income attributable to DJO Finance LLC									80,726	-14,647	100,363
Non-Guarantors
Net (loss) income									-5,972	-10,040	-4,187
Other comprehensive income, net of taxes:
Foreign currency translation adjustments, net of tax provision (benefit)									-13,167	19	1,108
Other comprehensive income (loss)									-13,167	19	1,108
Comprehensive (loss) income									-19,139	-10,021	-3,079
Comprehensive income attributable to noncontrolling interests									-591	-1,010	-824
Comprehensive (loss) income attributable to DJO Finance LLC									-19,730	-11,031	-3,903
Eliminations
Net (loss) income									-73,782	25,577	-95,394
Other comprehensive income, net of taxes:
Comprehensive (loss) income									-73,782	25,577	-95,394
Comprehensive (loss) income attributable to DJO Finance LLC									($73,782)	$25,577	($95,394)

Schedule_of_Condensed_Consolid4

Schedule of Condensed Consolidating Statements of Comprehensive Loss (Parenthetical) (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Foreign currency translation adjustment, tax benefit (provision)	$3,871	($1,212)	($1,386)

Schedule_of_Condensed_Consolid5

Schedule of Condensed Consolidating Statements of Cash Flows (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Cash Flows from Operating Activities:
Net (loss) income	($89,562)	($202,562)	($118,368)
Adjustments to reconcile net (loss) income to net cash (used in) provided by operating activities:
Depreciation	35,739	33,127	30,216
Amortization of intangible assets	93,071	95,539	97,243
Amortization of debt issuance costs and non-cash interest expense	8,692	8,012	9,732
Loss on modification and extinguishment of debt	938	1,059	36,889
Stock-based compensation expense	1,869	2,155	2,339
(Gain) loss on disposal of assets, net	-843	1,108	1,686
Impairment of goodwill		102,000
Impairment of intangible assets		4,600	7,397
Deferred income tax expense (benefit)	6,358	4,738	-11,581
Changes in operating assets and liabilities, net of acquired assets and liabilities:
Accounts receivable	-7,271	-17,865	-7,264
Inventories	-20,531	4,473	-21,937
Prepaid expenses and other assets	11,064	-8,755	1,313
Accounts payable and other current liabilities	6,963	2,151	16,954
Net cash (used in) provided by operating activities	46,487	29,780	44,619
Cash Flows From Investing Activities:
Cash paid in connection with acquisitions, net of cash acquired	-4,587	-1,953	-29,909
Purchases of property and equipment	-52,793	-37,484	-32,950
Other investing activities, net	-1,038	-1,626	-1,106
Net cash (used in) provided by investing activities	-58,418	-41,063	-63,965
Cash Flows From Financing Activities:
Proceeds from issuance of debt	1,000,294	549,417	1,342,450
Repayments of debt obligations	-990,219	-523,037	-1,276,045
Payment of debt issuance costs	-1,812	-2,387	-55,827
Investment by parent			2,000
Exercise of indirect parent stock options	22		24
Payment of contingent consideration	-5,690
Cancellation of vested options	-2,001	-2,000
Dividend paid by subsidiary to owners of noncontrolling interest	-617	-684	-649
Net cash (used in) provided by financing activities	-23	23,309	11,953
Effect of exchange rate changes on cash and cash equivalents	-480	329	447
Net (decrease) increase in cash and cash equivalents	-12,434	12,355	-6,946
Cash and cash equivalents at beginning of period	43,578	31,223	38,169
Cash and cash equivalents at end of period	31,144	43,578	31,223
DJOFL
Cash Flows from Operating Activities:
Net (loss) income	-90,534	-203,452	-119,150
Adjustments to reconcile net (loss) income to net cash (used in) provided by operating activities:
Amortization of debt issuance costs and non-cash interest expense	8,692	8,012	9,732
Loss on modification and extinguishment of debt	938	1,059	36,889
Equity in (income) loss of subsidiaries, net	-84,713	24,823	-100,648
Changes in operating assets and liabilities, net of acquired assets and liabilities:
Accounts payable and other current liabilities	-83	-1,839	10,648
Net cash (used in) provided by operating activities	-165,700	-171,397	-162,529
Cash Flows From Financing Activities:
Intercompany	149,870	156,598	149,292
Proceeds from issuance of debt	1,000,294	549,417	1,342,450
Repayments of debt obligations	-990,085	-523,037	-1,276,007
Payment of debt issuance costs	-1,812	-2,387	-55,827
Investment by parent			2,000
Exercise of indirect parent stock options	22		24
Cancellation of vested options	-2,001
Net cash (used in) provided by financing activities	156,288	180,591	161,932
Net (decrease) increase in cash and cash equivalents	-9,412	9,194	-597
Cash and cash equivalents at beginning of period	22,370	13,176	13,773
Cash and cash equivalents at end of period	12,958	22,370	13,176
Guarantors
Cash Flows from Operating Activities:
Net (loss) income	80,726	-14,647	100,363
Adjustments to reconcile net (loss) income to net cash (used in) provided by operating activities:
Depreciation	29,653	28,002	25,529
Amortization of intangible assets	89,172	90,170	93,038
Stock-based compensation expense	1,869	2,155	2,339
(Gain) loss on disposal of assets, net	-948	424	1,098
Impairment of goodwill		102,000
Impairment of intangible assets		4,600
Deferred income tax expense (benefit)	8,450	5,824	-8,493
Changes in operating assets and liabilities, net of acquired assets and liabilities:
Accounts receivable	338	-11,533	-4,491
Inventories	-13,212	5,799	-18,687
Prepaid expenses and other assets	6,504	-1,076	1,108
Accounts payable and other current liabilities	3,376	-2,863	9,675
Net cash (used in) provided by operating activities	205,928	208,855	201,479
Cash Flows From Investing Activities:
Cash paid in connection with acquisitions, net of cash acquired		-192	-29,909
Purchases of property and equipment	-46,321	-29,158	-27,929
Other investing activities, net	-676	-1,239	-1,106
Net cash (used in) provided by investing activities	-46,997	-30,589	-58,944
Cash Flows From Financing Activities:
Intercompany	-153,596	-181,030	-141,153
Repayments of debt obligations			-38
Payment of contingent consideration	-5,690
Net cash (used in) provided by financing activities	-159,286	-181,030	-141,191
Net (decrease) increase in cash and cash equivalents	-355	-2,764	1,344
Cash and cash equivalents at beginning of period	358	3,122	1,778
Cash and cash equivalents at end of period	3	358	3,122
Non-Guarantors
Cash Flows from Operating Activities:
Net (loss) income	-5,972	-10,040	-4,187
Adjustments to reconcile net (loss) income to net cash (used in) provided by operating activities:
Depreciation	6,265	5,383	5,049
Amortization of intangible assets	3,899	5,369	4,205
(Gain) loss on disposal of assets, net	105	684	588
Impairment of intangible assets			7,397
Deferred income tax expense (benefit)	-1,104	-1,233	-3,088
Changes in operating assets and liabilities, net of acquired assets and liabilities:
Accounts receivable	-7,609	-6,332	-2,773
Inventories	12,746	7,738	9,725
Prepaid expenses and other assets	4,851	-7,368	169
Accounts payable and other current liabilities	1,618	7,597	-5,420
Net cash (used in) provided by operating activities	14,799	1,798	11,665
Cash Flows From Investing Activities:
Cash paid in connection with acquisitions, net of cash acquired	-4,587	-1,761
Purchases of property and equipment	-6,597	-8,310	-5,008
Other investing activities, net	-362	-387
Net cash (used in) provided by investing activities	-11,546	-10,458	-5,008
Cash Flows From Financing Activities:
Intercompany	-4,687	14,944	-14,153
Repayments of debt obligations	-134
Dividend paid by subsidiary to owners of noncontrolling interest	-617	-684	-649
Net cash (used in) provided by financing activities	-5,438	14,260	-14,802
Effect of exchange rate changes on cash and cash equivalents	-480	329	447
Net (decrease) increase in cash and cash equivalents	-2,665	5,929	-7,698
Cash and cash equivalents at beginning of period	20,848	14,919	22,617
Cash and cash equivalents at end of period	18,183	20,848	14,919
Eliminations
Cash Flows from Operating Activities:
Net (loss) income	-73,782	25,577	-95,394
Adjustments to reconcile net (loss) income to net cash (used in) provided by operating activities:
Depreciation	-179	-258	-362
Deferred income tax expense (benefit)	-988	147
Equity in (income) loss of subsidiaries, net	84,713	-24,823	100,648
Changes in operating assets and liabilities, net of acquired assets and liabilities:
Inventories	-20,065	-9,064	-12,975
Prepaid expenses and other assets	-291	-311	36
Accounts payable and other current liabilities	2,052	-744	2,051
Net cash (used in) provided by operating activities	-8,540	-9,476	-5,996
Cash Flows From Investing Activities:
Purchases of property and equipment	125	-16	-13
Net cash (used in) provided by investing activities	125	-16	-13
Cash Flows From Financing Activities:
Intercompany	8,413	9,488	6,014
Net cash (used in) provided by financing activities	8,413	9,488	6,014
Net (decrease) increase in cash and cash equivalents	-2	-4	5
Cash and cash equivalents at beginning of period	2	6	1
Cash and cash equivalents at end of period		$2	$6

Recovered_Sheet8

Schedule II-Valuation and Qualifying Accounts (Detail) (Allowance for Sales Discounts and Other Allowances, USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Allowance for Sales Discounts and Other Allowances
Valuation and Qualifying Accounts Disclosure [Line Items]
Balance as of December 31, 2011	$67,023	$61,823	$53,370
Provision	225,528	209,057	194,656
Write-offs, net of recoveries	-226,316	-203,857	-186,203
Ending Balance	$66,235	$67,023	$61,823